EP1782071A2 - Liaison covalente de groupes fonctionnels a des proteines et substrats associes - Google Patents

Liaison covalente de groupes fonctionnels a des proteines et substrats associes

Info

Publication number
EP1782071A2
EP1782071A2 EP05857556A EP05857556A EP1782071A2 EP 1782071 A2 EP1782071 A2 EP 1782071A2 EP 05857556 A EP05857556 A EP 05857556A EP 05857556 A EP05857556 A EP 05857556A EP 1782071 A2 EP1782071 A2 EP 1782071A2
Authority
EP
European Patent Office
Prior art keywords
hydrolase
substrate
amino acid
protein
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP05857556A
Other languages
German (de)
English (en)
Other versions
EP1782071B1 (fr
Inventor
Aldis Darzins
Lance P. Encell
Tonny Johnson
Dieter Klaubert
Georgyi V. Los
Mark Mcdougall
Keith V. Wood
Monika G. Wood
Chad Zimprich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promega Corp
Original Assignee
Promega Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promega Corp filed Critical Promega Corp
Priority to EP17152698.1A priority Critical patent/EP3179252B1/fr
Priority to EP11003761.1A priority patent/EP2395078B1/fr
Priority to EP11003760.3A priority patent/EP2395358B1/fr
Publication of EP1782071A2 publication Critical patent/EP1782071A2/fr
Application granted granted Critical
Publication of EP1782071B1 publication Critical patent/EP1782071B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
    • C12Y113/12005—Renilla-luciferin 2-monooxygenase (1.13.12.5), i.e. renilla-luciferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y308/00—Hydrolases acting on halide bonds (3.8)
    • C12Y308/01—Hydrolases acting on halide bonds (3.8) in C-halide substances (3.8.1)
    • C12Y308/01005—Haloalkane dehalogenase (3.8.1.5)

Definitions

  • This invention relates to the field of biochemical assays and reagents. More specifically, this invention relates to mutant proteins covalently linked (tethered) to one or more functional groups and to methods for their use.
  • Labels e.g., those that are covalently linked to a molecule of interest, permit the ready detection of that molecule in a complex mixture.
  • the label may be one that is added by chemical synthesis in vitro or attached in vivo, e.g., via recombinant techniques. For instance, the attachment of fluorescent or other labels onto proteins has traditionally been accomplished by in vitro chemical modification after protein purification (Hermanson, 1996).
  • green fluorescent protein from the jellyfish Aequorea victoria can be genetically fused with many host proteins to produce fluorescent chimeras in situ (Tsien, 1998; Chalfie et al., 1998).
  • GFP-based indicators are currently employed in a variety of assays, e.g., measuring pH (Kneen et al., 1998; Llopis et al., 1998; Miesenb ⁇ ck et al., 1998), Ca 2+ (Miyawaki et al., 1997; Rosomer et al., 1997), and membrane potential (Siegel et al., 1997)
  • the fluorescence of intrinsically labeled proteins such as GFP is limited by the properties of protein structure, e.g., a limited range of fluorescent colors and relatively low intrinsic brightness (Cubitt et al., 1995; Orm ⁇ et al., 1996).
  • Griffen et al. synthesized a tight-binding pair of molecular components: a small receptor domain composed of as few as six natural amino acids and a small ( ⁇ 700 dalton), synthetic ligand that could be linked to various spectroscopic probes or crosslinks.
  • the receptor domain included four cysteines at the i, i + 1, i + 4, and i + 5 positions of an ⁇ helix and the ligand was 4',5'-bis(l,3,2-dithioarsolan-2- yl)fluorescein (FLASH). Griffen et al.
  • the ligand had relatively few binding sites in nontransfected mammalian cells, was membrane-permeant and was nonfluorescent until it bound with high affinity and specificity to a tetracysteine domain in a recombinant protein, resulting in cells being fluorescently labeled ("FLASH" labeled) with a nanomolar or lower dissociation constant.
  • FLASH fluorescently labeled
  • Stroffekova et al. disclose that FLASH-EDT 2 binds non-specif ⁇ cally to endogenous cysteine-rich proteins.
  • labeling proteins by FLASH is limited by the range of fluorophores that may be used.
  • Receptor-mediated targeting methods use genetically encoded targeting sequences to localize fluorophores to virtually any cellular site, provided that the targeted protein is able to fold properly.
  • cDNA transfection was used to target a single-chain antibody (sFv) to a specified site in a cell.
  • sFv single-chain antibody
  • conjugates of a hapten (4- ethoxymethylene-2-phenyl-2-oxazolin-5-one, phOx) and a fluorescent probe e.g., BODIPY Fl, tetramethylrhodamine, and fluorescein
  • a fluorescent probe e.g., BODIPY Fl, tetramethylrhodamine, and fluorescein
  • the invention provides methods, compositions and kits for tethering
  • a protein of the invention is structurally related to a wild-type (native) hydrolase but includes at least one amino acid substitution, and in some embodiments at least two amino acid substitutions, relative to the corresponding wild-type hydrolase, and binds a substrate of the corresponding wild-type hydrolase but lacks or has reduced catalytic activity relative to the corresponding wild-type hydrolase (which mutant protein is referred to herein as a mutant hydrolase).
  • tethering occurs, for instance, in solution or suspension, in a cell, on a solid support or at solution/surface interfaces, by employing a substrate for a hydrolase which includes a reactive group and which has been modified to include one or more functional groups.
  • a substrate includes a substrate having a reactive group and optionally one or more functional groups.
  • a substrate which includes one or more functional groups is generally referred to herein as a substrate of the invention.
  • a "functional group” is a molecule which is detectable or is capable of detection, for instance, a molecule which is measurable by direct or indirect means (e.g., a photoactivatable molecule, digoxigenin, nickel NTA (nitrilotriacetic acid), a chromophore, fluorophore or luminophore), can be bound or attached to a second molecule (e.g., biotin, hapten, or a cross-linking group), or may be a solid support.
  • a photoactivatable molecule e.g., digoxigenin, nickel NTA (nitrilotriacetic acid), a chromophore, fluorophore or luminophore
  • a second molecule e.g., biotin, hapten, or a cross-linking group
  • a functional group may have more than one property such as being capable of detection and of being bound to another molecule.
  • a "reactive group” is the minimum number of atoms in a substrate which are specifically recognized by a particular wild-type or mutant hydrolase of the invention. The interaction of a reactive group in a substrate and a wild-type hydrolase results in a product and the regeneration of the wild-type hydrolase.
  • a substrate e.g., a substrate of the invention, may also optionally include a linker, e.g., a cleavable linker, which physically separates one or more functional groups from the reactive group in the substrate, and in one embodiment, the linker is preferably 12 to 30 atoms in length.
  • the linker may not always be present in a substrate of the invention, however, in some embodiments, the physical separation of the reactive group and the functional group may be needed so that the reactive group can interact with the reactive residue in the mutant hydrolase to form a covalent bond.
  • the linker does not substantially alter, e.g., impair, the specificity or reactivity of a substrate having the linker with the wild-type or mutant hydrolase relative to the specificity or reactivity of a corresponding substrate which lacks the linker with the wild-type or mutant hydrolase.
  • the presence of the linker preferably does not substantially alter, e.g., impair, one or more properties, e.g., the function, of the functional group.
  • a substrate of the invention can include a linker of sufficient length and structure so that the one or more functional groups of the substrate of the invention do not disturb the 3-D structure of the hydrolase (wild-type or mutant).
  • a substrate of the invention for a dehalogenase includes a reactive group such as (CHb) 2-3 X where X is a halide and a functional group such as carboxytetramethylrhodamine, e.g., carboxytetramethyrrhodamine-C i oH 21 NO 2 -Cl.
  • the invention provides a compound of fo ⁇ nula (I): R-linker-A-X, wherein R is one or more functional groups, wherein the linker is a multiatom straight or branched chain including C, N, S, or O, or a group that comprises one or more rings, e.g., saturated or unsaturated rings, such as one or more aryl rings, heteroaryl rings, aryl rings, heteroaryl rings, or any combination thereof, wherein A-X is a substrate for a dehalogenase, e.g., a haloalkane dehalogenase or a dehalogenase that cleaves carbon-halogen bonds in an aliphatic or aromatic halogenated substrate, such as a substrate for Rhodococcus, Sphingomonas, Staphylococcus, Pseudomonas, Burkholderia, Agrobacterium or Xanthobacter dehalogenase, and wherein X is
  • an alkylhalide is covalently attached to a linker, L, which is a group or groups that covalently attach one or more functional groups to form a substrate for a dehalogenase.
  • a mutant of a Rhodococcus dehalogenase (see Figure 2 for an exemplary wild-type Rhodococcus dehalogenase "DhaA.WT" sequence), DhaA.H272F, was bound to substrates for DhaA which included 5-(and 6-) carboxyfluorescein, e.g., carboxyfluorescein-CioH 2 iN ⁇ 2 -Cl, carboxytetramethylrhodamine, e.g., carboxytetramethyrrhodamine-C 10 H 2 i NO 2 - Cl, and biotin, e.g., biotin-CioH 2 iN0 2 -Cl, and there was no significant que
  • DhaA Rhodococcus de
  • a mutant dehalogenase e.g., DhaA.D106C and DhaA.D106E as well as DhaA.D106C:H272F and DhaA.D106E:H272F, bound carboxyfluorescein- CioH 2 iN0 2 -Cl and/or carboxytetramethylrhodamine-CioH 2 iN0 2 -Cl.
  • the substrate is R-(CH 2 ) 2 O(CH 2 ) 2 O(CH 2 ) 2 ⁇ (CH 2 ) 6 Cl, wherein R is a functional group.
  • substrates of the invention are permeable to the plasma membranes of cells.
  • the plasma membranes of prokaryotic (E. coli) and eukaryotic (CHO-Kl) cells were permeable to carboxytetramethylrhodamine-CioH 2 i NO 2 -Cl and biotin- CioH 2 iN0 2 -Cl and, these substrates were rapidly and efficiently loaded into and washed out of cells in the absence of a mutant hydrolase.
  • the substrate of the invention includes two or more functional groups.
  • one of the functional groups is an enzyme.
  • one of the functional groups is a substrate for an enzyme.
  • one functional group may be luciferin and the other a protease recognition site, i.e., one which contains sequences sufficient for recognition by the protease including the site to be cleaved
  • one functional group may be biotin and the other a fluorophore
  • one functional group may be a protease recognition site and the other a fluorophore.
  • the invention further provides methods for preparing a substrate for a hydrolase which substrate is modified to include one or more functional groups.
  • a mutant hydrolase of the invention comprises at least one amino acid substitution relative to a corresponding wild- type hydrolase, wherein the at least one amino acid substitution results in the mutant hydrolase forming a bond with the substrate which is more stable than the bond formed between the corresponding wild-type hydrolase and the substrate.
  • the at least one amino acid substitution in the mutant hydrolase is a substitution at an amino acid residue in the corresponding wild-type hydrolase that is associated with activating a water molecule which cleaves the bond formed between the corresponding wild-type hydrolase and the substrate or at an amino acid residue in the corresponding wild-type hydrolase that forms an ester intermediate with the substrate.
  • the mutant hydrolase comprises at least two amino acid substitutions relative to a corresponding wild- type hydrolase, wherein one substitution is in a residue which, in the wild-type hydrolase, is associated with activating a water molecule or in a residue which, in the wild-type hydrolase, forms an ester intermediate by nucleophilic attack of a substrate for the hydrolase, and another substitution in a residue which, in the wild-type hydrolase, is at or near a binding site(s) for a hydrolase substrate, e.g., the residue within 3 to 5 A of a hydrolase substrate bound to a wild-type hydrolase but is not in a residue that in the corresponding wild-type hydrolase is associated with activating a water molecule or which forms ester intermediate with a substrate.
  • the mutant hydrolase may be a fusion protein, e.g., a fusion protein expressed from a recombinant DNA which encodes the mutant hydrolase and at least one protein of interest or a fusion protein formed by chemical synthesis.
  • the fusion protein may comprise a mutant hydrolase and an enzyme of interest, e.g., luciferase, RNasin or RNase, and/or a channel protein, a receptor, a membrane protein, a cytosolic protein, a nuclear protein, a structural protein, a phosphoprotein, a kinase, a signaling protein, a metabolic protein, a mitochondrial protein, a receptor associated protein, a fluorescent protein, an enzyme substrate, a transcription factor, a transporter protein and/or a targeting sequence, e.g., a myristilation sequence, a mitochondrial localization sequence, or a nuclear localization sequence, that directs the mutant hydrolase, for example, a fusion protein, to a particular location.
  • the protein of interest may be fused to the N-terminus or the C-terminus of the mutant hydrolase.
  • the fusion protein comprises a protein of interest at the N-terminus, and another protein, e.g., a different protein, at the C-terminus, of the mutant hydrolase.
  • the protein of interest may be a fluorescent protein or an antibody.
  • the proteins in the fusion are separated by a connector sequence, e.g., preferably one having at least 2 amino acid residues, such as one having 13 to 17 amino acid residues. The presence of a connector sequence in a fusion protein of the invention does not substantially alter the function of either protein in the fusion relative to the function of each individual protein.
  • an isolated nucleic acid molecule comprising a nucleic acid sequence encoding a hydrolase, e.g., a mutant hydrolase of the invention.
  • the isolated nucleic acid molecule comprises a nucleic acid sequence which is optimized for expression in at least one selected host.
  • Optimized sequences include sequences which are codon optimized, i.e., codons which are employed more frequently in one organism relative to another organism, e.g., a distantly related organism, as well as modifications to add or modify Kozak sequences and/or introns, and/or to remove undesirable sequences, for instance, potential transcription factor binding sites.
  • the polynucleotide includes a nucleic acid sequence encoding a dehalogenase, which nucleic acid sequence is optimized for expression is a selected host cell.
  • the optimized polynucleotide no longer hybridizes to the corresponding non-optimized sequence, e.g., does not hybridize to the non-optimized sequence under medium or high stringency conditions.
  • the polynucleotide has less than 90%, e.g., less than 80%, nucleic acid sequence identity to the corresponding non-optimized sequence and optionally encodes a polypeptide having at least 80%, e.g., at least 85%, 90% or more, amino acid sequence identity with the polypeptide encoded by the non-optimized sequence.
  • Constructs e.g., expression cassettes, and vectors comprising the isolated nucleic acid molecule, as well as kits comprising the isolated nucleic acid molecule, construct or vector are also provided.
  • the invention includes a solid support comprising a substrate of the invention, a solid support comprising a mutant hydrolase of the invention or a fusion thereof, a kit comprising a substrate of the invention, a kit comprising a vector encoding a dehalogenase of the invention or a fusion thereof, or a kit comprising a vector encoding a serine beta-lactamase of the invention or a fusion thereof.
  • the substrates and mutant hydrolases of the invention are useful to isolate, detect, identify, image, display, or localize molecules of interest, label cells, including live cell imaging, or label proteins in vitro and/or in vivo.
  • a substrate of the invention bound to a solid support or a mutant hydrolase bound to a solid support may be used to generate protein arrays, cell arrays, vesicle/organelle arrays, gene arrays, and/or cell membrane arrays.
  • the invention provides a method to isolate a molecule of interest.
  • the method includes providing a sample comprising one or more fusion proteins at least one of which comprises a mutant hydrolase of the invention and a protein which is bound to the molecule of interest, and a solid support comprising one or more hydrolase substrates.
  • the sample and the solid support are then contacted so as to isolate the molecule of interest.
  • the method may be employed to isolate DNA bound to a protein fused to a mutant hydrolase.
  • the invention includes a method to identify an agent that alters the interaction of a protein of interest with a molecule suspected of interacting with the protein of interest.
  • the method includes contacting at least one agent with the molecule suspected of interacting with the protein of interest, a fusion protein comprising mutant hydrolase of the invention and the protein of interest, and a hydrolase substrate which comprises one or more functional groups. Then it is determined whether the agent alters the interaction between the protein of interest and the molecule suspected of interacting with the protein of interest.
  • the invention thus provides methods to monitor the expression, location and/or movement (trafficking) of proteins in a cell as well as to monitor changes in microenvironments within a cell.
  • the use of a mutant hydrolase of the invention and a substrate of the invention permits functional analysis of proteins, e.g., ion channels.
  • the use of two pairs of a mutant hydrolase/substrate permits multiplexing, simultaneous detection, and FRET- or BRET-based assays.
  • a mutant hydrolase of the invention may be expressed on the outside surface of cells (e.g., via a fusion with a plasma membrane protein or a membrane anchoring signal).
  • cells which express a fusion of a cytoplasmic and transmembrane domains of an integrin with a mutant hydrolase, or a fusion of a glycosylphosphatidyl inositol signal sequence and a mutant hydrolase may be isolated ("captured") by contacting those cells with a substrate of the invention, for instance, one bound to a solid support.
  • the mutant hydrolase is expressed on the cytosolic surface of the organelle of interest.
  • the mutant hydrolase is fused with an extracellular matrix component or an outer membrane protein and tethered to a three-dimensional cell culture or a platform for tissue engineering.
  • primary neurons or embryonic stem cells may be grown on the platform to form a feeder layer.
  • a mutant hydrolase of the invention and a corresponding substrate of the invention permits the detection of cells, for instance, to detect cell migration in vitro or in vivo after implantation or injection into animals (e.g., angiogenesis/chemotaxis assays, migration of implanted neurons, normal, malignant, or recombinantly modified cells implanted/injected into animals, and the like), and live cell imaging followed by immunocytochemistry.
  • the invention provides a method to label newly synthesized proteins. For example, cells comprising a vector which expresses a mutant hydrolase of the invention or a fusion thereof, are contacted with a substrate for the hydrolase which lacks a functional group.
  • Cells are then contacted with an agent, e.g., an inducer of gene expression, and a substrate for the hydrolase which contains one or more functional groups.
  • an agent e.g., an inducer of gene expression
  • a substrate for the hydrolase which contains one or more functional groups e.g., an inducer of gene expression
  • the presence, amount or location of the mutant hydrolase or fusion thereof is then detected or determined.
  • the presence, amount or location of the mutant hydrolase or fusion thereof is due to newly synthesized mutant hydrolase or a fusion thereof.
  • cells comprising a vector which expresses a mutant hydrolase of the invention or a fusion thereof are contacted with a substrate for the hydrolase having a functional group, e.g., a green fluorophore, then contacted with an agent and a substrate having a different functional group, e.g., a red fluorophore.
  • the mutant hydrolase is fused to a membrane localization signal and so can be employed to monitor events
  • the invention provides a method in which a sample comprising one or more fusion proteins, at least one of which comprises a mutant hydrolase of the invention and a protein of interest, and a solid support comprising one or more hydrolase substrates.
  • the sample and the solid support are contacted so as to isolate the protein of interest.
  • the invention provides a method to isolate one or more molecules of interest from a sample.
  • the method includes providing a solid support comprising a mutant hydrolase of the invention, and a hydrolase substrate which comprises one or more functional groups at least one of which is capable of binding the one or more molecules of interest.
  • the sample, the solid support and the hydrolase substrate are combined, thereby isolating the one or more molecules of interest.
  • the invention also provides a method to label a cell, e.g., in a transgenic or non-transgenic non-human animal.
  • the mutant hydrolase may be expressed on the outside surface of cells (e.g., via a fusion with a plasma membrane protein or a membrane anchoring signal).
  • the invention includes a method to label cells in a transgenic animal.
  • the method includes providing a transgenic non- human animal, the genome of cells of which is augmented with an expression cassette comprising a transcriptional regulatory element which is optionally tissue- or cell-specific operably linked to nucleic acid fragment encoding a mutant hydrolase of the invention and optionally a targeting peptide.
  • the transgenic non-human animal is then contacted with a hydrolase substrate that comprises one or more functional groups, thereby labeling cells that express the mutant hydrolase.
  • the method includes providing a cell comprising an expression cassette comprising a nucleic acid sequence encoding a fusion protein.
  • the fusion protein comprises a selectable marker protein, e.g., one which confers resistance to at least one antibiotic, and a second protein that is capable of stably and optionally irreversibly binding a substrate or a portion thereof which includes an optically detectable molecule.
  • the protein may be an alkyl transferase which irreversibly transfers an alkyl group and an optically detectable molecule from a substrate to itself, thereby labeling the alkyl transferase, e.g., an alkyl transferase such as O 6 -alkylguanine DNA alkyltransferase.
  • Exemplary proteins useful in this embodiment of the invention include, but are not limited to, alkyl transferases, peptidyl glycine- alpha-amidating monoxygenases, type I topoisomerases, hydrolases, e.g., serine and epoxide hydrolases as well as the mutant hydrolases described herein, aminotransferases, cytochrome P450 monooxygenases, acetyl transferases, decarboxylases, oxidases, e.g., monoamine oxidases, reductases, e.g., ribonucleotide reductase, synthetases, e.g., cyclic ADP ribose synthetase or thymidylate synthetase, dehydrogenases, e.g., aldehyde dehydrogenase, synthases, e.g., nitric oxide synthase (NOS),
  • a stable bond i.e., one which is formed between a substrate and a wild-type or mutant enzyme, has a tvi of at least 30 minutes and preferably at least 4 hours, and up to at least 10 hours, and is resistant to disruption by washing, protein denaturants, and/or high temperatures, e.g., the bond is stable to boiling in SDS.
  • the cell which expresses the fusion protein is contacted with the substrate so as to label the cell.
  • the cell is fixed prior to contact with the substrate.
  • the substrate and fixative are contacted with the cell at the same time.
  • the fixative is added to the cell after the cell is contacted with the substrate.
  • the fusion protein forms an ester bond with the substrate.
  • the fusion protein forms a thioester bond with the substrate.
  • the invention provides a method in which cells comprising an expression cassette comprising a transcriptional regulatory element which is optionally tissue- or cell-specific operably linked to nucleic acid fragment encoding a mutant hydrolase of the invention and optionally a targeting peptide, are introduced to a non-human animal such as a non-human mammal or an animal including a human.
  • the animal is contacted with a hydrolase substrate that comprises one or more functional groups concurrently, before or after contacting the animal with the cells, thereby labeling cells that express the mutant hydrolase.
  • the one or more functional groups are then detected.
  • the cells are contacted with the hydrolase substrate before introducing the cells to the animal.
  • the method includes contacting a sample, a mutant hydrolase of the invention and a hydrolase substrate which comprises one or more functional groups, at least one of which binds the molecule of interest, a sample comprising a mutant hydrolase of the invention and a hydrolase substrate which comprises one or more functional groups at least one of which binds the molecule of interest, or a sample comprising a hydrolase substrate which comprises one or more functional groups at least one of which binds the molecule of interest and a mutant hydrolase of the invention, so as to isolate the one or more molecules.
  • the method includes contacting a sample, a mutant hydrolase of the invention and a hydrolase substrate which comprises one or more functional groups at least one of which binds the molecule of interest, a sample comprising a mutant hydrolase of the invention and a hydrolase substrate which comprises one or more functional groups at least one of which binds the molecule of interest, or a sample comprising and a hydrolase substrate which comprises one or more functional groups at least one of which binds the molecule of interest, and a mutant hydrolase of the invention, Then the presence or amount of the molecule of interest is detected or determined.
  • a cell comprising a mutant hydrolase of the invention is contacted with a hydrolase substrate which comprises two or more functional groups at least one of which binds the molecule of interest and which binding alters a property of the second functional group. Then the presence or amount of the second functional group is detected or determined.
  • the invention also provides a method to selectively inactive one or more proteins of interest and/or cellular activities in a cell.
  • the method provides for contacting a sample comprising a fusion protein comprising a mutant hydrolase of the invention and protein of interest, or cells with an expression cassette encoding a fusion protein comprising a mutant hydrolase of the invention and protein of interest with a hydrolase substrate which comprises one or more functional groups at least one of which when exposed to certain wavelengths of light produces a singlet oxygen, yielding a mixture.
  • the mixture is exposed to a particular wavelength of light in an amount that selectively, e.g., locally, inactivates one or more proteins of interest and/or cellular activities in the cell.
  • a change in the function of one or more proteins and/or cellular activities is detected or determined.
  • a method to detect a molecule of interest in a sample includes providing a complex comprising a first fusion protein comprising a mutant hydrolase of the invention and a first protein which is capable of binding a second protein, which mutant hydrolase is bound to a first hydrolase substrate comprising one or more functional groups one of which is a fluorophore, and providing a second fusion protein comprising a third protein, such as a mutant hydrolase of the invention, and the second protein, which third protein is bound to a second substrate comprising one or more functional groups one of which quenches the fluorophore, which second substrate is a substrate of the third protein.
  • the complex is combined with the sample and the fluorescence is detected or determined.
  • the invention includes a method that provides a complex comprising a first fusion protein comprising a mutant hydrolase of the invention and a first protein which is capable of binding a second protein, which mutant hydrolase is bound to a first hydrolase substrate comprising one or more functional groups one of which is a fluorophore, and a second fusion protein comprising the second protein and a fluorescent or luminescent reporter protein.
  • the complex and the sample are combined, and the interaction detected by resonance energy transfer of the luminescence to the fluorophore (BRET).
  • the invention includes a method that provides a first fusion protein comprising a mutant hydrolase of the invention and a first protein which is capable of binding a second protein, which mutant hydrolase is bound to a first hydrolase substrate comprising one or more functional groups one of which is a fluorophore, and a second fusion protein comprising the second protein and a fluorescent or luminescent reporter protein.
  • the first and second fusion proteins are combined and the interaction detected by BRET.
  • a method to detect one or more proteases in a cell is provided.
  • the method includes providing a cell or a lysate thereof comprising a first expression cassette comprising a first promoter, e.g., an inducible or constitutive promoter, linked to a first nucleic acid fragment which binds a first transcriptional repressor protein linked to a first reporter gene, and a second expression cassette comprising a second promoter, e.g., an inducible or constitutive promoter, linked to a second nucleic acid fragment encoding a first modified transcription repressor protein which includes a protease recognition site, hi one embodiment, the reporter gene is a luciferase or a mutant hydrolase of the invention.
  • a first expression cassette comprising a first promoter, e.g., an inducible or constitutive promoter, linked to a first nucleic acid fragment which binds a first transcriptional repressor protein linked to a first reporter gene
  • a second expression cassette comprising a second promoter, e.g., an induc
  • the first modified transcription repressor protein in the absence of cleavage by the protease, is capable of binding the first nucleic acid fragment and inhibiting transcription from the first promoter, and so inhibits transcription of the reporter gene.
  • the modified transcription repressor protein In the presence of the protease, the modified transcription repressor protein is cleaved and has no or reduced binding to the first nucleic acid fragment. Reporter gene expression is detected or determined. Expression or increased expression of the reporter is thus indicative of the presence of the protease.
  • the method includes providing a cell-free expression system, for instance, a S30, wheat germ, rabbit reticulocyte, insect cell or mammalian cell lysate, which comprises an expression cassette comprising a first promoter linked to a nucleic acid fragment which binds a transcriptional repressor protein linked to a first reporter gene, hi one embodiment, the reporter gene is a luciferase or a mutant hydrolase of the invention.
  • a cell-free expression system for instance, a S30, wheat germ, rabbit reticulocyte, insect cell or mammalian cell lysate, which comprises an expression cassette comprising a first promoter linked to a nucleic acid fragment which binds a transcriptional repressor protein linked to a first reporter gene,
  • the reporter gene is a luciferase or a mutant hydrolase of the invention.
  • Isolated modified transcription repressor protein which includes a protease recognition site, and/or isolated protease(s), a lysate with one or more protease(s), or a sample suspected of having one or more protease(s), is added to the cell-free lysate. Reporter gene expression is detected or determined. Expression or increased expression of the reporter is indicative of the presence of the protease.
  • a cell or a lysate thereof comprising a first expression cassette comprising a first promoter linked to a first nucleic acid fragment which binds a first transcription repressor protein linked to a reporter gene, a second expression cassette comprising a second promoter linked to a second nucleic acid fragment which binds a first protein of a fusion protein, operably linked to a coding region for the transcription repressor protein, and the fusion protein, is provided.
  • the reporter gene is a luciferase or a mutant hydrolase of the invention.
  • the fusion protein comprises the first protein which binds the second nucleic acid fragment, a protease recognition site, and a second protein which activates the second promoter when the first protein binds to the second nucleic acid fragment. Reporter gene expression is detected or determined. Expression or increased expression of the reporter gene is indicative of the presence of the protease.
  • a cell or a lysate thereof comprising a first expression cassette comprising a first promoter linked to a first nucleic acid fragment which binds a transcription activator protein linked to a transcription repressor protein gene, a second expression cassette comprising a second promoter linked to a second nucleic acid fragment which binds the transcription repressor protein, operably linked to a reporter gene, a third expression cassette comprising a third promoter linked to a nucleic acid sequence encoding a fusion protein comprising a DNA binding protein, a protease recognition site and the transcription activator protein.
  • the reporter gene is a luciferase or mutant hydrolase of the invention.
  • the fusion protein activates the expression of the transcription repressor protein, which in turn inhibits the expression of the reporter protein. Reporter gene expression is detected or determined.
  • the fusion protein is cleaved, the expression of the transcription repressor protein from the first expression cassette is inhibited, which results in the expression of the reporter protein from the second expression cassette.
  • the invention also provides a method to detect one or more proteases in a cell which includes providing a cell comprising an expression cassette comprising a promoter linked to a nucleic acid encoding a fusion protein comprising a protein destabilization sequence, a protease recognition site, and a reporter protein, and detecting or determining reporter expression, wherein expression or prolonged expression of the reporter is indicative of the presence of the protease.
  • the invention provides a method to detect one or more proteases in a cell.
  • the cell comprises an expression cassette comprising a promoter linked to a nucleic acid encoding a fusion protein comprising a protein destabilization sequence, a protease recognition site, and a reporter protein. Reporter expression is detected or determined, wherein expression or increased expression of the reporter is indicative of the presence of the protease.
  • the reporter gene is a luciferase or mutant hydrolase of the invention.
  • the method includes providing a solid support comprising a hydrolase substrate bound to a fusion protein comprising a mutant hydrolase of the invention, a protease recognition site, and a reporter protein or providing a solid support comprising a hydrolase substrate and a fusion protein comprising a mutant hydrolase of the invention, a protease recognition site, and a reporter protein.
  • a sample is contactedwith the solid substrate comprising the hydrolase substrate bound to the fusion protein or with the solid substrate and the fusion protein.
  • the solution phase is collected. Reporter activity is then detected or determined.
  • the invention provides a method to detect one or more proteases in a sample, in which a mixture is provided.
  • the mixture comprises a sample comprising a cell or a lysate thereof comprising a First expression cassette comprising a first promoter linked to a first nucleic acid fragment which binds a first transcription repressor protein linked to a first reporter gene, and isolated modified transcription repressor protein which includes a heterologous protease recognition site, or the mixture comprises a sample, a cell or a lysate thereof comprising a first expression cassette comprising a first promoter linked to a first nucleic acid fragment which binds a first transcription repressor protein linked to a first reporter gene, and isolated modified transcription repressor protein which includes a heterologous protease recognition site.
  • the first modified transcription repressor protein In the absence of the protease the first modified transcription repressor protein is capable of binding the first nucleic acid fragment and inhibiting transcription from the first promoter, and in the presence of the protease the binding of the first modified transcription repressor protein to the first nucleic acid fragment is inhibited.
  • the reporter gene in the mixture is detected or determined. Expression or increased expression of the first reporter gene is indicative of the presence of the protease in the sample.
  • a solid support comprising a hydrolase substrate bound to a fusion protein comprising a mutant hydrolase, a protease recognition site, and a reporter protein is provided or a solid support comprising a hydrolase substrate and a fusion protein comprising a mutant hydrolase, a protease recognition site, and a reporter protein is provided.
  • the mutant hydrolase comprises at least one amino acid substitution relative to a corresponding wild- type hydrolase, wherein the at least one amino acid substitution results in the mutant hydrolase forming a bond with the substrate which is more stable than the bond formed between the corresponding wild-type hydrolase and the substrate, wherein the mutant hydrolase comprises at least one amino acid substitution in the mutant hydrolase is a substitution at an amino acid residue in the corresponding wild-type hydrolase that is associated with activating a water molecule which cleaves a bond formed between the corresponding wild-type hydrolase and the substrate or at an amino acid residue in the corresponding wild-type hydrolase that forms an ester intermediate with the substrate.
  • a sample is contacted with the solid support comprising the hydrolase substrate bound to the fusion protein or with the solid support and the fusion protein. Reporter activity is detected or determined.
  • the invention also provides a biosensor.
  • the invention provides a method to detect a substrate for an enzyme in a sample.
  • the method includes providing a sample, one or more fusion proteins at least one of which comprises a mutant hydrolase of the invention and the enzyme, and a solid support comprising one or more hydrolase substrates or providing a sample and a solid support comprising one or more hydrolase substrates bound to one or more fusion proteins at least one of which comprises a mutant hydrolase of the invention and the enzyme.
  • the binding of the mutant hydrolase to the hydrolase substrate alters the electrochemical properties of the solid support, e.g., a platinum electrode, gold coated surface, gold nanoparticles or carbon nanotubes.
  • the sample is a physiological sample such as a physiological fluid sample.
  • a method to label proteins includes contacting a cell or an in vitro translation mixture with a hydrolase substrate which comprises one or more functional groups, at least one of which is an aminoacylated tRNA or an amino acid, so as to label newly synthesized proteins.
  • a mutant hydrolase of the invention is employed to isolate the newly synthesized proteins.
  • An isolated nucleic acid molecule is also provided.
  • the isolated nucleic acid molecule comprises a nucleic acid sequence encoding a fusion polypeptide comprising at least one heterologous protein destabilization sequence, a protease recognition site and a reporter protein, which fusion polypeptide has a reduced half-life relative to a corresponding reporter protein which lacks the heterologous protein destabilization sequence.
  • nucleic acid molecule comprising a promoter, a nucleic acid fragment that binds a transcription repressor protein operably linked to a coding region for a mutant hydrolase of the invention.
  • Figure 2A shows a molecular model of the DhaA.H272F protein.
  • the helical cap domain is shown in light blue.
  • the ⁇ / ⁇ hydrolase core domain (dark blue) contains the catalytic triad residues.
  • the red shaded residues near the cap and core domain interface represent H272F and the D106 nucleophile.
  • the yellow shaded residues denote the positions of E130 and the halide-chelating residue Wl 07.
  • Figure 2B shows the sequence of a Rhodococcus rhodochroiis dehalogenase (DhaA) protein (Kulakova et al., 1997) (SEQ ID NO:82).
  • DhaA Rhodococcus rhodochroiis dehalogenase
  • the catalytic triad residues Asp(D), GIu(E) and His(H) are underlined. The residues that make up the cap domain are shown in italics.
  • the DhaA.H272F and DhaA.D 106C protein mutants, capable of generating covalent linkages with alkylhalide substrates, contain replacements of the catalytic triad His (H) and Asp (D) residues with Phe (F) and Cys (C), respectively.
  • Figure 2D depicts the mechanism of covalent intermediate formation by DhaA.D 106C with an alkylhalide substrate. Nucleophilic displacement of the halide by the Cys 106 thiolate generates a thioether intermediate that is stable to hydrolysis.
  • Figure 2E depicts a structural model of the DhaA.H272F variant with a covalently attached carboxytetramethylrhodamine-CioH 2 iN ⁇ 2 -Cl ligand situated in the active site activity.
  • the red shaded residues near the cap and core domain interface represent H272F and the D106 nucleophile.
  • the yellow shaded residues denote the positions of E130 and the halide-chelating residue W107.
  • Figure 2F shows a structural model of the DhaA.H272F substrate binding tunnel.
  • Figure 3 A illustrates the physical map of plasmid pGEX5X3DhaA.H272F.FLAG.
  • This plasmid and pGEX5X3DhaA.D106C.FLAG (not shown) were used as the parental templates in mutagenesis and screening studies.
  • the DhaA coding regions are fused at the N-terminus with glutathione S-transferase (GST) and at the C-terminus with the FLAG epitope.
  • GST glutathione S-transferase
  • a Factor Xa cleavage site is situated between the GST and DhaA coding regions.
  • Figure 3B shows the purification of GST-DhaA fusion proteins.
  • DhaA. WT odd numbered lanes
  • DhaA.H272F even numbered lanes
  • GSS- Sepharose 4FF lanes 3 and 4-crude E. coli supernatant; lanes 5 and 6-washes; lanes 7 through 10-purified proteins.
  • Treatment of the fusion proteins with Factor Xa led to the formation of two proteins, GST and DhaA (WT or H272F mutant; lanes 11 and 12, respectively).
  • GST was efficiently removed on GSS-Sepharose 4FF (DhaA.WT or mutant; lanes 13 and 14, respectively). All proteins had the predicted molecular weight.
  • FIG. 4 illustrates the hydrolysis of 1-Cl-butane by DhaA.WT and mutant DhaAs.
  • FIGS 7A-B show substrates for DhaA which include a functional group (e.g., 5-(and 6-)-carboxyfluorescein, Anth (anthracene) or biotin) and a linker.
  • a functional group e.g., 5-(and 6-)-carboxyfluorescein, Anth (anthracene) or biotin
  • linker e.g., 5-(and 6-)-carboxyfluorescein, Anth (anthracene) or biotin
  • Biotin- 14-Cl refers to biotin-Ci 0 H 2 iNO 2 -Cl
  • biotin-X-14-Cl refers to biotin-Ci 6 H 32 N 2 O 3 -Cl
  • biotin-PEG4-14-Cl refers to biotin-C 2 iH 42 N 2 O 7 -Cl.
  • Figure 8 A shows a HPLC separation of products of carboxyfluorescein- Ci 0 H 2I NO 2 -Cl hydrolysis by DhaA.WT and DhaA.H272F.
  • Figure 8B shows a HPLC analysis of product (as a percent of substrate) generated by DhaA.WT and DhaA.H272F hydrolysis of carboxyfluorescein- CioH 2 iN0 2 -Cl over time.
  • Figure 9 shows SDS-PAGE analysis of the binding of DhaA.WT (lanes 1, 3, and 5 in panel A and lanes 1-8 in panel B) and DhaA.H272F (lanes 2, 4, and 6 in panel A and lanes 9-14 in panel B), to carboxytetramethylrhodamine- CioH 2 iN0 2 -Cl (lanes 1 and 2 in panel A); carboxy-X-rhodamine-CioH 2 iN ⁇ 2 -Cl (lanes 3 and 4 in panel A); carboxyfluorescein-CtoH 2 iN0 2 ⁇ Cl (lanes 5 and 6 in panel A); or biottn-CioH 2 iN0 2 -Cl (panel B).
  • the concentration of biotin- CioH 2 iN0 2 -Cl in panel B as: 0 ⁇ M (lanes 1 and 8), 125 ⁇ M (lanes 2 and 9) 25 ⁇ M (lanes 3 and 10), 5 ⁇ M (lanes 4 and 1 1), 1 ⁇ M (lanes 5 and 12), 0.2 ⁇ M (lanes 6 and 13), and 0.04 ⁇ M (lanes 7 and 14).
  • Figure 10 illustrates that pretreatment of a mutant DhaA with a substrate, biotin-CioH 2 iN0 2 -Cl, blocks binding of another substrate.
  • Samples 2, 4, 6, 8, and 10 were pretreated with biotin- CoH 21 NO 2 -Cl.
  • Figure 12 illustrates SDS-PAGE analysis of the binding properties of DhaA mutants with substitutions at residue 106, and DhaA mutants with substitutions at residue 106 and residue 272, to carboxytetramethylrhodamine- CioH 2 iN0 2 -Cl.
  • 2 ⁇ g of protein and 25 ⁇ M carboxytetramethylrhodamine- CioH 2 iN0 2 -Cl in 32 ⁇ l were incubated for one hour at room temperature. 10 ⁇ l of each reaction was loaded per lane.
  • the gel was imaged with a 570 nm filter.
  • Figure 13 depicts analysis of Renilla luciferase activity in samples having a fusion of luciferase and DhaA.H272 tethered to a solid support (a streptavidin coated plate).
  • FIG. 14 shows SDS-PAGE analysis of two-fold serial dilutions of E. coli expressing either DhaA.WT (lanes 1-4 of each panel) or DhaA.H272F (lanes 5-7 of each panel) treated with biotin-CioH 2 iN ⁇ 2 -Cl (panel A) or carboxytetramethylrhodamine-CioH 2 iN0 2 -Cl (panel B) in vivo. Arrows mark proteins with M r corresponding to M r of DhaA.
  • Figure 15 shows the binding of carboxytetramethylrhodamine-
  • CioH 2 ]N0 2 -Cl CioH 2 ]N0 2 -Cl to eukaryotic cell proteins in vivo.
  • Two-fold serial dilutions of proteins from CHO-Kl cells expressing either DhaA.WT-Flag (lanes 1-4) or DhaA.H272F-Flag (lanes 5-8) were treated with carboxytetramethylrhodamine- C ]oH 2 i NO 2 -Cl.
  • Figure 18 shows Western blot analysis of proteins from cells transfected with GFP-connector-DhaA.WT-Flag (lanes 1-4) or GFP-connector-
  • Figures 19A-B illustrate the toxicity of selected substrates (panel A, carboxytetramethylrhodamine and panel B, carboxy-X-rhodamine) for CHO-Kl cells.
  • Figure 20 illustrates a reaction scheme for a serine beta-lactamase.
  • the reaction begins with the formation of a precovalent encounter complex (Figure 19A), and moves through a high-energy acylation tetrahedral intermediate
  • BlaZ.E166D, BlaZ.N170Q or BlaZ.E166D:N170Q Lane 1-dye/no BIaZ; lane 2- BIaZ. WT; lane 3-BlaZ.E166D; lane 4-BlaZ.N170Q; and lane 5- BlaZ.E166D:N170Q.
  • Figure 23 shows the binding of CCF2 to fusions of GST and BlaZ.E166D, BlaZ.N170Q or BlaZ.E166D:N170Q.
  • Lane 1-dye/no BIaZ lane 2- GST-BIaZ. WT; lane 3-GST-BlaZ.E166D; lane 4-GST-BlaZ.N170Q; and lane 5- GST- BlaZ.E166D:N170Q.
  • Figure 24 provides fluorescence and DIC images of living CHO-Kl cells transfected with a construct encoding GFP-connector-DhaA.H272F-NLS3 and stained with carboxytetramethylrhodamine-CioH 2 iN ⁇ 2 -Cl.
  • FIG. 25 shows fluorescence images of living CHO-Kl cells transfected with a construct encoding GFP- ⁇ -arrestin2 (left) and a construct encoding DhaA.H272F- ⁇ -arrestin2 and stained with carboxytetramethylrhodamine- C 10 H 2I NO 2 -Cl (right).
  • Figure 26 shows an SDS-PAGE analysis of DhaA expression in E. coli.
  • FIG. 27 shows an immunoblot analysis of DhaA containing lysates. Lanes: 1, DhaA. WT crude lysate; 2, DhaA.
  • WT cell-free lysate 3, DhaA.H272F crude lysate; 4, DhaA.H272F cell-free lysate; 5, vector control crude lysate; 6, vector control cell-free lysate; 7, Molecular weight standards; 8, DhaA.E130Q Cl crude lysate; 9, DhaA.EBOQ Cl cell-free lysate; 10, DhaA.E130L A5 crude lysate; 11, DhaA.E130L A5 cell-free lysate; 12, DhaA.E130A A12 crude lysate; 13, DhaA.EOOA A12 cell-free lysate; 14, Molecular weight standards.
  • the arrow indicates the location of the DhaA protein.
  • Figure 28 provides fluoroimage analysis of in vitro covalent alkyl- enzyme formation. Lanes: 1, Fluorescent molecular weight standards; 2, DhaA. WT; 3, DhaA.H272F mutant; 4, DhaA- (vector only control); 5, DhaA.E130Q mutant; 6, DhaA.E130L mutant; 7, DhaA.E130A mutant. The arrow indicates the location of the fluorescent enzyme-alkyl covalent intermediate.
  • Figure 29 provides fluoroimage analysis of covalent alkyl-enzyme formation in whole cells. Lanes: 1, Fluorescent molecular weight standards; 2, DhaA.
  • FIG. 30C-D illustrate analyses of hRXuc-DhaA captured on SA coated beads.
  • CHO-Kl cells transiently expressing hR.Luc-connector- DhaA.H272F-Flag were treated with or without biotin-CioH 2 iNi0 2 -Cl (25 ⁇ M, 0.1% DMSO, 60 minutes, 37 0 C).
  • FIG. 32 depicts an overview of the MagneGSTTM assay developed for high-throughput screening of DhaA libraries using carboxytetramethylrhodamine-CioH 2 iN ⁇ 2 -Cl.
  • Figures 33A-B shows the identification of potential improvements (i.e., hits) from mutant DhaA protein libraries. Representative screening plates from the DhaA.H272F C176 (panel A) and DhaA.D106C K175/C176 NNK (panel B) libraries are shown. Arrows indicate potentially improved clones.
  • Figures 34A-B show the identification of potential improvements (i.e., hits) from mutant DhaA protein libraries. Shown are two representative plates from the DhaA.H272F Y273 (NNK) library screening using the MagneGSTTM- based screening assay. Arrows indicate potentially improved clones.
  • Figures 37A-C demonstrate the relative labeling rates of purified DhaA mutants with carboxytetramethylrhodamine-CioHoiNCVCl.
  • A SDS-PAGE and fluorimage gel analysis of labeling time-course.
  • Figures 39A-B show fluorescence polarization analysis of DhaA mutants using (A) carboxytetramethylrhodamine-CioH 2 i NO 2 -Cl and (B) carboxyfluorescein-C i oH 21 NO 2 -Cl.
  • Figure 40 shows the second order rate constants (M "1 sec "1 ) of parental (DhaA.H272F and DhaA.D106C), and first and second generation DhaA mutants determined by fluorescence polarization (FP).
  • Figure 42 depicts the structural models of the DhaA.H272F and DhaA.H272F Hl IYL substrate tunnels without (panels A and C) and with (panels B and D) carboxytetramethylrhodamine-coupled substrate.
  • FIG 43 shows the results of thermostability studies of purified DhaA proteins.
  • A). Analysis of DhaA.H272F parental and select first generation DhaA mutants.
  • B). Analysis of DhaA.H272F-based second generation DhaA mutants.
  • Figure 44 demonstrates the effect of low temperature on DhaA.H272F Hl IYL reaction rates. Following incubation at either 4 0 C or 23°C, 10 ⁇ L aliquots of the reaction mixture were quickly added to an equivalent amount of SDS-loading dye preincubated at 95°C. The resulting SDS-PAGE gel was examined by fluorimage analysis.
  • Figure 45 illustrates the immobilization of DhaA to solid supports.
  • A). General reaction scheme between DhaA.H272F mutants and immobilized biotin- chloroalkanes.
  • B). Titration of select DhaA mutants against immobilized biotin- PEG-14-C1.
  • Figures 46C-D demonstrate the in vivo labeling of first and second generation DhaA mutants expressed in CHO-Kl cells.
  • C SDS-PAGE fluorimage gel analysis of DhaA mutants following in vivo labeling with carboxytetramethylrhodamine-C 10 H 21 N0 2 -Cl (5 ⁇ M). Lanes: 1-4, DhaA.H272F A7; lanes 5-8, DhaA.H272F Hl IYL; and lanes 9-12, DhaA.D106C 30H4. Each lane in the series represents 5, 15, 30 and 120 minute time points.
  • D Quantitation of carboxytetramethylrhodamine-CioHTiNOo-Cl binding to DhaA mutants.
  • Figure 47A-C show the labeling of DhaA.H272F A7 and DhaA.H272F Hl IYL with different concentrations of carboxytetramethylrhodamine- C 10 H 21 NO 2 -CI in mammalian cell lysates.
  • Figures 48C-D shows a comparison of the stability of DhaA.H272 mutants in vivo.
  • A Fluorimage gel analysis of carboxytetramethylrhodamine- CioH 2 iN0 2 -Cl labeled DhaA mutants. Lanes: 1-3, DhaA.H272F A7; lanes 4-6, DhaA.H272F Hl IYL; and lane 7 standards. Lanes 1 and 4 represent samples taken 12 hours post-transfection. Lanes 2 and 5 represent samples taken 24 hours post-transfection. Lanes 3 and 6 represent samples taken 48 hours post- transfection. Arrow indicates location of DhaA variants. B). Quantitation of the fluorimaged gel.
  • Figure 49 shows the nucleotide (SEQ ID NO: 80) and amino acid (SEQ ID NO:81) sequence of DhaA.H272 Hl IYL which is in pHT2.
  • the restriction sites listed were incorporated to facilitate generation of functional N- and C- terminal fusions.
  • Figures 50A-B provide fluorescence and DIC images of living HeLa cells transfected with a vector coding for DhaA.H272F Hl IYL stained with carboxytetramethylrhodamine-CioH 2 iN0 2 -Cl, and counterstained with MitoTracker 11 Green FM (left panel); or stained with DiAc-carboxyfluorescein- CioH 2 iN0 2 -Cl and counterstained with MitoTracker R Orange CMTMRos (right panel).
  • FIG. 50C-D provide fluorescence and DIC images of living CHO-Kl cells transfected with a vector plasmid pHT2 coding for DhaA.H272F Hl IYL HT2 (see Figure 49) or pCIneo harboring DhaA.H272F, stained with 0.2, 1.0 or 5.0 ⁇ M carboxytetramethylrhodamine-CioHiiNOi-Cl, and fixed with 3.7% of paraformaldehyde.
  • FIG. 5 IA-B show the capture of a hRLuc-DhaA.H272F H11YLHT2 fusion protein expressed in transiently transfected CHO-Kl cells. Capturing hRLuc activity on streptavidin coated 96-well plates (A) and streptavidin- MagneSphere paramagnetic particles (B).
  • Figures 52A-C show the relative labeling rates of and product accumulation for purified DhaA.H272F Hl IYL with carboxytetramethylrhodamine-CioH 2 iN ⁇ 2 -Cl, carboxytetramethylrhodamine-p- phenethyl-Cl and carboxytetramethylrhodamine-furanyl-propyl-Cl.
  • B SDS-PAGE and fluorimage gel analysis.
  • C Quantitation of fluorescent product accumulation.
  • Figures 53 A-C show the relative labeling rates of and product accumulation for purified DhaA.H272F Hl IYL with carboxyfluorescein- CioH 2 iN0 2 -Cl, carboxyfluorescein-p-phenethyl-Cl and carboxyfluorescein- furanyl-propyl-Cl.
  • C Quantitation of fluorescent product accumulation.
  • Figures 54A-B demonstrate the in vivo labeling of DhaA.H272F Hl IYL with different carboxytetramethylrhodamine chloroalkanes.
  • A Fluorimage gel analysis. Lanes: 1-3, carboxytetramethylrhodamine-14-Cl, 5, 15 and 60 minutes, respectively; lanes 4-6, carboxytetramethylrhodamine-furanyl-propyl-Cl, 5, 15 and 60 minutes, respectively; and lanes 7-9, carboxytetramethylrhodamine-p- phenethyl-Cl, 5, 15 and 60 minutes, respectively.
  • B Quantitation of the DhaA.Hl 1Y273L in vivo labeling rates using 1, 5 and 20 ⁇ M substrate.
  • Figures 55 A-B demonstrate the reactivity of immobilized DhaA.H272F Hl IYL to biotin-coupled chloroalkane substrates.
  • A). General reaction and detection scheme.
  • B). Reactivity of biotin-PEG4-14-Cl, bio tin- 14-Cl and biotin- p-phenethyl-14-Cl with immobilized DhaA.H272F Hl 1Y273L protein.
  • Figure 56 shows exemplary substrates with ring structures.
  • Figure 57 illustrates the use of a hydrolase substrate of the invention and a mutant hydrolase of the invention for the immobilization and capture of proteins of interest.
  • Figure 58 is a schematic of a hydrolase substrate of the invention and a mutant hydrolase of the invention for immunoprecipitation.
  • Figures 59 A-B illustrate the use of a hydrolase substrate of the invention and a mutant hydrolase of the invention to detect cAMP.
  • Figure 6OA is a schematic of a cell-based protease detection system.
  • Figure 6OB is a schematic of a cell-based protease detection system.
  • Figure 6OC is a schematic of the use of short lived reporters to detect a protease of interest.
  • a “nucleophile” is a molecule which donates electrons.
  • a “selectable marker protein” encodes an enzymatic activity that confers to a cell the ability to grow in medium lacking what would otherwise be an essential nutrient (e.g., the TRPl gene in yeast cells) or in a medium with an antibiotic or other drug, i.e., the expression of the gene encoding the selectable marker protein in a cell confers resistance to an antibiotic or drug to that cell relative to a corresponding cell without the gene.
  • the marker is said to be a positive selectable marker (e.g., antibiotic resistance genes which confer the ability to grow in the presence of the appropriate antibiotic).
  • Selectable markers can also be used to select against host cells containing a particular gene (e.g., the sacB gene which, if expressed, kills the bacte ⁇ al host cells grown in medium containing 5% sucrose); selectable markers used in this manner are referred to as negative selectable markers or counter-selectable markers
  • Common selectable marker gene sequences include those for resistance to antibiotics such as ampicillin, tetracycline, kanamycm, puromycm, bleomycin, streptomycin, hygromycm, neomycin, ZeocinTM, and the like.
  • Selectable auxotrophic gene sequences include, for example, hisD, which allows growth in histidine free media in the presence of histidinol
  • Suitable selectable marker genes include a bleomycm-resistance gene, a metallothionem gene, a hygromycm B- phosphotransferase gene, the AURI gene, an adenosine deaminase gene, an aminoglycoside phosphotransferase gene, a dihydrofolate reductase gene, a thymidine kinase gene, a xanthine-guanine phospho ⁇ bosyltransferase gene, and the like
  • a "nucleic acid”, as used herein, is a covalently linked sequence of nucleotides in which the 3' position of the pentose of one nucleotide is joined by a phosphodiester group to the 5' position of the pentose of the next
  • a "polynucleotide”, as used herein, is a nucleic acid containing a sequence that is greater than about 100 nucleotides in length.
  • An "oligonucleotide” or “primer”, as used herein, is a short polynucleotide or a portion of a polynucleotide.
  • the term “oligonucleotide” or “oligo” as used herein is defined as a molecule comprised of 2 or more deoxyribonucleotides or ribonucleotides, preferably more than 3, and usually more than 10, but less than 250, preferably less than 200, deoxyribonucleotides or ribonucleotides.
  • the oligonucleotide may be generated in any manner, mcluding chemical synthesis, DNA replication, amplification, e.g., polymerase chain reaction (PCR), reverse transcription (RT), or a combination thereof.
  • a "primer” is an oligonucleotide which is capable of acting as a point of initiation for nucleic acid synthesis when placed under conditions in which primer extension is initiated.
  • a primer is selected to have on its 3' end a region that is substantially complementary to a specific sequence of the target (template).
  • a primer must be sufficiently complementary to hybridize with a target for primer elongation to occur.
  • a primer sequence need not reflect the exact sequence of the target.
  • a non-complementary nucleotide fragment may be attached to the 5' end of the primer, with the remainder of the primer sequence being substantially complementary to the target.
  • Non- complementary bases or longer sequences can be interspersed into the primer provided that the primer sequence has sufficient complementarity with the sequence of the target to hybridize and thereby form a complex for synthesis of the extension product of the primer.
  • Primers matching or complementary to a gene sequence may be used in amplification reactions, RT-PCR and the like.
  • DNA molecules are said to have "5' ends” and "3' ends” because mononucleotides are reacted to make oligonucleotides in a manner such that the 5' phosphate of one mononucleotide pentose ring is attached to the 3' oxygen of its neighbor in one direction via a phosphodiester linkage. Therefore, an end of an oligonucleotides referred to as the "5' end” if its 5' phosphate is not linked to the 3' oxygen of a mononucleotide pentose ring and as the "3' end” if its 3' oxygen is not linked to a 5' phosphate of a subsequent mononucleotide pentose ring.
  • a nucleic acid sequence even if internal to a larger oligonucleotide or polynucleotide, also may be said to have 5' and 3' ends.
  • discrete elements are referred to as being "upstream” or 5' of the "downstream” or 3' elements. This terminology reflects the fact that transcription proceeds in a 5' to 3' fashion along the DNA strand.
  • promoter and enhancer elements that direct transcription of a linked gene are generally located 5' or upstream of the coding region.
  • enhancer elements can exert their effect even when located 3' of the promoter element and the coding region.
  • Transcription termination and polyadenylation signals are located 3' or downstream of the coding region.
  • the term "codon” as used herein, is a basic genetic coding unit, consisting of a sequence of three nucleotides that specify a particular amino acid to be incorporation into a polypeptide chain, or a start or stop signal.
  • the term "coding region" when used in reference to structural gene refers to the nucleotide sequences that encode the amino acids found in the nascent polypeptide as a result of translation of a mRNA molecule.
  • the coding region is bounded on the 5' side by the nucleotide triplet "ATG” which encodes the initiator methionine and on the 3' side by a stop codon (e.g., TAA, TAG, TGA).
  • ATG nucleotide triplet
  • TGT stop codon
  • the coding region is also known to initiate by a nucleotide triplet "TTG”.
  • isolated and/or purified refer to in vitro preparation, isolation and/or purification of a nucleic acid molecule, a polypeptide, peptide or protein, so that it is not associated with in vivo substances.
  • isolated when used in relation to a nucleic acid, as in “isolated oligonucleotide” or “isolated polynucleotide” refers to a nucleic acid sequence that is identified and separated from at least one contaminant with which it is ordinarily associated in its source. An isolated nucleic acid is present in a form or setting that is different from that in which it is found in nature. In contrast, non-isolated nucleic acids (e.g., DNA and RNA) are found in the state they exist in nature.
  • isolated nucleic acid e.g., DNA and RNA
  • a given DNA sequence e.g., a gene
  • RNA sequences e.g., a specific mRNA sequence encoding a specific protein
  • RNA sequences are found in the cell as a mixture with numerous other mRNAs that encode a multitude of proteins.
  • the "isolated nucleic acid molecule” which includes a polynucleotide of genomic, cDNA, or synthetic origin or some combination thereof, the "isolated nucleic acid molecule” (1) is not associated with all or a portion of a polynucleotide in which the "isolated nucleic acid molecule” is found in nature, (2) is operably linked to a polynucleotide which it is not linked to in nature, or (3) does not occur in nature as part of a larger sequence.
  • the isolated nucleic acid molecule may be present in single-stranded or double-stranded form.
  • the nucleic acid When a nucleic acid molecule is to be utilized to express a protein, the nucleic acid contains at a minimum, the sense or coding strand (i.e., the nucleic acid may be single-stranded), but may contain both the sense and anti-sense strands (i.e., the nucleic acid may be double-stranded).
  • wild-type refers to a gene or gene product that has the characteristics of that gene or gene product isolated from a naturally occurring source.
  • a wild-type gene is that which is most frequently observed in a population and is thus arbitrarily designated the "wild-type” form of the gene.
  • mutant refers to a gene or gene product that displays modifications in sequence and/or functional properties (i.e., altered characteristics) when compared to the wild-type gene or gene product. It is noted that naturally-occurring mutants can be isolated; these are identified by the fact that they have altered characteristics when compared to the wild-type gene or gene product.
  • the term "recombinant DNA molecule” means a hybrid DNA sequence comprising at least two nucleotide sequences not normally found together in nature.
  • vector is used in reference to nucleic acid molecules into which fragments of DNA may be inserted or cloned and can be used to transfer DNA segment(s) into a cell and capable of replication in a cell. Vectors may be derived from plasmids, bacteriophages, viruses, cosmids, and the like.
  • the terms "recombinant vector”, “expression vector” or “construct” as used herein refer to DNA or RNA sequences containing a desired coding sequence and appropriate DNA or RNA sequences necessary for the expression of the operably linked coding sequence in a particular host organism.
  • Prokaryotic expression vectors include a promoter, a ribosome binding site, an origin of replication for autonomous replication in a host cell and possibly other sequences, e.g. an optional operator sequence, optional restriction enzyme sites.
  • a promoter is defined as a DNA sequence that directs RNA polymerase to bind to DNA and to initiate RNA synthesis.
  • Eukaryotic expression vectors include a promoter, optionally a polyadenylation signal and optionally an enhancer sequence.
  • the coding region utilized in the expression vectors of the present invention may contain endogenous enhancers/promoters, splice junctions, intervening sequences, polyadenylation signals, etc.
  • the coding region may contain a combination of both endogenous and exogenous control elements.
  • transcription regulatory element refers to a genetic element or sequence that controls some aspect of the expression of nucleic acid sequence(s).
  • a promoter is a regulatory element that facilitates the initiation of transcription of an operably linked coding region.
  • Other regulatory elements include, but are not limited to, transcription factor binding sites, splicing signals, polyadenylation signals, termination signals and enhancer elements, and include elements which increase or decrease transcription of linked sequences, e.g., in the presence of trans- acting elements.
  • Transcriptional control signals in eukaryotes comprise "promoter" and
  • Promoters and enhancers consist of short arrays of DNA sequences that interact specifically with cellular proteins involved in transcription.
  • Promoter and enhancer elements have been isolated from a variety of eukaryotic sources including genes in yeast, insect and mammalian cells.
  • Promoter and enhancer elements have also been isolated from viruses and analogous control elements, such as promoters, are also found in prokaryotes. The selection of a particular promoter and enhancer depends on the cell type used to express the protein of interest. Some eukaryotic promoters and enhancers have a broad host range while others are functional in a limited subset of cell types.
  • the SV40 early gene enhancer is very active in a wide variety of cell types from many mammalian species and has been widely used for the expression of proteins in mammalian cells.
  • Two other examples of promoter/enhancer elements active in a broad range of mammalian cell types are those from the human elongation factor 1 gene and the long terminal repeats of the Rous sarcoma virus; and the human cytomegalovirus.
  • promoter/enhancer denotes a segment of DNA containing sequences capable of providing both promoter and enhancer functions (i.e., the functions provided by a promoter element and an enhancer element as described above).
  • promoter/promoter may be "endogenous” or “exogenous” or “heterologous.”
  • An “endogenous” enhancer/promoter is one that is naturally linked with a given gene in the genome.
  • an “exogenous” or “heterologous” enhancer/promoter is one that is placed in juxtaposition to a gene by means of genetic manipulation (i.e., molecular biological techniques) such that transcription of the gene is directed by the linked enhancer/promoter.
  • Splicing signals mediate the removal of introns from the primary RNA transcript and consist of a splice donor and acceptor site (Sambrook et al., 1989).
  • a commonly used splice donor and acceptor site is the splice junction from the 16S RNA of SV40.
  • Expression systems include in vitro gene expression assays where a gene of interest (e.g., a reporter gene) is linked to a regulatory sequence and the expression of the gene is monitored following treatment with an agent that inhibits or induces expression of the gene. Detection of gene expression can be through any suitable means including, but not limited to, detection of expressed mRNA or protein (e.g., a detectable product of a reporter gene) or through a detectable change in the phenotype of a cell expressing the gene of interest.
  • a gene of interest e.g., a reporter gene
  • Detection of gene expression can be through any suitable means including, but not limited to, detection of expressed mRNA or protein (e.g., a detectable product of a reporter gene) or through a detectable change in the phenotype of a cell expressing the gene of interest.
  • Expression systems may also comprise assays where a cleavage event or other nucleic acid or cellular change is detected.
  • the te ⁇ n "gene” refers to a DNA sequence that comprises coding sequences and optionally control sequences necessary for the production of a polypeptide from the DNA sequence.
  • the polypeptide can be encoded by a full- length coding sequence or by any portion of the coding sequence so long as the portion encodes a gene product with substantially the same activity as the full- length polypeptide.
  • hybridization stringency can be used to maximize or minimize stability of such duplexes.
  • Hybridization stringency can be altered by: adjusting the temperature of hybridization; adjusting the percentage of helix destabilizing agents, such as formamide, in the hybridization mix; and adjusting the temperature and/or salt concentration of the wash solutions.
  • the final stringency of hybridizations often is determined by the salt concentration and/or temperature used for the post-hybridization washes.
  • nucleic acid molecules of the invention encode a variant (mutant) of a naturally-occurring (wild-type) protein or fragment thereof which has substantially the same activity as the full length mutant protein.
  • a mutant protein has an amino acid sequence that is at least 85%, preferably 90%, and most preferably 95%) or 99%, identical to the amino acid sequence of a corresponding wild-type protein.
  • Polypeptide molecules are said to have an "amino terminus” (N-terminus) and a “carboxy terminus” (C-terminus) because peptide linkages occur between the backbone amino group of a first amino acid residue and the backbone carboxyl group of a second amino acid residue.
  • N-terminal and C-terminal in reference to polypeptide sequences refer to regions of polypeptides including portions of the N-terminal and C-terminal regions of the polypeptide, respectively.
  • a sequence that includes a portion of the N-terminal region of polypeptide includes amino acids predominantly from the N-terminal half of the polypeptide chain, but is not limited to such sequences.
  • an N-terminal sequence may include an interior portion of the polypeptide sequence including bases from both the N-terminal and C-terminal halves of the polypeptide.
  • N-terminal and C-terminal regions may, but need not, include the amino acid defining the ultimate N-terminus and C-terminus of the polypeptide, respectively.
  • isolated when used in relation to a polypeptide, as in "isolated protein” or “isolated polypeptide” refers to a polypeptide that is identified and separated from at least one contaminant with which it is ordinarily associated in its source.
  • an isolated polypeptide (1) is not associated with proteins found in nature, (2) is free of other proteins from the same source, e.g., free of human proteins, (3) is expressed by a cell from a different species, or (4) does not occur in nature.
  • non-isolated polypeptides e.g., proteins and enzymes
  • isolated polypeptide include a polypeptide, peptide or protein encoded by cDNA or recombinant RNA including one of synthetic origin, or some combination thereof.
  • recombinant protein or “recombinant polypeptide” as used herein refers to a protein molecule expressed from a recombinant DNA molecule.
  • native protein is used herein to indicate a protein isolated from a naturally occurring (i.e., a nonrecombinant) source.
  • fusion polypeptide refers to a chimeric protein containing a protein of interest (e.g., luciferase, an affinity tag or a targeting sequence) joined to a different protein, e.g., a mutant hydrolase.
  • a protein of interest e.g., luciferase, an affinity tag or a targeting sequence
  • Antibodies may exist as intact immunoglobulins, or as modifications in a variety of forms including, for example, FabFc 2 , Fab, Fv, Fd, (Fab') 2 , an Fv fragment containing only the light and heavy chain variable regions, a Fab or (Fab)' 2 fragment containing the variable regions and parts of the constant regions, a single-chain antibody, e.g., scFv, CDR-grafted antibodies and the like.
  • the heavy and light chain of a Fv may be derived from the same antibody or different antibodies thereby producing a chimeric Fv region.
  • the antibody may be of animal (especially mouse or rat) or human origin or may be chimeric or humanized.
  • the term "antibody" includes these various forms.
  • transformed cell is meant a cell into which (or into an ancestor of which) has been introduced a nucleic acid molecule of the invention.
  • a nucleic acid molecule of the invention may be introduced into a suitable cell line so as to create a stably transfected cell line capable of producing the protein or polypeptide encoded by the nucleic acid molecule.
  • Vectors, cells, and methods for constructing such cell lines are well known in the art.
  • the words “transformants” or “transformed cells” include the primary transformed cells derived from the originally transformed cell without regard to the number of transfers. AU progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Nonetheless, mutant progeny that have the same functionality as screened for in the originally transformed cell are included in the definition of transformants.
  • homology refers to a degree of complementarity. There may be partial homology or complete homology (i.e., identity). Homology is often measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group. University of Wisconsin Biotechnology Center. 1710 University Avenue. Madison, WI 53705). Such software matches similar sequences by assigning degrees of homology to various substitutions, deletions, insertions, and other modifications.
  • sequence analysis software e.g., Sequence Analysis Software Package of the Genetics Computer Group. University of Wisconsin Biotechnology Center. 1710 University Avenue. Madison, WI 53705
  • Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.
  • purified or “to purify” means the result of any process that removes some of a contaminant from the component of interest, such as a protein or nucleic acid. The percent of a purified component is thereby increased in the sample.
  • poly-histidine tract refers to a molecule comprising two to ten histidine residues, e.g., a poly-histidine tract of five to ten residues.
  • a poly-histidine tract allows the affinity purification of a covalently linked molecule on an immobilized metal, e.g., nickel, zinc, cobalt or copper, chelate column or through an interaction with another molecule (e.g., an antibody reactive with the His tag).
  • pure means an object species is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition), and preferably a substantially purified fraction is a composition wherein the object species comprises at least about 50 percent (on a molar basis) of all macromolecular species present.
  • a substantially pure composition will comprise more than about 80 percent of all macromolecular species present in the composition, more preferably more than about 85%, about 90%, about 95%, and about 99%.
  • the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species.
  • a "quantum dot" is an ultrasmall, bright, highly photostable semiconductor crystallite with a broad excitation band that a narrow emission band, i.e., it is a fluorescent crystalline nanoparticle.
  • an "upconverting nanoparticle” means a nanoparticle which is a combination of an absorber which is excited by infrared (IR) light and an emitter ion in a crystal lattice, which converts IR light into visible radiation.
  • IR infrared
  • a "triplet sensitizer” is a molecule or a group that is substantially chemically inert and that can absorb light at wavelengths that are not or are only weakly absorbed by a substrate. The “sensitizer” can then release energy which will cause an oxygen atom in the substrate or compound to be excited to a singlet oxygen state.
  • the substrate with an oxygen atom in a singlet oxygen state can destroy molecules, such as proteins in close proximity thereto.
  • triplet sensitizers include, for example, eosin or malachite green.
  • a radionuclide useful in a diagnostic application includes, e.g., metallic radionuclides (i.e., metallic radioisotopes or metallic paramagnetic ions), including Antimony-124, Antimony-125, Arsenic-74, Barium-103, Barium-140, Beryllium-7, Bismuth-206, Bismuth-207, Cadmium-109, Cadmium- 115m, Calcium-45, Cerium-139, Cerium-141, Cerium-144, Cesium-137, Chromium- 51, Cobalt-55, Cobalt-56, Cobalt-57, Cobalt-58, Cobalt-60, Cobalt-64, Copper- 67, Erbium-169, Europium-152, Gallium-64, Gallium-68, Gadolinium- 153, Gadolinium-157 Gold-195, Gold-199, Hafnium-175, Hafnium-175-181, Holmium-166, Indium-110, Indium-I l
  • Radionuclides useful for imaging include radioisotopes of copper (Cu), gallium (Ga), indium (In), rhenium (Rh), and technetium (Tc), including isotopes 64 Cu, 67 Cu, 111 In, "mTc, 67 Ga or 68 Ga.
  • Metals useful for X-ray contrast agents include radioisotopes of Re, Sm, Ho, Lu, Yt, Pm, Bi, Pd, Gd, La, Au, Yb, Dy, Cu, Rh, Ag and Ir.
  • a “protein destabilization sequence” or “protein destabilization domain” includes one or more amino acid residues, which, when present at the N- terminus or C-terminus of a protein, reduces or decreases the half-life of the linked protein of by at least 80%, preferably at least 90%, more preferably at least 95% or more, e.g., 99%, relative to a corresponding protein which lacks the protein destabilization sequence or domain.
  • a protein destabilization sequence includes, but is not limited to, a PEST sequence, for example, a PEST sequence from cyclin, e.g., mitotic cyclins, uracil permease or ODC, a sequence from the C-terminal region of a short-lived protein such as ODC, early response proteins such as cytokines, lymphokines, protooncogenes, e.g., c-myc or c-fos, MyoD, HMG CoA reductase, S-adenosyl methionine decarboxylase, CL sequences, a cyclin destruction box, N-degron, or a protein or a fragment thereof which is ubiquitinated in vivo.
  • a PEST sequence for example, a PEST sequence from cyclin, e.g., mitotic cyclins, uracil permease or ODC
  • a "protein of interest” includes but is not limited to a selectable marker protein, membrane protein, cytosolic protein, nuclear protein, structural protein, an enzyme, an enzyme substrate, a receptor protein, a transporter protein, a transcription factor, a channel protein, a phospho-protein, a kinase, a signaling protein, a metabolic protein, a mitochondrial protein, a receptor associated protein, a nucleic acid binding protein, an extracellular matrix protein, a secreted protein, a receptor ligand, a serum protein, an immunogenic protein, a fluorescent protein, or a protein with reactive cysteines.
  • a protein of interest may target the mutant hydrolase to the cell membrane or endoplasmic reticulum, e.g., the protein of interest is an integrin protein or a domain thereof, and in one embodiment, the mutant hydrolase is fused to a sequence which targets the mutant hydrolase to the endoplasmic reticulum and to a glycosylphosphatidylinositol (GPI) signal sequence.
  • GPI glycosylphosphatidylinositol
  • Mutant hydrolases within the scope of the invention include but are not limited to those prepared via recombinant techniques, e.g., site-directed mutagenesis or recursive mutagenesis, and comprise one or more amino acid substitutions which render the mutant hydrolase capable of forming a stable, e.g., covalent, bond with a substrate, such as a substrate modified to contain one or more functional groups, for a corresponding nonmutant (wild-type) hydrolase which bond is more stable than the bond formed between a corresponding wild- type hydrolase and the substrate.
  • a substrate such as a substrate modified to contain one or more functional groups
  • Hydrolases within the scope of the invention include, but are not limited to, peptidases, esterases (e.g., cholesterol esterase), glycosidases (e.g., glucosamylase), phosphatases (e.g., alkaline phosphatase) and the like.
  • esterases e.g., cholesterol esterase
  • glycosidases e.g., glucosamylase
  • phosphatases e.g., alkaline phosphatase
  • hydrolases include, but are not limited to, enzymes acting on ester bonds such as carboxylic ester hydrolases, thiolester hydrolases, phosphoric monoester hydrolases, phosphoric diester hydrolases, triphosphoric monoester hydrolases, sulfuric ester hydrolases, diphosphoric monoester hydrolases, phosphoric triester hydrolases, exodeoxyribonucleases producing 5'- phosphomonoesters, exoribonucleases producing 5'-phosphomonoesters, exoribonucleases producing 3'-phosphomonoesters, exonucleases active with either ribo- or deoxyribonucleic acid, exonucleases active with either ribo- or deoxyribonucleic acid, endodeoxyribonucleases producing 5'- phosphomonoesters, endodeoxyribonucleases producing other than 5'- phosphomonoesters, site-specific endodeoxyribonuclea
  • hydrolases acting on halide bonds include, but are not limited to, alkylhalidase, 2-haloacid dehalogenase, haloacetate dehalogenase, thyroxine deiodinase, haloalkane dehalogenase, 4-chlorobenzoate dehalogenase, 4-chlorobenzoyl-CoA dehalogenase, and atrazine chlorohydrolase.
  • hydrolases that act on carbon-nitrogen bonds in cyclic amides include, but are not limited to, barbiturase, dihydropyrimidinase, dihydroorotase, carboxymethylhydantoinase, allantoinase, ⁇ -lactamase, imidazolonepropionase, 5-oxoprolinase (ATP- hydrolysing), creatininase, L-lysine-lactamase, 6-aminohexanoate-cyclic-dimer hydrolase, 2,5-dioxopiperazine hydrolase, N-methylhydantoinase (ATP- hydrolysing), cyanuric acid amidohydrolase, maleimide hydrolase.
  • Beta- lactamase as used herein includes Class A, Class C and Class D beta-lactamases as well as D-ala carboxypeptidase/transpeptidase, esterase EstB, penicillin binding protein 2X, penicillin binding protein 5, and D-amino peptidase.
  • the beta-lactamase is a serine beta-lactamase, e.g., one having a catalytic serine residue at a position corresponding to residue 70 in the serine beta-lactamase of S. aureus PCl, and a glutamic acid residue at a position corresponding to residue 166 in the serine beta-lactamase of S.
  • the mutant hydrolase of the invention comprises at least one amino acid substitution in a residue which, in the wild-type hydrolase, is associated with activating a water molecule, e.g., a residue in a catalytic triad or an auxiliary residue, wherein the activated water molecule cleaves the bond formed between a catalytic residue in the wild-type hydrolase and a substrate of the hydrolase.
  • an "auxiliary residue” is a residue which alters the activity of another residue, e.g., it enhances the activity of a residue that activates a water molecule.
  • Residues which activate water within the scope of the invention include but are not limited to those involved in acid-base catalysis, for instance, histidine, aspartic acid and glutamic acid.
  • the mutant hydrolase of the invention comprises at least one amino acid substitution in a residue which, in the wild-type hydrolase, forms an ester intermediate by nucleophilic attack of a substrate for the hydrolase.
  • a substrate useful with a mutant hydrolase of the invention is one which is specifically bound by a mutant hydrolase, and preferably results in a bond formed with an amino acid, e.g., the reactive residue, of the mutant hydrolase which bond is more stable than the bond formed between the substrate and the corresponding amino acid of the wild-type hydrolase. While the mutant hydrolase specifically binds substrates which may be specifically bound by the corresponding wild- type hydrolase, no product or substantially less product, e.g., 2-, 10-, 100-, or 1000-fold less, is formed from the interaction between the mutant hydrolase and the substrate under conditions which result in product formation by a reaction between the corresponding wild-type hydrolase and substrate.
  • the lack of, or reduced amounts of, product formation by the mutant hydrolase is due to at least one substitution in the mutant hydrolase, which substitution results in the mutant hydrolase forming a bond with the substrate which is more stable than the bond formed between the corresponding wild-type hydrolase and the substrate.
  • the bond formed between a mutant hydrolase and a substrate of the invention has a half-life (i.e., t /2 ) that is greater than, e.g., at least 2-fold, and more preferably at least 4- or even 10-fold, and up to 100-, 1000- or 10,000-fold greater or more, than the fc /2 of the bond formed between a corresponding wild- type hydrolase and the substrate under conditions which result in product formation by the corresponding wild-type hydrolase.
  • the bond formed between the mutant hydrolase and the substrate has a t /2 of at least 30 minutes and preferably at least 4 hours, and up to at least 10 hours, and is resistant to disruption by washing, protein denaturants, and/or high temperatures, e.g., the bond is stable to boiling in SDS.
  • the mutant hydrolase of the invention comprises at least two amino acid substitutions, one substitution in a residue which, in the wild-type hydrolase, is associated with activating a water molecule or in a residue which, in the wild-type hydrolase, forms an ester intermediate by nucleophilic attack of a substrate for the hydrolase, and another substitution in a residue which, in the wild-type hydrolase, is at or near a binding site(s) for a hydrolase substrate, e.g., the residue is within 3 to 5 A of a hydrolase substrate bound to a wild-type hydrolase but is not in a residue that, in the corresponding wild-type hydrolase, is associated with activating a water molecule or which forms ester intermediate with a substrate.
  • the second substitution is in a residue which, in the wild-type hydrolase lines the site(s) for substrate entry into the catalytic pocket of the hydrolase, e.g., a residue that is within the active site cavity and within 3 to 5 A of a hydrolase substrate bound to the wild-type hydrolase such as a residue in a tunnel for the substrate that is not a residue in the corresponding wild-type hydrolase which is associated with activating a water molecule or which forms an ester intermediate with a substrate.
  • the additional substitution(s) preferably increase the rate of stable covalent bond formation of those mutants to a substrate of a corresponding wild- type hydrolase.
  • one substitution is at a residue in the wild- type hydrolase that activates the water molecule, e.g., a histidine residue, and is at a position corresponding to amino acid residue 272 of a Rhodococcus rhodochrous dehalogenase, e.g., the substituted amino acid at the position corresponding to amino acid residue 272 is phenylalanine or glycine.
  • one substitution is at a residue in the wild-type hydrolase which forms an ester intermediate with the substrate, e.g., an aspartate residue, and at a position corresponding to amino acid residue 106 of a Rhodococcus rhodochrous dehalogenase.
  • the second substitution is at an amino acid residue corresponding to a position 175, 176 or 213 of Rhodococcus rhodochrous dehalogenase, e.g., the substituted amino acid at the position corresponding to amino acid residue 175 is methionine, valine, glutamate, aspartate, alanine, leucine, serine or cysteine, the substituted amino acid at the position corresponding to amino acid residue 176 is serine, glycine, asparagine, aspartate, threonine, alanine or arginine, and/or the substituted amino acid at the position corresponding to amino acid residue 273 is leucine, methionine or cysteine.
  • the substituted amino acid at the position corresponding to amino acid residue 175 is methionine, valine, glutamate, aspartate, alanine, leucine, serine or cysteine
  • the substituted amino acid at the position corresponding to amino acid residue 176 is serine, gly
  • the mutant hydrolase further comprises a third and optionally a fourth substitution at an amino acid residue in the wild- type hydrolase that is within the active site cavity and within 3 to 5 A of a hydrolase substrate bound to the wild-type hydrolase, e.g., the third substitution is at a position corresponding to amino acid residue 175, 176 or 273 of a Rhodococciis rhodochroiis dehalogenase, and the fourth substitution is at a position corresponding to amino acid residue 175, 176 or 273 of a Rhodococcus rhodochroiis dehalogenase.
  • a mutant hydrolase may include other substitution(s), e.g., those which are introduced to facilitate cloning of the corresponding gene or a portion thereof, and/or additional residue(s) at or near the N- and/or C-terminus, e.g., those which are introduced to facilitate cloning of the corresponding gene or a portion thereof but which do not necessarily have an activity, e.g., are not separately detectable.
  • wild-type dehalogenase DhaA cleaves carbon-halogen bonds in halogenated hydrocarbons (HaIoC 3 -HaIoCiO).
  • the catalytic center of DhaA is a classic catalytic triad including a nucleophile, an acid and a histidine residue.
  • the amino acids in the triad are located deep inside the catalytic pocket of DhaA (about 10 A long and about 20 A 2 in cross section).
  • the halogen atom in a halogenated substrate for DhaA for instance, the chlorine atom of a Cl- alkane substrate, is positioned in close proximity to the catalytic center of DhaA.
  • DhaA binds thetsubstrate, likely forms an ES complex, and an ester intermediate is formed by nucleophilic attack of the substrate by Asp 106 (the numbering is based on the protein sequence of DhaA) of DhaA ( Figures IA-B). His272 of DhaA then activates water and the activated water hydrolyzes the intermediate, releasing product from the catalytic center.
  • mutant DhaAs e.g., a DhaA.H272F mutant, which likely retains the 3-D structure based on a computer modeling study and basic physico-chemical characteristics of wild- type DhaA (DhaA.WT), were not capable of hydrolyzing one or more substrates of the wild-type enzyme, e.g., for Cl-alkanes, releasing the corresponding alcohol released by the wild-type enzyme.
  • DhaA.WT basic physico-chemical characteristics of wild- type DhaA
  • mutant serine beta-lactamases e.g., a BlaZ.E166D mutant, a BlaZ-.N170Q mutant and a BlaZ.E166D:N170Q mutant, were not capable of hydrolyzing one or more substrates of a wild-type serine beta-lactamase.
  • a mutant hydrolase is a mutant dehalogenase comprising at least one amino acid substitution in a residue which, in the wild-type dehalogenase, is associated with activating a water molecule, e.g., a residue in a catalytic triad or an auxiliary residue, wherein the activated water molecule cleaves the bond formed between a catalytic residue in the wild-type dehalogenase and a substrate of the dehalogenase.
  • at least one substitution is in a residue corresponding to residue 272 in DhaA from Rhodococcus rhodochrous.
  • a "corresponding residue” is a residue which has the same activity (function) in one wild-type protein relative to a reference wild-type protein and optionally is in the same relative position when the primary sequences of the two proteins are aligned.
  • a residue which forms part of a catalytic triad and activates a water molecule in one enzyme may be residue 272 in that enzyme, which residue 272 corresponds to residue 73 in another enzyme, wherein residue 73 forms part of a catalytic triad and activates a water molecule.
  • a mutant dehalogenase of the invention has a residue other than histidine, e.g., a phenylalanine residue, at a position corresponding to residue 272 in DhaA from Rhodococcus rhodochrous.
  • a mutant hydrolase is a mutant dehalogenase comprising at least one amino acid substitution in a residue corresponding to residue 106 in DhaA from Rhodococcus rhodochrous, e.g., a substitution to a residue other than aspartate.
  • a mutant dehalogenase of the invention has a cysteine or a glutamate residue at a position corresponding to residue 106 in DhaA from
  • the mutant hydrolase is a mutant dehalogenase comprising at least two amino acid substitutions, one in a residue corresponding to residue 106 and one in a residue corresponding to residue 272 in DhaA from Rhodococcus rhodochrous.
  • the mutant hydrolase is a mutant dehalogenase comprising at least two amino acid substitutions, one in a residue corresponding to residue 272 in DhaA from Rhodococcus rhodochrous and another in a residue corresponding to residue 175, 176, 245 and/or 273 in DhaA from Rhodococcus rhodochrous.
  • the mutant hydrolase is a mutant serine beta-lactamase comprising at least one amino acid substitution in a residue corresponding to residue 166 or residue 170 in a serine beta-lactamase of Staphylococcus aureus PCl .
  • the mutant hydrolase is a haloalkane dehalogenase, e.g., such as those found in Gram-negative (Keuning et al., 1985) and Gram- positive haloalkane-utilizing bacteria (Keuning et al., 1985; Yokota et al., 1987; Scholtz et al., 1987; Sallis et al., 1990).
  • Haloalkane dehalogenases including DhIA from Xanthobacter autotrophicus GJlO (Janssen et al., 1988, 1989), DhaA from Rhodococcus rhodochroiis , and LinB from Spingomonas paucimobilis UT26 (Nagata et al., 1997) are enzymes which catalyze hydro lytic dehalogenation of corresponding hydrocarbons.
  • Halogenated aliphatic hydrocarbons subject to conversion include C 2 -CiQ saturated aliphatic hydrocarbons which have one or more halogen groups attached, wherein at least two of the halogens are on adjacent carbon atoms.
  • Such aliphatic hydrocarbons include volatile chlorinated aliphatic (VCA) hydrocarbons.
  • VGA's include, for example, aliphatic hydrocarbons such as dichloroethane, 1,2-dichloro-propane, 1 ,2-dichlorobutane and 1,2,3-trichloropropane.
  • halogenated hydrocarbon as used herein means a halogenated aliphatic hydrocarbon.
  • halogen includes chlorine, bromine, iodine, fluorine, astatine and the like. A preferred halogen is chlorine.
  • the mutant hydrolase is a thermostable hydrolase such as a thermostable dehalogenase comprising at least one substitution at a position corresponding to amino acid residue 117 and/or 175 of a Rhodococcus rhodochrous dehalogenase, which substitution is correlated with enhanced thermostability.
  • the thermostable hydrolase is capable of binding a hydrolase substrate at low temperatures, e.g., from O 0 C to about 25 0 C.
  • thermostable hydrolase is a thermostable mutant hydrolase, i.e., one having one or more substitutions in addition to the substitution at a position corresponding to amino acid residue 117 and/or 175 of a Rhodococcus rhodochrous dehalogenase.
  • a thermostable mutant dehalogenase has a substitution which results in removal of a charged residue, e.g., lysine.
  • a thermostable mutant dehalogenase has a serine or methionine at a position corresponding to residue 117 and/or 175 in DhaA from Rhodococciis rhodochrous.
  • the invention also provides a fusion protein comprising a mutant hydrolase and amino acid sequences for a protein or peptide of interest, e.g., sequences for a marker protein, e.g., a selectable marker protein, affinity tag, e.g., a polyhistidine sequence, an enzyme of interest, e.g., luciferase, RNasin, RNase, and/or GFP, a nucleic acid binding protein, an extracellular matrix protein, a secreted protein, an antibody or a portion thereof such as Fc, a bio luminescence protein, a receptor ligand, a regulatory protein, a serum protein, an immunogenic protein, a fluorescent protein, a protein with reactive cysteines, a receptor protein, e.g., NMDA receptor, a channel protein, e.g., an ion channel protein such as a sodium-, potassium- or a calcium-sensitive channel protein including a HERG channel protein, a membrane protein, a
  • the fusion protein may be expressed from a recombinant DNA which encodes the mutant hydrolase and at least one protein of interest, or formed by chemical synthesis.
  • the protein of interest may be fused to the N-terminus or the C-terminus of the mutant hydrolase.
  • the fusion protein comprises a protein of interest at the N-terminus, and another protein, e.g., a different protein, at the C-terminus, of the mutant hydrolase.
  • the protein of interest may be a fluorescent protein or an antibody.
  • the proteins in the fusion are separated by a connector sequence, e.g., preferably one having at least 2 amino acid residues, such as one having 13 to 17 amino acid residues.
  • a connector sequence in a fusion protein of the invention does not substantially alter the function of either protein in the fusion relative to the function of each individual protein.
  • the presence of a connector sequence does not substantially alter the stability of the bond formed between the mutant dehalogenase and a substrate therefor or the activity of the luciferase.
  • the connector sequence is a sequence recognized by an enzyme, e.g., a cleavable sequence.
  • the connector sequence may be one recognized by a caspase, e.g., DEVD (SEQ ID NO: 17), or is a photocleavable sequence.
  • the fusion protein may comprise a protein of interest at the N-terminus and, optionally, a different protein of interest at the C-terminus of the mutant hydrolase.
  • fusions of a mutant DhaA with GST (at the N-terminus), a Flag sequence (at the C-te ⁇ ninus) and Renilla luciferase (at the N-terminus or C-terminus) had no detectable effect on bond formation between the mutant DhaA and a substrate for wild-type DhaA which includes a functional group.
  • a fusion of a Flag sequence and DhaA.H272F could be attached to a solid support via a streptavidin-biotin- CioH 2 iNi ⁇ 2 -Cl-DhaA.H272F bridge (an SFlag-ELISA experiment).
  • a fusion protein includes a mutant hydrolase and a protein that is associated with a membrane or a portion thereof, e.g., targeting proteins such as those for endoplasmic reticulum targeting, cell membrane bound proteins, e.g., an integrin protein or a domain thereof such as the cytoplasmic, transmembrane and/or extracellular stalk domain of an integrin protein, and/or a protein that links the mutant hydrolase to the cell surface, e.g., a glycosylphosphoinositol signal sequence.
  • isolated nucleic acid molecule comprising a nucleic acid sequence encoding a hydrolase or a fusion thereof.
  • the isolated nucleic acid molecule comprises a nucleic acid sequence which is optimized for expression in at least one selected host.
  • Optimized sequences include sequences which are codon optimized, i.e., codons which are employed more frequently in one organism relative to another organism, e.g., a distantly related organism, as well as modifications to add or modify Kozak sequences and/or introns, and/or to remove undesirable sequences, for instance, potential transcription factor binding sites.
  • the polynucleotide includes a nucleic acid sequence encoding a dehalogenase, which nucleic acid sequence is optimized for expression is a selected host cell.
  • the optimized polynucleotide no longer hybridizes to the corresponding non-optimized sequence, e.g., does not hybridize to the non-optimized sequence under medium or high stringency conditions.
  • the polynucleotide has less than 90%, e.g., less than 80%, - • nucleic acid sequence identity to the corresponding non-optimized sequence and optionally encodes a polypeptide having at least 80%, e.g., at least 85%, 90% or more, amino acid sequence identity with the polypeptide encoded by the non- optimized sequence.
  • Constructs e.g., expression cassettes, and vectors comprising the isolated nucleic acid molecule, as well as kits comprising the isolated nucleic acid molecule, construct or vector are also provided.
  • a nucleic acid molecule comprising a nucleic acid sequence encoding a fusion with hydrolase is optionally optimized for expression in a particular host cell and also optionally operably linked to transcription regulatory sequences, e.g., one or more enhancers, a promoter, a transcription termination sequence or a combination thereof, to form an expression cassette.
  • transcription regulatory sequences e.g., one or more enhancers, a promoter, a transcription termination sequence or a combination thereof
  • a nucleic acid sequence encoding a hydrolase or a fusion thereof is optimized by replacing codons in a wild-type or mutant hydrolase sequence with codons which are preferentially employed in a particular (selected) cell.
  • Preferred codons have a relatively high codon usage frequency in a selected cell, and preferably their introduction results in the introduction of relatively few transcription factor binding sites for transcription factors present in the selected host cell, and relatively few other undesirable structural attributes.
  • the optimized nucleic acid product has an improved level of expression due to improved codon usage frequency, and a reduced risk of inappropriate transcriptional behavior due to a reduced number of undesirable transcription regulatory sequences.
  • An isolated and optimized nucleic acid molecule of the invention may have a codon composition that differs from that of the corresponding wild-type nucleic acid sequence at more than 30%, 35%, 40% or more than 45%, e.g., 50%, 55%, 60% or more of the codons.
  • Preferred codons for use in the invention are those which are employed more frequently than at least one other codon for the same amino acid in a particular organism and, more preferably, are also not low-usage codons in that organism and are not low-usage codons in the organism used to clone or screen for the expression of the nucleic acid molecule.
  • preferred codons for certain amino acids may include two or more codons that are employed more frequently than the other (non-preferred) codon(s).
  • the presence of codons in the nucleic acid molecule that are employed more frequently in one organism than in another organism results in a nucleic acid molecule which, when introduced into the cells of the organism that employs those codons more frequently, is expressed in those cells at a level that is greater than the expression of the wild-type or parent nucleic acid sequence in those cells.
  • the codons that are different are those employed more frequently in a mammal, while in another embodiment the codons that are different are those employed more frequently in a plant.
  • Preferred codons for different organisms are known to the art, e.g., see www.kazusa.or.jp ./codon/.
  • a particular type of mammal e.g., a human, may have a different set of preferred codons than another type of mammal.
  • a particular type of plant may have a different set of preferred codons than another type of plant.
  • the majority of the codons that differ are ones that are preferred codons in a desired host cell.
  • preferred codons for organisms including mammals (e.g., humans) and plants are known to the art (e.g., Wada et al., 1990; Ausubel et al., 1997).
  • preferred human codons include, but are not limited to, CGC (Arg), CTG (Leu), TCT (Ser), AGC (Ser), ACC (Thr), CCA (Pro), CCT (Pro), GCC (Ala), GGC (GIy), GTG (VaI), ATC (He), ATT (He), AAG (Lys), AAC (Asn), CAG (GIn), CAC (His), GAG (GIu), GAC (Asp), TAC (Tyr), TGC (Cys) and TTC (Phe) (Wada et al., 1990).
  • synthetic nucleic acid molecules of the invention have a codon composition which differs from a wild type nucleic acid sequence by having an increased number of the preferred human codons, e.g., CGC, CTG, TCT, AGC, ACC, CCA, CCT, GCC, GGC, GTG, ATC, ATT, AAG, AAC, CAG, CAC, GAG, GAC, TAC, TGC, TTC, or any combination thereof.
  • the preferred human codons e.g., CGC, CTG, TCT, AGC, ACC, CCA, CCT, GCC, GGC, GTG, ATC, ATT, AAG, AAC, CAG, CAC, GAG, GAC, TAC, TGC, TTC, or any combination thereof.
  • the nucleic acid molecule of the invention may have an increased number of CTG or TTG leucine-encoding codons, GTG or GTC valine-encoding codons, GGC or GGT glycine-encoding codons, ATC or ATT isoleucine-encoding codons, CCA or CCT proline-encoding codons, CGC or CGT arginine-encoding codons, AGC or TCT serine-encoding codons, ACC or ACT threonine-encoding codon, GCC or GCT alanine-encoding codons, or any combination thereof, relative to the wild-type nucleic acid sequence.
  • preferred C preferred C.
  • elegans codons include, but are not limited, to UUC (Phe), UUU (Phe), CUU (Leu), UUG (Leu), AUU (He), GUU (VaI), GUG (VaI), UCA (Ser), UCU (Ser), CCA (Pro), ACA (Thr), ACU (Thr), GCU (Ala), GCA (Ala), UAU (Tyr), CAU (His), CAA (GIn), AAU (Asn), AAA (Lys), GAU (Asp), GAA (GIu), UGU (Cys), AGA (Arg), CGA (Arg), CGU (Arg), GGA (GIy), or any combination thereof.
  • preferred Drosophilia codons include, but are not limited to, UUC (Phe), CUG (Leu), CUC (Leu), AUC (He), AUU (lie), GUG (VaI), GUC (VaI), AGC (Ser), UCC (Ser), CCC (Pro), CCG (Pro), ACC (Thr), ACG (Thr), GCC (Ala), GCU (Ala), UAC (Tyr), CAC (His), CAG (GIn), AAC (Asn), AAG (Lys), GAU (Asp), GAG (GIu), UGC (Cys), CGC (Arg), GGC (GIy), GGA (gly), or any combination thereof.
  • Preferred yeast codons include but are not limited to UUU (Phe), UUG (Leu), UUA (Leu), CCU (Leu), AUU (He), GUU (VaI), UCU (Ser), UCA (Ser), CCA (Pro), CCU (Pro), ACU (Thr), ACA (Thr), GCU (Ala), GCA (Ala), UAU (Tyr), UAC (Tyr), CAU (His), CAA (Gm), AAU (Asn), AAC (Asn), AAA (Lys), AAG (Lys), GAU (Asp), GAA (GIu), GAG (GIu), UGU (Cys), CGU (Tip), AGA (Arg), CGU (Arg), GGU (GIy), GGA (GIy), or any combination thereof.
  • nucleic acid molecules having an increased number of codons that are employed more frequently in plants have a codon composition which differs from a wild-type or parent nucleic acid sequence by having an increased number of the plant codons including, but not limited to, CGC (Arg), CTT (Leu), TCT (Ser), TCC (Ser), ACC (Thr), CCA (Pro), CCT (Pro), GCT (Ser), GGA (GIy), GTG (VaI), ATC (He), ATT (He), AAG (Lys), AAC (Asn), CAA (GIn), CAC (His), GAG (GIu), GAC (Asp), TAC (Tyr), TGC (Cys), TTC (Phe), or any combination thereof (Murray et al., 1989).
  • an optimized nucleic acid sequence encoding a hydrolase or fusion thereof has less than 100%, e.g., less than 90% or less than 80%, nucleic acid sequence identity relative to a non-optimized nucleic acid sequence encoding a corresponding hydrolase or fusion thereof.
  • an optimized nucleic acid sequence encoding DhaA has less than about 80% nucleic acid sequence identity relative to non-optimized (wild-type) nucleic acid sequence encoding a corresponding DhaA, and the DhaA encoded by the optimized nucleic acid sequence optionally has at least 85% amino acid sequence identity to a corresponding wild-type DhaA.
  • the activity of a DhaA encoded by the optimized nucleic acid sequence is at least
  • An exemplary optimized DhaA gene has the following sequence; hDhaA.v2.1-6F (FINAL, with flanking sequences)
  • the nucleic acid molecule or expression cassette may be introduced to a vector, e.g., a plasmid or viral vector, which optionally includes a selectable marker gene, and the vector introduced to a cell of interest, for example, a prokaryotic cell such as E. coli, Streptomyces spp., Bacillus spp., Staphylococcus spp. and the like, as well as eukaryotic cells including a plant (dicot or monocot), fungus, yeast, e.g., Pichia, Saccharomyces or Schizosaccharomyces, or mammalian cell.
  • a vector e.g., a plasmid or viral vector, which optionally includes a selectable marker gene
  • a cell of interest for example, a prokaryotic cell such as E. coli, Streptomyces spp., Bacillus spp., Staphylococcus spp. and the like, as well as
  • Preferred mammalian cells include bovine, caprine, ovine, canine, feline, non-human primate, e.g., simian, and human cells.
  • Preferred mammalian cell lines include, but are not limited to, CHO, COS, 293, HeIa, CV- 1, SH-SY5Y (human neuroblastoma cells), HEK293, and NIH3T3 cells.
  • the expression of the encoded mutant hydrolase may be controlled by any promoter capable of expression in prokaryotic cells or eukaryotic cells.
  • Preferred prokaryotic promoters include, but are not limited to, SP6, T7, T5, tac, hla, trp, gal, lac or maltose promoters.
  • Preferred eukaryotic promoters include, but are not limited to, constitutive promoters, e.g., viral promoters such as CMV, SV40 and RSV promoters, as well as regulatable promoters, e.g., an inducible or repressible promoter such as the tet promoter, the hsp70 promoter and a synthetic promoter regulated by CRE.
  • Preferred vectors for bacterial expression include pGEX-5X-3, and for eukaryotic expression include pCIneo-CMV.
  • the nucleic acid molecule, expression cassette and/or vector of the invention may be introduced to a cell by any method including, but not limited to, calcium-mediated transformation, electroporation, microinjection, lipofection, particle bombardment and the like.
  • Functional Groups Functional groups useful in the substrates and methods of the invention are molecules that are detectable or capable of detection.
  • a functional group within the scope of the invention is capable of being covalently linked to one reactive substituent of a bifunctional linker or a substrate for a hydrolase, and, as ' part of a substrate of the invention, has substantially the same activity as a functional group which is not linked to a substrate found in nature and is capable of forming a stable complex with a mutant hydrolase.
  • Functional groups thus have one or more properties that facilitate detection, and optionally the isolation, of stable complexes between a substrate having that functional group and a mutant hydrolase.
  • functional groups include those with a characteristic electromagnetic spectral property such as emission or absorbance, magnetism, electron spin resonance, electrical capacitance, dielectric constant or electrical conductivity as well as functional groups which are ferromagnetic, paramagnetic, diamagnetic, luminescent, electrochemiluminescent, fluorescent, phosphorescent, chromatic, antigenic, or have a distinctive mass.
  • a functional group includes, but is not limited to, a nucleic acid molecule, i.e., DNA or RNA, e.g., an oligonucleotide or nucleotide, such as one having nucleotide analogs, DNA which is capable of binding a protein, single stranded DNA corresponding to a gene of interest, RNA corresponding to a gene of interest, niRNA which lacks a stop codon, an aminoacylated initiator tRNA, an aminoacylated amber suppressor tRNA, or double stranded RNA for RNAi, a protein, e.g., a luminescent protein, a peptide, a peptide nucleic acid, an epitope recognized by a ligand, e.g., biotin or streptavidin, a hapten, an amino acid, a lipid, a lipid bilayer, a solid support, a fluorophore, a chromophore
  • a variety of molecules with physical properties based on the interaction and response of the molecule to electromagnetic fields and radiation can be used to detect complexes between a mutant hydrolase and a substrate of the invention. These properties include absorption in the UV, visible and infrared regions of the electromagnetic spectrum, presence of chromophores which are Raman active, and can be further enhanced by resonance Raman spectroscopy, electron spin resonance activity and nuclear magnetic resonances and molecular mass, e.g., via a mass spectrometer.
  • linker refers to a group or groups that covalently attach one or more functional groups to a substrate which includes a reactive group or to a reactive group.
  • a linker as used herein, is not a single covalent bond.
  • the structure of the linker is not crucial, provided it yields a substrate that can be bound by its target enzyme.
  • the linker can be a divalent group that separates a functional group (R) and the reactive group by about 5 angstroms to about 1000 angstroms, inclusive, in length.
  • linkers include linkers that separate R and the reactive group by about 5 angstroms to about 100 angstroms, as well as linkers that separate R and the substrate by about 5 angstroms to about 50 angstroms, by about 5 angstroms to about 25 angstroms, by about 5 angstroms to about 500 angstroms, or by about 30 angstroms to about 100 angstroms.
  • the linker is a peptide.
  • the linker is a divalent branched or unbranched carbon chain comprising from about 2 to about 30 carbon atoms, which chain optionally includes one or more (e.g., 1, 2, 3, or 4) double or triple bonds, and which chain is optionally
  • the linker is a divalent branched or unbranched carbon chain comprising from about 2 to about 30 carbon atoms, which chain optionally includes one or more (e.g., 1, 2, 3, or 4) double or triple bonds.
  • the linker is a divalent branched or unbranched carbon chain comprising from about 2 to about 20 carbon atoms, which chain optionally includes one or more (e.g., 1, 2, 3, or 4) double or triple bonds.
  • the linker comprises one or more divalent heteroaryl groups.
  • aromatic includes aryl and heteroaryl groups.
  • Aryl denotes a phenyl radical or an ortho-fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic.
  • Heteroaryl encompasses a radical attached via a ring carbon of a monocyclic aromatic ring containing five or six ring atoms consisting of carbon and one to four heteroatoms each selected from the group consisting of non- peroxide oxygen, sulfur, and N(X) wherein X is absent or is H, O, (Q-C ⁇ alkyl, phenyl or benzyl, as well as a radical of an ortho-fused bicyclic heterocycle of about eight to ten ring atoms derived therefrom, particularly a benz-derivative or one derived by fusing a propylene, trimethylene, or tetramethylene diradical thereto.
  • amino acid when used with reference to a linker, comprises the residues of the natural amino acids (e.g., Ala, Arg, Asn, Asp, Cys, GIu, GIn, GIy, His, HyI, Hyp, He, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and VaI) in D or L form, as well as unnatural amino acids (e.g., phosphoserine, phosphothreonine, phosphotyrosine, hydroxyproline, gamma-carboxyglutamate; hippuric acid, octahydroindole-2-carboxylic acid, statine, l,2,3,4,-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, citruline, ⁇ -methyl-alanine, para-benzoylphenylalanine, phenylglycine, propargylglycine,
  • the term also includes natural and unnatural amino acids bearing a conventional amino protecting group (e.g., acetyl or benzyloxycarbonyl), as well as natural and unnatural amino acids protected at the carboxy terminus (e.g. as a (Ci-C 6 )alkyl, phenyl or benzyl ester or amide).
  • a conventional amino protecting group e.g., acetyl or benzyloxycarbonyl
  • natural and unnatural amino acids protected at the carboxy terminus e.g. as a (Ci-C 6 )alkyl, phenyl or benzyl ester or amide.
  • Other suitable amino and carboxy protecting groups are known to those skilled in the art (see for example, Greene, Protecting Groups In Organic Synthesis; Wiley: New York, 1981, and references cited therein).
  • An amino acid can be linked to another molecule through the carboxy terminus, the amino terminus, or through any other convenient point of attachment, such as, for
  • peptide when used with reference to a linker, describes a sequence of 2 to 25 amino acids (e.g. as defined hereinabove) or peptidyl residues.
  • the sequence may be linear or cyclic.
  • a cyclic peptide can be prepared or may result from the formation of disulfide bridges between two cysteine residues in a sequence.
  • a peptide can be linked to another molecule through the carboxy terminus, the amino terminus, or through any other convenient point of attachment, such as, for example, through the sulfur of a cysteine.
  • a peptide comprises 3 to 25, or 5 to 21 amino acids.
  • Peptide derivatives can be prepared as disclosed in U.S.
  • a substrate of the invention for a dehalogenase which has a linker has the formula (I):
  • A-X is a haloaliphatic or haloaromatic substrate for a dehalogenase.
  • 2-(2- ⁇ 2-[2-(2-Chloroethoxy)-ethoxy]-ethoxy ⁇ -ethyl)-isoindole-l,3-dione 2-(2- ⁇ 2-[2-(2-Hydroxy-ethoxy)-ethoxy]-ethoxy ⁇ -ethyl)-isoindole-l,3-dione (0.5 g, 1.55 mmol) was prepared by the method of Nielsen, J. and Janda, K.D. (Methods: A Companion to Methods in Enzymology 6, 361-371 (1994)).
  • the intermediate compound 2- ⁇ 2-[4-(2-chloroethyl)phenoxy]- ethoxy ⁇ ethanaminium chloride which can be used to prepare substrates of the invention can be prepared as illustrated below and as described in the following steps a-c. a. tert-bvLtyl 2- ⁇ 2-[4-(2-hydroxyethyI)phenoxy]etkoxy ⁇ - ethylcarbamate.
  • the DCM was washed with brine, dried with sodium sulfate, filtered, and evaporated to yield 380 mg (58% yield). Used without further purification.
  • XXXIV of the invention were prepared. 2- ⁇ 2-[4-(2-chIoroethyl)phenoxy]ethoxy ⁇ ethyl-tetramethyIrhodamine-6- carboxamide.
  • the title compound was prepared using the general methodology starting with 6-carboxytetramethylrhodamine succinimidyl ester. Purification was accomplished using preparative scale HPLC. Separation of structural isomers was realized.
  • This compound is referred to herein as carboxytetramethylrhodamine-p-phenethyl-Cl.
  • a substrate which includes a functional group with optical properties is employed with a mutant hydrolase to label a sample.
  • a substrate is combined with the sample of interest comprising the mutant hydrolase for a period of time sufficient for the mutant hydrolase to bind the substrate, after which the sample is illuminated at a wavelength selected to elicit the optical response of the functional group.
  • the sample is washed to remove residual, excess or unbound substrate.
  • the labeling is used to determine a specified characteristic of the sample by further comparing the optical response with a standard or expected response.
  • the mutant hydrolase bound substrate is used to monitor specific components of the sample with respect to their spatial and temporal distribution in the sample.
  • the mutant hydrolase bound substrate is employed to determine or detect the presence or quantity of a certain molecule.
  • the mutant hydrolase bound substrate is used to analyze the sample for the presence of a molecule that responds specifically to the functional group.
  • a mutant hydrolase bound to a fluorescent substrate does not require a native protein structure to retain fluorescence.
  • the mutant hydrolase may be detected, for example, in denaturing electrophoretic gels, e.g., SDS-PAGE, or in cells fixed with organic solvents, e.g., paraformaldehyde. Fragments of the mutant hydrolase that contain the reactive nucleophilic amino acid may also be detected by the bound fluorophore, for example, to monitor proteolytic processes.
  • a detectable optical response means a change in, or occurrence of, a parameter in a test system that is capable of being perceived, either by direct observation or instrumentally.
  • detectable responses include the change in, or appearance of, color, fluorescence, reflectance, chemiluminescence, light polarization, light scattering, or X-ray scattering.
  • the detectable response is a change in fluorescence, such as a change in the intensity, excitation or emission wavelength distribution of fluorescence, fluorescence lifetime, fluorescence polarization, or a combination thereof.
  • the detectable optical response may occur throughout the sample comprising a mutant hydrolase or a fusion thereof or in a localized portion of the sample comprising a mutant hydrolase or a fusion thereof. Comparison of the degree of optical response with a standard or expected response can be used to determine whether and to what degree the sample comprising a mutant hydrolase or a fusion thereof possesses a given characteristic.
  • the functional group is a ligand for an acceptor molecule.
  • the substrate comprises a functional group that is a member of a specific binding pair (a ligand)
  • the complementary member (the acceptor) or the substrate may be immobilized on a solid or semi-solid surface, such as a polymer, polymeric membrane or polymeric particle (such as a polymeric bead), or both may be in solution.
  • protein-protein interactions may be detected using an electrical conducting substrate coated surface.
  • Ligands for which naturally occurring receptors exist include natural and synthetic proteins, including avidin and streptavidin, antibodies, enzymes, and hormones; nucleotides and natural or synthetic oligonucleotides, including primers for RNA and single- and double-stranded DNA; lipids; polysaccharides and carbohydrates; and a variety of drugs, including therapeutic drugs and drugs of abuse and pesticides.
  • the functional group is a chelator of calcium, sodium, magnesium, potassium, or another biologically important metal ion
  • the substrate comprising such a functional group functions as an indicator of the ion.
  • such a substrate may act as a pH indicator.
  • the detectable optical response of the ion indicator is a change in fluorescence.
  • a sample comprising a mutant hydrolase or a fusion thereof is typically labeled by passive means, i.e., by incubation with the substrate.
  • any method of introducing the substrate into the sample comprising a mutant hydrolase or a fusion thereof such as microinjection of a substrate into a cell or organelle, can be used to introduce the substrate into the sample comprising a mutant hydrolase or a fusion thereof.
  • the substrates of the present invention are generally non-toxic to living cells and other biological components, within the concentrations of use.
  • a sample comprising a mutant hydrolase or a fusion thereof can be observed immediately after contact with a substrate of the invention.
  • the sample comprising a mutant hydrolase or a fusion thereof is optionally combined with other solutions in the course of labeling, including wash solutions, permeabilization and/or fixation solutions, and other solutions containing additional detection reagents. Washing following contact with the substrate generally improves the detection of the optical response due to the decrease in non-specific background after washing. Satisfactory visualization is possible without washing by using lower labeling concentrations.
  • fixatives and fixation conditions are known in the art, including formaldehyde, paraformaldehyde, formalin, glutaraldehyde, cold methanol and 3: 1 methanol: acetic acid.
  • Fixation is typically used to preserve cellular morphology and to reduce biohazards when working with pathogenic samples. Selected embodiments of the substrates are well retained in cells. Fixation is optionally followed or accompanied by permeabilization, such as with acetone, ethanol, DMSO or various detergents, to allow bulky substrates of the invention, to cross cell membranes, according to methods generally known in the art.
  • the use of a substrate may be combined with the use of an additional detection reagent that produces a detectable response due to the presence of a specific cell component, intracellular substance, or cellular condition, in a sample comprising a mutant hydrolase or a fusion thereof. Where the additional detection reagent has spectral properties that differ from those of the substrate, multi-color applications are possible.
  • the sample comprising a mutant hydrolase or a fusion thereof is illuminated with a wavelength of light that results in a detectable optical response, and observed with a means for detecting the optical response. While some substrates are detectable colorimetrically, using ambient light, other substrates are detected by the fluorescence properties of the parent fluorophore.
  • the substrates including substrates bound to the complementary specific binding pair member, display intense visible absorption as well as fluorescence emission.
  • Selected equipment that is useful for illuminating the substrates of the invention includes, but is not limited to, hand-held ultraviolet lamps, mercury arc lamps, xenon lamps, argon lasers, laser diodes, and YAG lasers. These illumination sources are optionally integrated into laser scanners, fluorescence microplate readers, standard or mini fluorometers, or chromatographic detectors.
  • This colorimetric absorbance or fluorescence emission is optionally detected by visual inspection, or by use of any of the following devices: CCD cameras, video cameras, photographic film, laser scanning devices, fluorometers, photodiodes, quantum counters, epifluorescence microscopes, scanning microscopes, flow cytometers, fluorescence microplate readers, or by means for amplifying the signal such as photomultiplier tubes.
  • the instrument is optionally used to distinguish and discriminate between the substrate comprising a functional group which is a fluorophore and a second fluorophore with detectably different optical properties, typically by distinguishing the fluorescence response of the substrate from that of the second fluorophore.
  • examination of the sample comprising a mutant hydrolase or a fusion thereof optionally includes isolation of particles within the sample comprising a mutant hydrolase or a fusion thereof based on the fluorescence response of the substrate by using a sorting device.
  • a mutant hydrolase and a corresponding substrate which includes a functional group are employed to label a cell, e.g., a cell in an organism such as a cell in transgenic animal, a cell in an animal administered cells comprising the mutant hydrolase and/or substrate of the invention, or cells in culture, or a cellular component.
  • cells are contacted with a vector encoding the mutant hydrolase, such as one encoding a fusion between the mutant hydrolase and a nuclear localization signal.
  • the expression of the vector in the cell which may be in a transgenic animal or administered to an animal, may be transient, regulatable or stable. Then the cell or an animal comprising the cell is contacted with a substrate of the invention recognized by the mutant hydrolase.
  • cells are concurrently contacted with the vector and the substrate. Then the presence or location of the functional group in the animal, cell, a lysate thereof, or a subcellular fraction thereof, is detected or determined.
  • a mutant hydrolase and a corresponding substrate which includes a functional group comprising a triplet sensitizer are employed to selectively inactivate or destroy a molecule and/or cellular activity, e.g., in a cell.
  • the sample is exposed to UV light.
  • a hydrolase substrate may be attached to an amino acid or a tRNA, e.g., an aminoacylated tRNA such as an aminoacylated initiator methionyl tRNA for N-terminal modification of in vitro synthesized proteins, to an amber suppressor tRNA for C-terminal labeling of proteins, including amino acids attached to a tRNA using a mutant tRNA synthetase.
  • a hydrolase substrate may also be attached to a protein by an intein- mediated method.
  • the protein of interest is expressed as a fusion protein with a carboxyl terminal intein domain, preferably a "mini-intein” lacking a homing endonuclease domain, and more preferably the Mycobacterium xenopi (Mxe) GyrA mini-intein.
  • a carboxyl terminal intein domain preferably a "mini-intein” lacking a homing endonuclease domain, and more preferably the Mycobacterium xenopi (Mxe) GyrA mini-intein.
  • cysteine-hydrolase substrate e.g., cysteine-haloalkane
  • a cysteine-hydrolase substrate e.g., cysteine-haloalkane
  • proteins can be expressed from cDNA or mRNA without the need for making fusion proteins and those proteins can be pu ⁇ fied using a mutant hydrolase.
  • protein microarrays can be made from the in vitro translated proteins, for instance, using immobilized mutant hydrolase, without the need for a fusion tag, and those proteins as well as proteins which interact with those proteins, isolated Further, the use of a substrate which includes a fluorophore allows for the rapid detection, as well as the purification, of expressed proteins.
  • a substrate which includes a methionine or other naturally occurring or nonnaturally occurring amino acid may be employed, and newly synthesized proteins as well as protems which interact with those proteins, can be purified optionally using an immobilized muant hydrolase, without the need for a fusion tag.
  • This approach may also be used for isolating marker proteins for differential protein expression analysis, and also with mass spectrometry. Multiplexing is also possible using substrates with different fluorophores.
  • a protein microarray may be prepared in which a mutant hydrolase is immobilized onto a surface of a solid support and a substrate of the invention modified to include one or more functional groups which bind a single protein, a functional or structural class of proteins, or proteins in general, for protein immobilization ( Figure 57).
  • fusion protein systems such as a thioredoxin patch, intein based approaches or other methods are employed to immobilize a mutant hydrolase onto a solid surface. Modified substrates for immobilizing proteins are then added.
  • the substrate may be modified with succinimidyl ester/aldehyde (for general immobilization of proteins), glutathione (for immobilizing GST fusion proteins), NTA or metal (for immobilizing His-tagged proteins), or specific ligands for immobilizing specific classes of proteins.
  • an enzyme substrate or an inhibitor of an enzyme linked to a hydrolase substrate may be used for immobilizing a particular class of enzymes, e.g., caspases or reverse transcriptases, or a DNA which binds certain proteins linked to a hydrolase substrate may be used to prepare a protein microarray for DNA binding proteins, e.g., for developing chip based assays.
  • a mutant hydrolase can be immobilized on magnetic or non-magnetic particles, e.g., MagneSil particles. These methods can avoid preparing new fusion proteins, e.g., a new library, as only a substrate for a protein(s) of interest needs to be prepared, for instance, for GST fusion libraries.
  • the substrate may be immobilized onto a surface to allow stable attachment of mutant hydrolases, and fusions thereof, onto the surface.
  • the mutant hydrolases may be obtained from living cells or by cell- free methods, e.g., coupled transcription and translation in a cellular lysate.
  • the bound proteins may be useful for analyzing characteristics such as binding to other molecules or enzymatic activity. It may also be useful for stably immobilizing an enzymatic activity for bioconversions or detection capabilities. It may also be useful for stably immobilizing a specific binding activity for purification or selective adsorption capabilities.
  • Multiple substrates may be immobilized onto the surface, either at different locations or as a mixture, to allow attachment of multiple mutant hydrolases.
  • the substrate may also be immobilized with other binding molecules such as biotin or para-substituted benzylguanine.
  • a fusion to a mutant hydrolase may be used to identify proteins that bind to the fusion.
  • Proteins that bind to the fusion protein may be separated from other unbound proteins by binding the mutant hydrolase to a substrate immobilized onto a surface. By this means, the unbound proteins in solution may be washed from the stationary bound proteins.
  • Other molecules that bind to the fusion protein such as nucleic acids or small molecules, may also be identified by this method.
  • various chemical cross-linking methods may be employed to covalently interconnect the bound molecules. Reversible cross-linkers are preferred, so that the bound molecules may be subsequently unbound for analysis, e.g., identification and/or isolation.
  • a mutant hydrolase with a substrate, it may be necessary to inactivate remaining unreacted substrate in the mixture. This may be done by adding wild-type hydrolase to the mixture to convert the remaining unreacted substrate into product.
  • unreacted chloroalkane substrate may be converted to the corresponding alcohol by addition of a wild-type or other catalytically competent dehalogenase.
  • the unreacted substrate may be free in solution or bound to a surface. If bound to a surface, addition of a catalytically competent hydrolase would convert the substrate its corresponding product, thereby preventing further binding of mutant hydrolase to the surface.
  • the substrates and mutant hydrolases of the invention may also be used in tandem affinity purification (TAP), a method for the purification of proteins or protein complexes, which uses two consecutive affinity purification steps.
  • TAP tandem affinity purification
  • Each purification step employs a ligand for an affinity tag, for instance, His-tag, a GST-tag, a Strep-tag, a biotin-tag, an immunoglobulin binding domain, e.g., an IgG binding domain, a calmodulin binding peptide and the like, which is fused to a protein of interest.
  • a mutant hydrolase of the invention may be employed as an affinity tag.
  • a fusion containing a mutant hydrolase and calmodulin binding peptide (CBP) or protein complexes therewith may be purified by calmodulin attached to a solid phase followed by a hydrolase substrate attached to a solid phase.
  • the purified proteins or complexes may then be analyzed by Western blotting or mass spectrometry.
  • proteins or protein complexes may be purified from various types of host cells, such as bacteria, Drosophila, plant, mammalian cells, as well as cell free protein expression systems, and can identify protein-protein interactions.
  • a mutant hydrolase and hydrolase substrate in TAP allows for the analysis of proteins in real-time, followed by TAP at various time points or after various drug treatments. Since the mutant hydrolase fusion is attached covalently to the substrate, purified protein complexes will not contain the hydrolase.
  • a biotinylated hydrolase substrate binds avidin labeled antibodies which bind to an antigen. This complex may be subjected to immunoprecipitation, e.g., by using eppendorff tubes containing immobilized mutant hydrolase ( Figure 58). To detect some molecules, a solution (tree) or immobilized system may be employed.
  • a hydrolase substrate modified with a small molecule or a compound could be used for detecting modifications of the attached small molecule or a compound.
  • a hydrolase substrate modified with a lipid such as phosphatidylinositol 3 (PI3) kinase
  • PI3 phosphatidylinositol 3
  • a hydrolase substrate modified with a lipid such as phosphatidylinositol is contacted with a sample containing a PI3 kinase, which phosphorylates phosphatidylinositol.
  • the resulting modified hydrolase substrate is then covalently attached to the hydrolase.
  • the phosphorylated phosphatidylinositol is detected by electrophoretic or fluorescencemethods.
  • Electrophoretic detection methods include performing a standard kinase asssay using radiolabeld nucleotides such as gamma 32 PATP followed by autoradiography or by fluorescence detection using fluorescently labeled NTA complexed with Ga 3+ or Fe 3+ . Specific binding of Ga 3+ or Fe 3+ complexed NTA to phosphate groups allows for the electrophoretic detection of phosphorylated phosphatidylinositol. PI3 kinase activity may also be detected in free solution using FRET or fluorescence polarization (FP). For this, a fluorescently labeled, phosphatidylinositol containing hydrolase substrate may be used.
  • radiolabeld nucleotides such as gamma 32 PATP
  • fluorescence detection using fluorescently labeled NTA complexed with Ga 3+ or Fe 3+ .
  • Specific binding of Ga 3+ or Fe 3+ complexed NTA to phosphate groups allows for the electrophoretic detection of phosphorylated phosphat
  • Phosphorylated phosphatidylinositol is detected using a different fluorophore labeled NTA complexed with Ga 3+ or Fe 3+ .
  • fluorescence polarization FP
  • a nonfluorescent phosphatidylinositol containing hydrolase substrate is added to a test sample, followed by the addition of Ga 3+ or Fe 3+ .
  • the resulting hydrolase substrate is added to immobilized or free mutant hydrolase. Fluorescence polarization is assayed using fluorescence labeled NTA, which binds to Ga 3+ or Fe 3+ .
  • a hydrolase substrate which includes fluorescently labeled cAMP and a different fluorophore may be employed.
  • Hydrolysis of cAMP indicates phosphodiesterase activity.
  • Phosphodiesterase activity can be detected using FRET after capturing the substrate with free or immobilized dehalogenase, e.g., in protein microarray format.
  • Nucleic acid molecules attached to a hydrolase substrate may be employed to purify or display other nucleic acid molecules, proteins or protein based complexes.
  • a hydrolase substrate is bound at the 3' end of a mRNA without a stop codon. 1 he substrate is added to an in vitro translation mixture and the resulting protein-DNA-mRNA complex is purified using immobilized mutant hydrolase.
  • a hydrolase substrate which includes fluorophore labeled DNA or RNA, e.g., a fluorophore labeled single stranded DNA, which binds a gene of interest, and a different fluorophore or quencher, is used to isolate, detect or display that gene from a complex mixture using fluorescence based methods such as FRET.
  • fluorescence based methods such as FRET.
  • the substrates and mutant hydrolases of the invention may be employed in various formats to detect c AMP ( Figures 59 A-B).
  • fluorescence quenching is used with two fusion proteins and two substrates.
  • One substrate includes a fluorophore and the other includes quencher dye for the fluorophore.
  • One fusion protein includes a mutant hydrolase and the regulatory subunit of PKA, and the other includes a mutant hydrolase and PKA catalytic subunit ( Figure 59A).
  • Each fusion protein is contacted with one of the substrates and then the complexes are mixed together.
  • the quencher dye is no longer in close proximity to the fluorophore.
  • cAMP is measured by measuring fluorescence.
  • two hydrolase substrates ' each with a different fluorophore are employed and cAMP is measured by measuring FRET.
  • one fusion protein includes a first mutant hydrolase and the regulatory subunit of PKA, and the other fusion protein includes a protein that is different than the first mutant hydrolase (a second protein) and binds a second substrate and the PKA catalytic subunit.
  • the mutant hydrolase binds a hydrolase substrate that includes at least one fluorophore.
  • the second protein binds a second substrate, which is modified with a quencher for the at least one fluorophore that does not affect the substrate's binding to the second protein.
  • the second protein may be GST, thioredoxin, AGT, a different mutant hydrolase which is specific for a different substrate than the first mutant hydrolase, a mutant hydrolase that is capable of binding the same substrate as the first mutant hydrolase, or other substrate binding protein.
  • Each fusion protein is contacted with the respective substrate, the complexes are mixed together, and cAMP is measured by measuring fluorescence.
  • the quencner is no longer m close proximity to the fluorophore
  • the second piotem binds a second substrate which is modified with a different fluorophore than the fluorophore linked to the hydrolase substrate, which different fluorophore does not affect the binding of the second substrate to the second protein
  • Each fusion protein is contacted with its respective substrate, the complexes are mixed together, and FRET employed to measuie cAMP In the presence of cAMP, the two fluorophores are no longer in close proximity
  • one fusion protein includes a mutant hydrolase and the regulatory subumt of PKA, and the other fusion protein includes a fluorescent protein and the PKA catalytic subumt Fluorescent proteins include but are not limited to GFP, YFP, EGFP, and DsRed Each fusion protein is contacted with its respective substrate and then the complexes are mixed together In the presence of cAMP, the fluorescence protein and the mutant hyd
  • a mutant hydrolase and substrate may be employed in molecular imprinting, a technique devised to generate a polymeric material that is analyte specific Molecular imprinting is a process for prepa ⁇ ng polymers that are selective for a particular compound (the print molecule) (Arshady et al , 1981)
  • the technique involves (1) prearranging the print molecule and the monomers and allowing complementary interactions (non-covalent or reversible covalent) to develop, (2) polymerizing around the print molecule-monomer complex, and (3) removing the print molecule from the polymer by extraction Polymerization thus preserves the complementa ⁇ ty to the print molecule and the polymer will selectively adsorb the p ⁇ nt molecule
  • MIPS Molecularly imprinted polymers
  • An example of a functional group that binds reversibly to a protein is a hapten that binds to an antibody, e.g., a single-chain antibody (scFv).
  • An example of a functional group that binds covalently to another protein is a chloroalkane that binds to a mutant dehalogenase, or a para- substituted benzylguanine that binds to O-alkylguanine-DNA alkyltransferase (AGT).
  • a first fusion protein comprising a mutant hydrolase may be bound to a second protein as a means for implementing or modulating a biochemical or biological process.
  • gene transcription may be modulated by a DNA binding protein fused to a mutant hydrolase bound to a transcriptional activator, e.g., VP 16.
  • gene transcription would be increased by addition of a substrate causing the mutant hydrolase fused to the DNA binding protein to bind to the transcriptional activator.
  • the activity of a protein in a cell may be modulated by its location(s) within the cell.
  • the activity of a protein may be changed by binding the protein to a mutant hydrolase fused to a second protein, which upon binding redirects or preferentially redistributes the protein to a different subcellular compartment.
  • An example may be a transcription factor located predominately in the non- nuclear portion of a cell, where upon binding to a mutant hydrolase fused to a nuclear targeting sequence, results in the transcription factor moving to the nucleus.
  • the addition of a substrate to cause binding of the transcription factor to the mutant hydrolase may thereby modulate gene expression mediated by the transcription factor.
  • the substrate may have multiple reactive groups to allow interconnection of mutant hydrolases.
  • interconnection of the mutant hydrolases may yield a multivalent binding complex.
  • Such multivalent complexes may have useful properties, such as higher apparent binding efficiency (e.g., higher avidity).
  • interconnecting two or more single-chain antibodies may yield more efficient binding to the corresponding antigen.
  • the DNA binding domain of a lambda phage repressor protein fused to a mutant hydrolase may bind more efficiently to DNA upon addition of a substrate to interconnect the mutant hydrolases.
  • Multivalent complexes having different binding proteins fused to mutant hydrolases can allow different molecules, e.g., antigens, to be bound together via the complex.
  • Fusing mutant hydrolases together may allow multiple substrates to bind to a single protein. These substrates may be the same or different. By this means, the fused mutant hydrolases may serve as a bridging molecule between the substrates. This may be useful to covalently interconnect molecules, such as functional groups, surfaces, or other molecules. For example, a substrate bound to a surface may be covalently attached to a polynucleotide bound to a substrate by using a bi-valent fused mutant hydrolase. Hetero-multivalent molecules may be made by fusing different mutant hydrolases, or fusing mutant hydrolases to other protein(s) capable of making stable covalent bonds, e.g., AGT.
  • a substrate includes more than one functional group, e.g., an optically detectable molecule and a ligand for an acceptor molecule, two different proteins, e.g., AGT and a fluorescent protein or a luciferase, an optically detectable molecule and a protease recognition site, or an optically detectable molecule and a protease recognition site, and a quencher of the optically detectable molecule.
  • a substrate of the invention may include a fluorophore, a protease recognition site and a quencher molecule. The substrate is taken up by a cell which expresses the mutant hydrolase.
  • the quencher In the presence of the protease, the quencher is removed from the substrate, resulting in a fluorescence signal.
  • the use of such a substrate can yield a real-time assay for the protease.
  • the mutant may also be used for the detection of infectious agents and thus may be employed in clinical diagnostic applications as well as to detect bioweapons.
  • Other formats may be used to detect proteases such as caspases or a proteosome, e.g., the 2OS proteosome may be detected (or isolated) with a branched peptide substrate.
  • a gene for a mutant hydrolase or another reporter protein, e.g., a luciferase is used in a mammalian cell based expression system.
  • a protease e.g., a caspase, recognition site is introduced into a protein which is a transcription repressor protein, e.g., a tet repressor protein or a lac repressor protein.
  • a protease recognition site is introduced into a loop region of the repressor protein or another region that does not inhibit the repressor function for the protein.
  • a vector which includes a promoter linked to DNA which binds the transcription repressor protein linked to the reporter gene is introduced to a cell which contains the modified transcription repressor protein. In absence of the protease, the modified transcription repressor protein inhibits the expression of the reporter gene.
  • the modified transcription repressor protein gene and/or the reporter gene are stably transfected into cells.
  • Such an assay may be used in conjunction with other assays, including those using a different reporter gene and/or for detecting a different molecule, for instance, a different protease, for multiplexing.
  • the assay may also be used to detect infectious agents, e.g., for clinical diagnostic applications, as well as to detect bioweapons.
  • a fusion of a mutant hydrolase and another protein is employed for chromatin immunoprecipitation.
  • a fusion comprising a mutant hydrolase and a DNA binding protein is expressed in a cell.
  • cells are fixed, sonicated and chromatin-hybrid protein complexes are isolated with a solid support having a hydrolase substrate or cells are lysed by sonication, and chromatin complexes are isolated by using a hydrolase substrate attached to a solid support. Unbound complexes or proteins are removed by washing followed by crosslinking the fusion protein to the chromatin or hydrolase substrate comprising a functional group, such as biotin, is added to the cells and incubated for a certain period of time. Cells are then fixed, sonicated and the chromatin complexes isolated with a solid support, e.g., one linked to streptavidin. An amplification reaction is employed to characterize the isolated chromatin.
  • a fusion of a mutant hydrolase and a nucleic acid binding protein is employed in an in vitro nucleic acid binding assay.
  • the fusion is immobilized onto a solid phase which contains a hydrolase substrate.
  • Cell lysates or purified nucleic acids are incubated the immobilized fusion protein and bound nucleic acids are detected by gel electrophoresis or a polymerase reaction.
  • the fusion is immobilized onto an electrochemically sensitive surface containing a hydrolase substrate. Nucleic acid binding is determined by an electrochemical alteration.
  • three vectors are employed: one vector expresses a GAL4, a protease recognition site, and VP 16 fusion; a second vector includes a promoter linked to a GAL4 binding site linked to a transcription repressor protein gene; and a third vector which includes a promoter linked to a transcription repressor protein binding site(s) linked to the reporter gene ( Figure 60B). Binding of the GAL4 fusion to the G AL4 binding site results in the constitutive transcriptional activation of RNA polymerase. When the transcription repressor protein is being constitutively expressed, the expression of the reporter gene is inhibited.
  • GAL4 and VP 16 are separated and the transcription repressor protein is not synthesized. This results in the expression of the reporter gene.
  • a split ubiquitin see U.S. Patent No. 5,503,977
  • adenyl cyclase, guanyl cyclase and/or modulator thereof see U.S. Patent No. 6,333,154
  • Such a system may be used for multiplexed assays using a combination of two or more different reporters such as luciferase and GFP or luciferase and a mutant hydrolase, multiplexed assays for proteases, e.g., using combinations of two or more protease recognition sites, for protease, e.g., caspase, inhibitor screening assays.
  • the assay may be used to detect infectious agents, for instance, in clinical diagnostic applications as well as to detect bioweapons.
  • a cell based assay that employs reporters such as a mutant hydrolase or luciferase with short or shortened half-lives due to the presence of degradation/instability domains (a "protein destabilization sequence") is employed to detect one or more proteases ( Figure 60C).
  • a protease e.g., a caspase, site is introduced between the reporter protein and the protein destabilization domain(s).
  • the reporter protein is rapidly degraded.
  • the destabilization domain is removed resulting in a reporter protein with a longer half-life.
  • Such a system may be used for multiplexed assays using a combination of two or more different reporters such as luciferase and GFP or luciferase and mutant hydrolase, multiplexed assays using a combination of two or more proteases, or for protease or caspase inhibitor screening assays.
  • reporters such as luciferase and GFP or luciferase and mutant hydrolase
  • multiplexed assays using a combination of two or more proteases or for protease or caspase inhibitor screening assays.
  • intracellular movements may be monitored using a fusion of the mutant hydrolase of the invention.
  • beta-arrestin is a regulator of G-protein coupled receptors, that moves from the cytoplasm to the cell membrane when it is activated.
  • a cell containing a fusion of a mutant hydrolase and beta-arrestin and a substrate of the invention allows the detection of the movement of beta-arrestin from the cytoplasm to the cell membrane as it associates with activated G-protein coupled receptors.
  • the assay may be used to detect infectious agents, and so may be employed in clinical diagnostic applications as well as to detect bioweapons.
  • a fusion of a mutant hydrolase and another reporter protein e.g., a luciferase
  • another reporter protein e.g., a luciferase
  • This fusion protein is immobilized onto a solid support and used for the detection of proteases in a sample.
  • a solid phase with the fusion protein is incubated with test sample lysate(s) and/or isolated protease(s). After a certain period of incubation, the lysate is removed and assayed for the presence of the reporter protein.
  • the reporter protein e.g., luciferase
  • This assay may be used in a protein microarray or a multi-well format and in conjuction with other assays, including those using a different reporter gene and/or for detecting a different molecule, for instance, a different protease, for multiplexing.
  • the method could also be used for the detection of infectious agents, and thus useful for clinical diagnostic applications, as well as for the detection of bioweapons.
  • FRET may be employed with a fusion of the mutant hydrolase and a fluorescent protein, e.g., GFP, or a fusion with a protein that binds fluorescent molecules, e.g., O-alkylguanine-DNA alkyltransferase (AGT) (Keppler et al, 2003).
  • a fusion of a mutant hydrolase and a protein of interest and a second fusion of a fluorescent protein and a molecule suspected of interacting with the protein of interest may be employed to study the interaction of the protein of interest with the molecule, e.g., using FRET.
  • One cell may contain the fusion of a mutant hydrolase and a protein of interest while another cell may contain the second fusion of a fluorescent protein and a molecule suspected of interacting with the protein of interest.
  • a population with those two cells may be contacted with a substrate and an agent, e.g., a drug, after which the cells are monitored to detect the effect of agent administration on the two populations.
  • a fusion of a mutant hydrolase and a protein of interest which protein of interest interacts with a second protein and a second fusion comprising the second protein and a mutant hydrolase may be employed to study the interaction of the protein of interest and the second protein or to detect a molecule which interacts with one or both proteins and alters their interaction, e.g., PKA regulatory subunit, PKA catalytic subunit and cAMP.
  • two substrates with at least one different functional group may be employed.
  • the mutant hydrolase is fused to a fluorescent protein. The fusion protein can thus be detected in cells by detecting the fluorescent protein or by contacting the cells with a substrate of the invention and detecting the functional group in the substrate.
  • the detection of the fluorescent protein may be conducted before the detection of the functional group.
  • the detection of the functional group may be conducted before the detection of the fluorescent protein.
  • those cells can be contacted with additional substrates, e.g., those having a different functional group, and the different functional group in the cell detected, which functional group is covalently linked to mutant hydrolase not previously bound by the first substrate.
  • a fusion of a mutant hydrolase and a transcription factor may be employed to monitor activation of transcription activation pathways.
  • a fusion of a mutant hydrolase to a transcription factor present in the cytoplasm in an inactive form but which is translocated to the nucleus upon activation e.g., NF kappa Beta
  • biotin is employed as a functional group in a substrate and the fusion includes a mutant hydrolase fused to a protein of interest suspected of interacting with another molecule, e.g., a protein, in a cell.
  • a mutant hydrolase fused to a protein of interest suspected of interacting with another molecule, e.g., a protein, in a cell.
  • the use of such reagents permits the capture of the other molecule which interacts in the cell with the protein fused to the mutant hydrolase, thereby identifying and/or capturing (isolating) the interacting molecule(s).
  • the mutant hydrolase is fused to a protein that is secreted. Using that fusion and a substrate of the invention, the secreted protein may be detected and/or monitored. Similarly, when the mutant hydrolase is fused to a membrane protein that is transported between different vesicular compartments, in the presence of the substrate, protein processing within these compartments can be detected. In yet another embodiment, when the mutant hydrolase is fused to an ion channel or transport protein, or a protein that is closely associated with the channel or transport protein, the movement of ions across cell or organelle membranes can be monitored in the presence of a substrate of the invention which contains an ion sensitive fluorophore. Likewise, when the mutant hydrolase is fused to proteins associated with vesicals or cytoskeleton, in the presense of the substrate, transport of proteins or vesicals along cytoskeletal structures can be readily detected.
  • the functional group is a drug or toxin.
  • a drug or toxin By combining a substrate with such a functional group with a fusion of a mutant hydrolase and a targeting molecule such as an antibody, e.g., one which binds to an antigen associated with specific tumor cells, a drug or toxin can be targeted within a cell or within an animal.
  • the functional group may be a fluorophore which, when present in a substrate and combined with a fusion of a mutant hydrolase and a targeting molecule such as a single chain antibody, the targeting molecule is labeled, e.g., a labeled antibody for in vitro applications such as an ELISA.
  • a mutant hydrolase on the cell surface when fused to a protein expressed on the cell surface, when combined with a substrate of the invention, e.g., one which contains a fluorophore, may be employed to monitor cell migration (e.g., cancer cell migration) in vivo or in vitro.
  • the substrate of the invention is one that has low or no permeability to the cell membrane.
  • such a system can he used to monitor the effect of different agents, e.g., drugs, on different pools of cells.
  • the mutant hydrolase is fused to a HERG channel.
  • Cells expressing such a fusion in the presence of a substrate of the invention which includes a K+-sensitive fluorophore, may be employed to monitor the activity of the HERG channel, e.g., to monitor drug-toxicity.
  • a fusion may be expressed on the surface of blood cells, such as exogenous cells introduced to an animal or endogenous cells in a transgenic animal the genome of which is modified to express such a fusion protein.
  • the substrate of the invention includes a functional group useful to monitor for hydrophobic regions, e.g., Nile Red, in a cell or organism.
  • the mutant hydrolases and substrates of the invention are useful in a wide variety of assays, e.g., phage display, panning, ELISA, mass spectrometry, Western blot, fluorometric microvolume assay technology (FMAT), whole animal imaging, X-ray imaging, and cell and subcellular staining, or as a biosensor.
  • assays e.g., phage display, panning, ELISA, mass spectrometry, Western blot, fluorometric microvolume assay technology (FMAT), whole animal imaging, X-ray imaging, and cell and subcellular staining, or as a biosensor.
  • FMAT fluorometric microvolume assay technology
  • cells expressing or containing a mutant hydrolase or a fusion protein which includes a mutant hydrolase are introduced, e.g., implanted or injected into an animal such as a human or non-human animal including a non-human mammal or non-human primate.
  • the cells may be transiently transfected or stably express the mutant hydrolase or fusion thereof, or be otherwise contacted with the mutant hydrolase or fusion thereof so that it is associated with the cell.
  • Different cell types can be used, including but not limited to cell lines, primary cultures, or stem cells (e.g., embryonic or adult stem cells).
  • the mutant hydrolase expressing or containing cells are contacted with a hydrolase substrate of the invention before introduction to an animal.
  • a hydrolase substrate of the invention is introduced to the animal before or after the mutant hydrolase expressing or containing cells are introduced to the animal.
  • the presence, location or amount of the functional group of the hydrolase substrate in the whole animal or in tissue preparations including but not limited to tissue biopsy or slices, cells isolated from a physiological sample, or in homogenized tissue), or physiological fluid samples such as blood samples and the like, is detected or determined.
  • the mutant hydrolase, a fusion comprising the mutant hydrolase, and/or one or more substrates of the invention can be used alone or in combination with other optical or nuclear reporting systems (e.g., fluorescent proteins, luciferases, radionuclides, etc.), for instance, to image biological processes, to image transcriptional regulation of endogeneous genes, and to image trafficking of cells (bone marrow-derived cells, blood cells, and the like).
  • optical or nuclear reporting systems e.g., fluorescent proteins, luciferases, radionuclides, etc.
  • Optical imaging systems include those for microscopic resolution, e.g., epi, confocal and two photon, mesoscopic resolution, e.g., optical projection tomography, optical coherence tomography or laser speckle imaging, and macroscopic resolation with intrinsic contrast or molecular contrast, e.g., hyperspectral imaging, endoscopy, polarization imaging, fluorescence reflectance imaging, diffuse optical tomography, fluorescence resonance imaging, fluorescence molecular imaging or luminescence imaging.
  • microscopic resolution e.g., epi, confocal and two photon
  • mesoscopic resolution e.g., optical projection tomography, optical coherence tomography or laser speckle imaging
  • macroscopic resolation with intrinsic contrast or molecular contrast e.g., hyperspectral imaging, endoscopy, polarization imaging, fluorescence reflectance imaging, diffuse optical tomography, fluorescence resonance imaging, fluorescence molecular imaging or luminescence imaging.
  • the mutant hydrolase, a fusion comprising the mutant hydrolase, and/or one or more substrates of the invention can be also used in combination with different optically dense/contrast reagents, which may be employed as a separate agent or chemically attached to a hydrolase substrate.
  • a hydrolase substrate containing a contrast agent is introduced to an animal which contains cells expressing the mutant hydrolase or a fusion thereof (e.g., a transgenic animal harboring the gene coding for mutant hydrolase or fusion thereof).
  • a hydrolase substrate containing a contrast agent is introduced to cells expressing the mutant hydrolase or a fusion thereof and those cells are introduced to an animal. The contrast agent can then be detected using X-ray, MRI, or other techniques.
  • a fusion of a mutant hydrolase and another protein and a hydrolase substrate bound to an electrochemically sensitive surface are employed to detect a molecule such as a physiological molecule, i.e., they are employed as a biosensor.
  • the surface contains immobilized hydrolase substrate, and the presence of a molecule of interest in a test solution is determined by an electrochemical alteration.
  • a fusion comprising a mutant hydrolase and glucose oxidase is immobilized onto a platinum electrode, gold surface, gold nanoparticles or carbon nanotubes, having a hydrolase substrate. A test sample is added and the presence or quantity of glucose in the test sample determined.
  • cholesterol in a test sample may be determined using a mutant hydrolase-cholesterol oxidase fusion immobilized onto an electrochemically sensitive surface.
  • the mutant hydrolase may be used as a biosensor for the detection of protease, protease inhibitor, kinase or kinase inhibitor and the like.
  • a protease site is fused to a mutant hydrolase protein and the resulting fusion immobilized onto an electrochemically sensitive surface such as electrode, a gold surface, gold nanoparticle, or carbon nanotube, having a hydrolase substrate.
  • an electrochemically sensitive surface such as electrode, a gold surface, gold nanoparticle, or carbon nanotube, having a hydrolase substrate.
  • Inhibitors of those changes include inhibitors of the protein fused to the mutant hydrolase, e.g., protease inhibitors, which may also be detected using this method.
  • a mutant hydrolase conjugated to a substrate other than hydrolase substrate e.g., at the C-terminal end of the mutant hydrolase and/or a fusion of a mutant hydrolase and a protein conjugated to a substrate other than the hydrolase substrate.
  • the biosensor surface contains immobilized hydrolase substrate.
  • the presence of a biomolecule in the test solution is determined by an electrochemical alteration.
  • the method may be used to capture, bind or otherwise provide a means for assaying certain molecules and could be used for the detection of pesticides, industrial toxic compounds, clinical diagnostics, infectious agents and bioweapons. In one embodiment, this method could be used for the detection of molecules including, but not limited to, a protease, protease inhibitor, kinase, kinase inhibitor, as well as the detection of the post-translational modification of proteins.
  • oligonucleotides were synthesized, purified and sequenced by Promega Corporation (Madison, WI) or the University of Iowa DNA Facility (Iowa City, Iowa). Restriction enzymes and DNA modifying enzymes were obtained from Promega Corporation (Madison, WI), New England Biolabs, Inc. (Beverly, MA) or Stratagene Cloning Systems (La Jolla, CA), and were used according to the manufacturer's protocols. Competent E. coli JM109 were provided by Promega Corporation or purchased from Stratagene Cloning Systems. Small-scale plasmid DNA isolations were done using the Qiagen Plasmid Mini Kit (Qiagen Inc., Chatsworth, CA).
  • DNA ligations were performed with pre-tested reagent kits purchased from Stratagene Cloning Systems. DNA fragments were purified with QIAquick Gel Extraction Kits or QIAquick PCR purification Kits purchased from Qiagen Inc.
  • the vectors used for generating DhaA mutants and their fusions were as follows: pET21 (Invitrogen, Carlsbad, CA), pRL-null (Promega, Madison, WI), pGEX-5x-3 (Amersham Biosciences; Piscataway, NJ), and EGFP and DsRED2 (both from CLONTECH, Palo Alto, CA),.
  • 1-Cl-butane, 1-Cl-hexane, 1-Cl-octane, 1-Cl-decane, 1 -Cl-butanol, 1-C1- hexanol, 1-Cl-octanol, and 1-Cl-decanol were obtained from Aldrich or from Fluka (USA). All salts, monobasic potassium phosphate, dibasic potassium phosphate, imidazole, HEPES, sodium EDTA, ammonium sulfate, and Tris free base were from Fisher (Biotech Grade).
  • Glutathione Sepharose 4 FF, glutathione, MonoQ and Sephadex G-25 prepackaged columns were from Amersham Biosciences. Luria-Broth ("LB") was provided by Promega Corporation.
  • DNA amplification was performed using standard polymerase chain reaction buffers supplied by Promega Corp. Typically, 50 ⁇ l reactions included Ix concentration of the manufacturer's supplied buffer, 1.5 mM MgCl 2 , 125 ⁇ M dATP, 125 ⁇ M dCTP, 125 ⁇ M dGTP, 125 ⁇ M dTTP, 0.10- 1.0 ⁇ M forward and reverse primers, 5 U AmpliTaq® DNA Polymerase and ⁇ 1 ng target DNA. Unless otherwise indicated, the thermal profile for amplification of DNA was 35 cycles of 0.5 minutes at 94 0 C; 1 minute at 55 0 C; and 1 minute at 72 0 C. DNA sequencing. All clones were confirmed by DNA sequencing using the dideoxy-terminal cycle-sequencing method (Sanger et al., 1977) and a Perkin-Elmer Model 310 DNA sequencer. (Foster City, CA).
  • the membranes were rinsed with TBST buffer (10 mM Tris-HCl, 150 mM NaCl, pH 7.6, containing 0.05% Tween 20) and incubated in blocking solution (3% dry milk or 1% BSA in TBST buffer) for 30 minutes at room temperature or overnight at 4 0 C. Then membranes were washed with 50 ml of TBST buffer and incubated with anti-FLAG monoclonal antibody M2 (dilution 1 :5,000), anti-Renilla luciferase monoclonal antibody (dilution 1 :5,000), or HRP-conjugated streptavidin (dilution 1 :10,000) for 45 minutes at room temperature.
  • TBST buffer 10 mM Tris-HCl, 150 mM NaCl, pH 7.6, containing 0.05% Tween 20
  • blocking solution 3% dry milk or 1% BSA in TBST buffer
  • Protein concentration was measured by the microtiter protocol of the Pierce BCA Protein assay (Pierce, Rockford, IL) using bovine serum albumin (BSA) as a standard.
  • coli BL21 ( ⁇ DE3) pET3a (stored in 10% glycerol, -8O 0 C) were used to inoculate Luria-Bertani agar plates supplemented with ampicillin (50 ⁇ g/ml) (Sambrook et al., 1989). Single colonies were selected and used to inoculate two 10 ml cultures of Luria-Bertani medium containing 50 ⁇ g/ml ampicillin. The cells were cultured for 8 hours at 37°C with shaking (220 rpm), after which time 2 ml was used to inoculate each of two 50 ml of Luria-Bertani medium containing 50 ⁇ g/ml ampicillin, which were grown overnight at 37 0 C with shaking.
  • CHO-Kl cells (ATCC-CCL61) were cultured in a 1 : 1 mixture of Ham's F12 nutrients and Dulbecco's modified minimal essential medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml streptomycin, in an atmosphere of 95% air and 5% CO 2 at 37 0 C.
  • Rat hippocampal (El 8) primary neurons were isolated as described below. Briefly, fragments of embryonic (E 18) rat hippocampus in Hibernate E media (GIBCO, Invitrogen, Carlsbad, CA), obtained from Dr.
  • Fluorescence Fluorescence in cells in 96 well plates was measured on fluorescent plate reader CytoFluorII (Beckman) at an E e ⁇ /E em appropriate for particular fluorophores (e.g., E e ⁇ /E em for carboxytetramethylrhodamine is 540/575 nm).
  • the haloalkane dehalogenase gene from Rhodococcus rhodochrous, dhaA encodes a monomelic 33 kDa enzyme that catalyzes the irreversible hydrolysis of a variety of haloalkanes (Kulakova et al. 1997), e.g., cleaves carbon-halogen bonds in aliphatic and aromatic halogenated compounds, e.g., HaloC 3 -HaloCio.
  • the DhaA enzyme contains 293 amino acids and is a member of a superfamily of proteins containing an ⁇ / ⁇ hydrolase fold ( Figure 2A).
  • the next step in the dehalogenase reaction pathway is hydrolysis of the intermediate ester by a water molecule activated by the active site His residue ( Figure IB). While the catalytic histidine residue is the base catalyst for the dealkylation of the covalent intermediate, it is not essential for the initial nucleophilic attack of the active site Asp. Protein variants that lack the crucial catalytic histidine residue have been shown to carry out the alkylation half reaction thereby producing a stable, covalent ester intermediate (Pries et al., 1995).
  • mutant DhaA vectors Promega's in vitro mutagenesis kit which is based on four primer overlap-extension method was employed (Ho et al., 1989) to produce DhaA.H272 to F, A, G, or H mutations.
  • the external primers were oligonucleotides 5'-
  • GCTTCACTTGTCGTCATCGTCCTTGTAGTCA-3' SEQ ID NO: 1
  • 5'- GCTTCACTTGTCGTCATCGTCCTTGTAGTCA-3' SEQ ID NO:2
  • the internal mutagenic primers were as follows: H272F (5'- CCGGGATTGTTCTACCTCCAGGAAGAC-3'), SEQ ID NO:3), H272A (5'- CCGGGATTGGCCTACCTCC AGG AAGAC-3 ' ; SEQ ID NO:4), H272G (5'- CCGGGATTGCAGT ACCTCCAGGAAGAC-3 ' ; SEQ ID NO: 5), and H272Q ( 5'-CCGGGATTGGGCTACCTCCAGGAAGAC-S': SEQ ID NO:6) (the mutated codons are underlined).
  • the mutated dehalogenase genes were subcloned into the pET-3a vector. For overexpression of mutant dehalogenases, the pET-3a
  • DhaA sequence in clones was confirmed by DNA sequencing. Unless otherwise noted DhaA. WT and DhaA.H272F proteins generally contain GST at the N- terminus and a FLAG epitope at the C-terminus.
  • GST-DhaA (WT or H272F/A/G/H mutants) fusion cassettes were constructed by cloning the appropriate DhaA coding regions into SaWNotl sites of pGEX5x3 vector. Two primers (5'-
  • the resulting fragments were inserted into the SaWNotl site of pGEX- 5X-3, a vector containing a glutathione S-transferase (GST) gene, a sequence encoding a Factor Xa cleavage site, and multiple cloning sites (MCS) followed by a stop codon.
  • GST glutathione S-transferase
  • MCS multiple cloning sites
  • DhaA.WT and DhaA.H272F proteins generally contain GST at the N-terminus and a FLAG epitope at the C-terminus.
  • enzyme expression was induced by the addition of isopropyl-b-D-thiogalactopyranoside (at a final concentration of 0.5 mM) when the culture reached an optical density of 0.6 at 600 nm.
  • the cells were harvested in Buffer A (IO mM Tris-SO 4 , 1 mM EDTA, 1 mM ⁇ - mercaptoethanol, and 10 % glycerol, pH 7.5), and disrupted by sonication using a Vibra CellTM sonicator (Sonics & Materials, Danbury, CT, USA). Cell debris was removed by centrifugation at 19,800 x g for 1 hour.
  • the crude extract was further purified on a GSS-Sepharose 4 fast flow column (Amersham Biosciences; Piscataway, NJ) according to the manufacturer's instructions.
  • the elution fractions containing GST-DhaA fusion protein were pooled, dialyzed against a 10 mM Tris-SO 4 buffer (containing 20 mM Na 2 SO 4 and 1 mM EDTA- Na 2 ) overnight at 4 0 C, and stored at -20 0 C until use.
  • DhaA WT or mutant
  • GST was cleaved from the fusion proteins with Factor Xa, and the products purified on GSS-Sepharose 4 (Amersham Biosciences; Piscataway, NJ) according to the manufacturer's instructions. Homogeneity of the proteins was verified by SDS-PAGE.
  • the cell free extract was fractionated using 45-70% saturated ammonium sulfate as described by Newman et al. (1999).
  • FIG. 3 shows robust, IPTG inducible production of DhaA.WT (lane 1) and DhaA.H272F (lane 2) fusion proteins. Moreover, the proteins were soluble and could be efficiently purified on Glutathione-Sepharose 4FF (lanes 5-10, odd numbered lanes correspond to DhaA.WT and even numbered lanes correspond to DhaA.H272F). Treatment of the fusion proteins with Factor Xa led to the formation of two proteins GST and DhaA (WT or H272F mutant, lanes 11 and 12, respectively), and GST was efficiently removed on Glutathione-Sepharose 4FF (WT or mutant, lanes 13 and 14, respectively). In addition, all proteins had the predicted molecular weight.
  • Inability of an enzyme to release product of the enzymatic reaction into surrounding media is essential for the tethering system. This inability can be detected by significant reduction of the hydro lytic activity of the enzyme.
  • the reaction buffer for a pH-indicator dye system consisted of 1 mM HEPES-SO 4 (pH 8.2), 20 mM Na 2 SO 4 , and 1 mM EDTA. Phenol red was added to a final concentration 25 ⁇ g/ml. The halogenated compounds were added to apparent concentrations that could insure that the dissolved fraction of the substrate was sufficient for the maximum velocity of the dehalogenation reaction.
  • the substrate-buffer solution was vigorously mixed for 30 seconds by vortexing, capped to prevent significant evaporation of the substrate and used within 1-2 hours. Prior to each kinetic determination, the phenol red was titrated with a standardized solution of HCl to provide an apparent extinction coefficient.
  • the steady-state kinetic constants for DhaA were determined at 558 nm at room temperature on a Beckman Du640 spectrophotometer (Beckman Coulter, Fullerton, CA). Kinetic constants were calculated from initial rates using the computer program SigmaPlot.
  • One unit of enzyme activity is defined as the amount required to dehalogenate 1.0 mM of substrate/minute under the specific conditions.
  • a linker was designed to connect the Cl- containing substrate with a functional group so that the functional group is located outside of the catalytic pocket, i.e., so as not to disturb/destroy the 3-D structure of DhaA.
  • DhaA was capable of hydrolyzing Cl-alkanes with a long hydrophobic carbon chain.
  • WT was contacted with various Cl-alkane alcohols. As shown in Figure 6, DhaA. WT can hydro lyze 1 -Cl-alkane alcohols with 4-10 carbon atoms.
  • Ethanol extracts of Cl-alkanes or products of Cl-alkane hydrolysis were analyzed using analytical reverse phase Cj 8 column (Adsorbosphere HS, 5 ⁇ , 150 x 4.6 mm; Hewlett-Packard, Clifton, NJ) with a linear gradient of 10 mM ammonium acetate (pH 7.0):ACN (acetonitrile) from 25:75 to 1:99 (v/v) applied over 30 minutes at 1.0 ml/minute. Quantitation of the separated compounds was based on the integrated surface of the collected peaks.
  • Figure 8A shows the complete separation of the substrate and the product of the reaction.
  • Figure 8B indicates that DhaA.WT very efficiently hydrolyzed Similar results were obtained when carboxytetramethylrhodamine-C i oH? i NO 2 -Cl or 5-carboxy-X-rhodamine-
  • H272F mutant or GST-DhaA (WT or H272F mutant) fusion protein (purified to about 90% homogeneity) in 200 ⁇ l of buffer (1 mM HEPES-SO 4 (pH 7.4), 20 mM Na 2 SO 4 , and 1 mM EDTA) were incubated with or without substrate
  • Oligonucleotides employed to prepare DhaA.DlO ⁇ mutants include for
  • DhaA.D106C 5'-CTTGGGTTTGGAAGAGGTCGTCCTGGTCATCCACTGCTGGGGC-S '
  • the annealed oligonucleotides contained a Styl site at the 5' end and the B IpI site at the 3' end.
  • the annealed oligonucleotides were digested with Styl and Blpl and subcloned into DhaA.WT or DhaA.H272F at Styl and B IpI sites. All mutants were confirmed by DNA sequencing.
  • the gels containing proteins were incubated with carboxyfluorescein- CioH 2 iN0 2 -Cl, carboxytetramethylrhodamine-CioH 2 iN0 2 -Cl, or 5-carboxy-X- rhodamine-Ci 0 H 2 [NO 2 -Cl and were analyzed by fluoroimager (Hitachi, Japan) at an E ex /E em appropriate for each fluorophore. Gels containing proteins incubated with biotin-CioH 2 iN0 2 -Cl were transferred to a nitrocellulose membrane and probed with HRP conjugated streptavidin.
  • carboxytetramethylrhodamine-C 10 H 21 NO 2 -Cl (lanes 1 and 2 in panel A), carboxyfluorescein-CioH 2 iN ⁇ 2 -Cl (lanes 3 and 4 in panel A), and 5-carboxy-X-rhodamine-CioH 2 iN0 2 -Cl (lanes 5 and 6 in panel A) bound to DhaA.H272F (lanes 2, 4 and 6 in panel A) but not to DhaA.WT (lanes 1, 3 and 5 in panel A).
  • DhaA.H272F mutant (or the GST-DhaA.H272F mutant fusion protein), these proteins were incubated with and without carboxyfluorescein-CioH 2 iN ⁇ 2 -Cl, and analyzed by MALDI.
  • the bond between mutant DhaA.H272F and carboxyfluorescein-CioH 2 iN ⁇ 2 -Cl is strong.
  • the analysis of the E*S complex indicated the covalent nature of the bond between the substrate (e.g., carboxyfluorescein-C ⁇ oH 2 iN ⁇ 2 -Cl) and DhaA.H272F.
  • the MALDI-TOF analysis also confirms that the substrate/protein adduct is formed in a 1 : 1 relationship.
  • DhaA mutants at another residue in the catalytic triad, residue 106 were prepared.
  • the residue at position 106 in wild-type DhaA is D, one of the known nucleophilic amino acid residues.
  • D at residue 106 in DhaA was substituted with nucleophilic amino acid residues other than D, e.g., C, Y and E, which may fo ⁇ n a bond with a substrate which is more stable than the bond formed between wild-type DhaA and the substrate.
  • cysteine is a known nucleophile in cysteine-based enzymes, and those enzymes are not known to activate water.
  • a control mutant, DhaA.D106Q, single mutants DhaA.D106C, DhaA.D106Y, and DhaA.D106E, as well as double mutants DhaA.D106C:H272F, DhaA.D106E:H272F, DhaA.D106Q:H272F, and DhaA.D106Y:H272F were analyzed for binding to carboxytetramethylrhodamine-CioH 2 iN ⁇ 2 -Cl ( Figure 12).
  • substitutions at position 106 alone or in combination with substitutions at other residues in DhaA may yield similar results. Further, certain substitutions at position 106 alone or in combination with substitutions at other residues in DhaA may result in a mutant DhaA that forms a bond with only certain substrates.
  • Example III Tethering of Luciferase to a Solid Support via a Mutant DhaA and a Substrate of the Invention
  • phRLuc-connector-DhaA.WT-Flag and phRLuc-connector- DhaA.H272F-Flag fusion cassettes were constructed by cloning the phRLuc coding region into the Nhel/Sall sites of the pCIneo vector which contains a myristic acid attachment peptide coding sequence (MAS).
  • Two primers (5'-)
  • GCTTCACTTGTCGTCATCGTCCTTGTAGTCA-3'; SEQ ID NO: 1 1) and (5'- GCTTCACTTGTCGTCATCGTCCTTGTAGTCA-3'; SEQ ID NO: 12) were designed to add Nhel and Sail sites to the 5' and 3' coding regions, respectively, of phRLuc and to amplify a 900 bp fragment from a phRLuc template (pGL3 vector, Promega).
  • DhaA.WT-Flag and DhaA.H272F-Flag coding regions were excised from pGEX-5X-3. DhaA.WT-Flag or pGEX-5X-3.DhaA.H272F-Flag, respectively, gel purified, and inserted into SaWNotl restriction sites of pCIneo.CMV vector (Promega). The constructs were confirmed by DNA sequencing.
  • CHO-Kl cells were plated in 24 well plates (Labsystems) and transfected with a pClneo-CMV.DhaA.WT-Flag or pCIneo-CMV.DhaA.H272F-Flag vector. Twenty-four hours later, media was replaced with fresh media containing 25 ⁇ M carboxytetramethylrhodamine-CioH 2 iN0 2 -Cl and the cells were placed into a CO 2 incubator for 60 minutes.
  • Figures 14A and B show the binding of biotin-C ⁇ oH 2 iN ⁇ 2 -Cl (A) and carboxytetramethylrhodamine-CioH ⁇ iNOi-Cl (B) to E. coli proteins in vivo.
  • the low molecular band on Figure 14A is an E. coli protein recognizable by HRP- SA, while the fluorescence detected in the bottom part of Panel B was fluorescence of free carboxytetramethylrhodamine-C
  • Figure 15 shows the binding of carboxytetramethylrhodamine-C ⁇ oH 2 iN ⁇ 2-Cl to eukaryotic cell proteins in vivo.
  • CHO-Kl Cells ATCC-CCL61 were cultured in a 1:1 mixture of Ham's F12 nutrients and Dulbecco's modified minimal essential medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml streptomycin, in an atmosphere of 95% air and 5% CO 2 at 37 0 C.
  • FBS fetal bovine serum
  • penicillin 100 U/ml penicillin
  • streptomycin 100 mg/ml streptomycin
  • the level of fluorescence in cells in 96 well plates was measured on fluorescent plate reader CytoFluor II (Beckman) at E ex /E em equal 480/520 nm and 540/575 nm for carboxyfluorescein- and carboxytetramethylrhodamine-modified substrates, respectively. Fluorescent images of the cells were taken on inverted epifluorescent microscope Axiovert-100 (Carl Zeiss) with filter sets appropriate for detection of
  • carboxyfluorescein-CioH 2 iN0 2 -Cl did not cross the plasma membrane of CHO-Kl cells, even when cells were pretreated with carboxyfluorescein-CioH 2
  • the different permeabilities of the cell plasma membrane for various substrates of the invention e.g., carboxytetramethylrhodamine-C 10 H 21 NO 2 -CI and carboxyfluorescein-C 10 H 2 ]NO 2 -Cl, provides a unique opportunity to label proteins expressed on the cell surface and proteins expressed inside the cell with different fluorophores, thereby allowing biplexing.
  • Example V e.g., carboxytetramethylrhodamine-C 10 H 21 NO 2 -CI and carboxyfluorescein-C 10 H 2 ]NO 2 -Cl
  • a GFP-connector-DhaA fusion cassette was constructed by replacing the Renilla luciferasc coding region in Packard's vector coding GFP-DEVD-Rluc(h) (Packard #6310066) with DhaA.WT-Flag or DhaA.H272F-Flag coding regions.
  • Two primers (5'- GGAATGGGCCCTCTAGAGCGACGATGTCA -3'; SEQ ID NO: 15, and 5'- CAGTCAGTCACGATGGATCCGCTC AA -3'; SEQ ID NO:
  • the cells were placed back into in a CO 2 incubator and after 60 minutes the cells were quickly washed with PBS (pH 7.4; four consecutive washes: 1.0 ml/cm 2 ; 5 seconds each). Fluorescent images of the cells were taken on inverted epifluorescent microscope Axiovert-100 (Carl Zeiss) with filter sets appropriate for detection of GFP and carboxytetramethylrhodamine. Results
  • cells transfected with either GFP- connector-DhaA.WT-Flag or GFP-connector-DhaA.H272F-Flag showed robust expression ot the protein(s) with light emitting characteristics of GFP.
  • Analysis of the images of the same cells taken with a carboxytetramethylrhodamine- filter set showed that cells expressing GFP-connector-DhaA.WT-Flag were dark and could not be distinguished from cells that do not express this fusion protein.
  • cells expressing GFP-connector-DhaA.H272F-Flag were very bright and unmistakably recognizable.
  • DhaA-based fusion proteins (see Table II) with DhaA at the C- or N-terminus of the fusion and a connector sequence, e.g., one having 13 to 17 amino acids, between the two proteins, were prepared. The data showed that the functional activity of both proteins in the fusion was preserved.
  • CHO-Kl cells were plated in 96 well plates to a density of 5,000 cells per well. The next day, media was replaced with fresh media containing 0-100 ⁇ M concentrations of Cl-alkanes and the cells were placed back into a CO 2 incubator for different periods of time. Viability of the cells was measured with CellTiter-Glo M Luminescence Cell Viability Assay ' (Promega) according to the manufacturer's protocol. Generally, 100 ⁇ l of CellTiter-GloTM reagent was added directly to the cells and the luminescence was recorded at 10 minutes using a DYNEX MLX microtiter plate luminometer.
  • carboxytetramethylrhodamine-CioH 2 iN0 2 -Cl showed no toxicity on CHO-Kl cells even after a 4 hour treatment at a 100 ⁇ M concentration the (the highest concentration tested). After a 24 hour treatment, no toxicity was detected at concentrations of 6.25 ⁇ M (the "maximum non-toxic concentration"). At concentrations > 6.25 ⁇ M, the relative luminescence in CHO-Kl cells was reduced in a dose-dependent manner with an IC 50 of about 100 ⁇ M. No toxicity of biotin-CioH 2 iNi0 2 -Cl was observed even after 24 hours of treatment at 100 ⁇ M.
  • CHO cells (ATCC, passage 4) were seeded into 8-well chamber slides (German coverglass system) at low density in DMEM:F12 media (Gibco) containing 10% FBS and 1 mM glutamine (growth media) without antibiotics. Two days later, cells were inspected using an inverted phase microscope. Two visual criteria were confirmed before applying the transfection reagents: 1) the level of cellular confluence per chamber was approximately 60-80%, and 2) >90% of the cells were adherent and showed a flattened morphology. The media was replaced with 150 ⁇ l of fresh pre-warmed growth media and cells were incubated for approximately 1 hour.
  • TKO lipid was diluted by adding 7 ⁇ l of lipid per 100 ⁇ l of serum-free DMEM:F12 media, and then 1.2 ⁇ g of transfection-grade DhaA.D 106C DNA was added per 100 ⁇ l of lipid containing media. The mixture was incubated at room temperature for 15 minutes, and then 25 ⁇ l aliquots were transferred into individual culture chambers (0.3 ⁇ g DNA). Cells were returned to the incubator for 5-6 hours, washed two times with growth media, 300 ⁇ l of fresh growth media was added, and then cells were incubated for an additional 24 hours.
  • Transfected or non-transfected control cells were incubated with 12.5 ⁇ M carboxytetramethylrhodamine-CioH 2 iN0 2 -Cl or 12.5 ⁇ M DiAc- carboxyfluorescein-Ci 0 H 21 NO 2 -Cl in 10% FBS/DMEM for 30 minutes at 37°C and 5%CO 2 . Cells were washed with warm growth media three times, 300 ⁇ l fresh growth media was added, and then cells were incubated for 1 hour.
  • the PBS was removed and cells were fixed with 3.7% paraformaldehyde/0.1% Triton in PBS for 15 minutes. The fixative was removed, PBS was added, and a second set of images was captured for both carboxytetramethylrhodamine-CioH 2 iN ⁇ 2 -Cl and DiAc- carboxyfluorescein- C 10 H 21 NO 2 -CI labeled cells.
  • Beta-Lactamase (BlaZ)-based Tethering The serine- ⁇ -lactamases, enzymes that confer bacterial resistance to ⁇ - lactam antibiotic, likely use the hydroxyl group of a serine residue (Ser70 in the class A consensus numbering scheme of Ambler et al. (1991)) to degrade a wide range of ⁇ -lactam compounds.
  • the reaction begins with the formation of a precovalent encounter complex (Figure 20A), and moves through a high- energy acylation tetrahedral intermediate (Figure 20B) to form a transiently stable acyl-enzyme intermediate, forming an ester through the catalytic residue Ser70 ( Figure 20C).
  • the plasmid pTS32 harboring Staphylococcus aureus PCl blaZ gene was kindly provided by Dr. O. Herzberg (University of Maryland Biotechnology Institute).
  • the blaZ gene has the following sequence: AGCTTACTAT GCCATTATTA ATAACTTAGC CATTTCAACA CCTTCTTTCA AATATTTATAATAAACTATT GACACCGATA TTACAATTGT AATATTATTG ATTTATAAAA ATTACAACTGTAATATCGGA GGGTTTATTT TGAAAAAGTT AATATTTTTA ATTGTAATTG CTTTAGTTTTAAGTGCATGT AATTCAAACA GTTCACATGC CAAAGAGTTA AATGATTTAG AAAAAAAATATAATGCTCAT ATTGGTGTTT ATGCTTTAGA TACTAAAAGT GGTAAGGAAG TAAAATTTAATTCAGATAAG AGATTTGCCT ATGCTTCAAC TTCAAAAGCG ATAAATAGTG CTATTTT
  • GST-t ⁇ Z (WT and E166D, N170Q, or E166D:N170Q mutants) fusion cassettes were constructed by introducing point mutations into the bkiL gene and cloning the blaZ coding regions into SalVAgel sites of pGEX5x3 vector.
  • the internal mutagenic primers were as follows: E166D (5'- CCAGTTAGATATGACATAGAATTAAATTACTATTCACC-S', SEQ ID NO: 56; 5 '-GGTG AAT AGTA ATTTAATTCTATGTCATATCT A ACTGG-3 ' , SEQ ID NO:57); N 170Q (5'- CCAGTTAGATATGAGATAGAATTACAGTACTATTCACC-S', SEQ ID NO:58; and 5'-GGTGAATAGTACTGTAATTCTATCTCATATCTAACTGG- 3', SEQ ID NO:59); and E166D:N170Q
  • CAACAGGTCGACGCCGCCATGAAAGAGTTAAATGATTTAG-S', SEQ ID NO:62; and 5'-GTAGTCACCGGTAAATTCCTTCATTACACTCTTGGC-S ', SEQ ID NO:63) were designed to add N-terminal Sail site and a Kozak sequence to the 5' coding region, add an Agel site to the 3' coding regions o ⁇ bl ⁇ Z, and to amplify a 806 bp fragment from a bl ⁇ Z.WT template.
  • the resulting fragment was inserted into the S ⁇ ll/Agel site of the vector pGEX-5X-3 containing a glutathione S-transferase (GST) gene, a sequence coding a Factor Xa cleavage site, and multiple cloning sites (MCS) followed by a sequence coding for Flag and stop codons.
  • GST glutathione S-transferase
  • MCS multiple cloning sites
  • the GST-BIaZ (WT or mutants) fusion proteins were overexpressed in competent E. coli BL21 ( ⁇ DE3) cells and purified essentially as described for DhaA and GST-DhaA fusion proteins (except the potassium phosphate buffer (0.1 M, pH 6.8) was used instead of Buffer A). Homogeneity of the proteins was verified by SDS-PAGE.
  • FAP 6- ⁇ -[(Furylacryloyl)amido]penicillanic acid triethylamine salt
  • BlaZ.E166D, BlaZ.N170Q, or BlaZ.E166D:N170Q mutants bind ⁇ -lactams, and therefore different functional groups could be tethered to these proteins via ⁇ -lactams
  • GST fusions of these mutants were incubated with BOCELLINTM FL, a fluorescent penicillin (Molecular Probes Inc., Eugene, OR). Proteins were resolved on SDS-PAGE and analyzed on fluoroimager (Hitachi, Japan) at an E ex /E em appropriate for the particular fluorophore.
  • fluoroimager Hitachi, Japan
  • a GFP-connector-DhaA.H272F-NLS3 fusion cassette was constructed by inserting a sequence encoding NLS3 (three tandem repeats of the Nuclear Localization Sequence (NLS) from simian virus large T-antigcn) into the Age ⁇ /BamHl sites of a pCIneo.GFP-connector-DhaA.H272F-Flag vector.
  • NLS3 nuclear Localization Sequence
  • a DhaA.H272F- ⁇ -arrestin2 fusion cassette was constructed by replacing the pGFP coding region in Packard's vector encoding GFP - ⁇ -arrestin2 (Packard #6310176-1 Fl) with the DhaA.H272F-Flag coding region.
  • Two primers (5'-ATTATGCTGAGTGATATCCC ⁇ '; SEQ ID NO: 39, and 5'-
  • CTCGGTACC AAGCTCCTTGT AGTC A-3 1 ; SEQ ID NO:40) were designed to add a Kpnl site to the 3' coding region of Z ) AaA, and to amplify a 930 bp fragment from a pGEX5X-3.DhaA.H272F-Flag template.
  • the pGFP 2 coding region was excised with Nhe ⁇ and Kpnl restriction enzymes, then the 930 bp fragment containing encoding DhaA.H272F was inserted into the NAeI and Kpnl sites of the GFP - ⁇ -arrestin2 coding vector.
  • the sequence of the fusion construct was confirmed by D ⁇ A sequencing.
  • CHO-Kl or 3T3 cells transiently expressing GFP-connector- DhaA.H272F- ⁇ LS3, GFP 2 - ⁇ -arrestin2 or DhaA.H272F- ⁇ -arrestin2 fusion proteins were plated in LT-II chambers (Nunc) at a density of 30,000 cells/cm 2 . The next day, media was replaced with fresh media containing 25 ⁇ M of carboxytetramethylrhodamine-CioH 2 iN ⁇ 2 -Cl and the cells were placed back into a CO 2 incubator for 60 minutes.
  • GFP and carboxytetramethylrhodamine were co-localized in the cell nucleus of cells expression GFP-connector-DhaA.H272F-NLS3 and contacted with carboxytetramethylrhodamine-CioH 2 iN ⁇ 2 -Cl.
  • GFP- ⁇ -arrestin2 expressing cells have a typical ⁇ -arrestin2 cytosolic localization.
  • a fluoroscan of the SDS-PAGE gel of DhaA.H272F- ⁇ -arrestin2 showed strong binding of a carboxytetramethylrhodamine containing DhaA substrate to cells expressing Dha ⁇ .H272F- ⁇ -arrestin2.
  • Haloalkane dehalogenases use a three-step mechanism for cleavage of the carbon-halogen bond ( Figures IA-B).
  • This reaction is catalyzed by a triad of amino acid residues composed of a nucleophile, base and acid which, for the haloalkane dehalogenase from Xanthobacter autotrophicus (DhIA), are residues Asp 124, His289 and Asp260, respectively (Franken et al., 1991), and in the Sphingomonas and Rhodococcus dehalogenase enzymes, LinB and DhaA, respectively, the analogous triad of residues have been identified as Asp 108, His272 and Glul32 (Hynkova et al., 1999) and AsplO6, His272 and Glul30 (Newman et al., 1999).
  • nucleophilic attack by the carboxylate of an Asp residue on the substrate causes the cleavage of the halogen-carbon bond and the formation of an alkyl-ester intermediate.
  • Site- directed mutagenesis studies on the DhIA Asp 124 residue shows that this first reaction proceeds by covalent catalysis with the formation of an alkyl-enzyme intermediate (Pries et al., 1994).
  • the next step in the dehalogenase reaction pathway is hydrolysis of the intermediate ester by a water molecule activated by the active site His residue. While the catalytic histidine residue is the base catalyst for the dealkylation of the covalent intermediate, it is not essential for the initial nucleophilic attack of the active site Asp.
  • Protein mutants that lack the crucial catalytic histidine residue have been shown to carry out the alkylation half reaction thereby producing a stable, covalent ester inte ⁇ nediate.
  • a His289Gln mutant of DhIA has previously been shown to accumulate the covalent alkyl-enzyme intermediate (Pries et al., 1995).
  • the role of the third member of the catalytic triad is not yet fully understood.
  • the catalytic acid is hydrogen bonded to the catalytic His residue and may assist the His residue in its function by increasing the basicity of nitrogen in the imidazole ring.
  • Krooshof et al. (1997), using site-directed mutagenesis to study the role of the DhIA catalytic acid Asp260, demonstrated that a D260N mutant was catalytically inactive. Furthermore, this residue apparently had an important structural role since the mutant protein accumulated mainly in inclusion bodies.
  • haloalkane dehalogenase from Sphinogom ⁇ nas paucimobilis is the enzyme involved in ⁇ -hexachlorocyclohexane degradation (Nagata et al., 1997).
  • Hynkova et al., (1999) replaced the putative catalytic residue (GIu-132) of the LinB with glutamine (Q) residue.
  • Q glutamine
  • coli strain JM109 (e!4-(McrA-) recAl endAl gyrA96 thi-1 hsdR17(rK- mK+) supE44 relAl ⁇ (lac-proAB) [F' traD36 proAB lacfZ ⁇ M15]) was used as the host for gene expression and whole cell enzyme labeling studies.
  • a mutant plasmid containing a H272F mutation in DhaA designated pGEX5X3DhaAH272F-FLAG, was used as a positive control in labeling studies and the cloning vector pGEX5X3 was used as a negative control.
  • Site-directed mutagenesis was performed using the QuikChange Multi kit according to the manufacturer's instructions (Stratagene, La Jolla, CA). The mutagenesis reactions were introduced into competent is. coli XLlO Gold cells and transformants were selected on LB agar plates containing ampicillin (100 ⁇ g/mL). Plasmid DNA isolated from individual transformants was initially screened for the loss of an EcoRl site due to replacement of the glutamate codon (GAAttc). Clones suspected of containing the desired codon change from each reaction were selected and subjected to DNA sequence analysis (SeqWright, Houston, TX). The primer used to confirm the sequence of the mutants in the pGEX5X3 vector was as follows: 5' GGGCTGGCAAGCCACGTTTGGTG 3' (SEQ ID NO:44).
  • DhaA mutant analysis The three.DhaA.E130 substitution mutants were compared to the following constructs: Wild-type DhaA, DhaA.H272F, and a DhaA negative control (pGEX5X3 vector only).
  • Overnight cultures of each clone were grown in 2 mL of LB containing ampicillin (100 ⁇ g/mL) by shaking at 30 0 C.
  • the overnight cultures were diluted 1 :50 into a sterile flask containing 50 mL fresh LB medium and ampicillin (100 ⁇ g/mL).
  • the cultures were incubated with shaking at 25 0 C to minimize the production of insoluble protein species.
  • IPTG 0.1 niM
  • OD6oo l prior to adding substrate to a concentration of 15 ⁇ M.
  • the cells were incubated with gentle agitation at 4 0 C for approximately 18 hours.
  • 20 ⁇ l of cells from each labeling reaction was added to 6 ⁇ l of 4X SDS loading dye and the samples were boiled for about 3 minutes prior to being loaded onto a 4-20% acrylamide gel (Tris glycine).
  • a 25 ⁇ l sample of each labeling reaction was added to 6 ⁇ l of 4X SDS loading dye and the samples were boiled for about 3 minutes prior to being loaded onto a 4-20% acrylamide gel (Tris glycine).
  • the gels were imaged using a Fluorlmager SI instrument (Amersham Biosciences, Piscataway, NJ) set to detect emission at 570 nm.
  • the DhaA.WT codon El 30 was replaced with a codon for glutamine (Q), leucine (L) or alanine (A), as these substitutions would likely be least disruptive to the structure of the enzyme.
  • restriction endonuclease screening and DNA sequence analysis was used to verify the desired codon changes.
  • the E 130 mutants were analyzed for protein expression and for their ability to form a covalent alkyl-enzyme intermediate with a carboxytetramethylrhodamine labeled haloalkane substrate.
  • the DhaA.E130 mutants were also examined for their ability to generate an alkyl-enzyme covalent intermediate. Crude lysates prepared from IPTG induced cultures of the various constructs were incubated in the presence of the carboxytetramethylrhodamine labeled substrate. Figure 28 showed that the DhaA.H272F mutant (lane 3) was very efficient at producing this intermediate. No such product could be detected with either the DhaA.WT or negative control lysates. Upon initial examination, the DhaA.E130 mutants did not appear to produce detectable levels of the covalent product. However, upon closer inspection of the fluoroimage extremely faint bands were observed that could potentially represent minute amounts of the covalent intermediate ( Figure 28; lanes 5-7). Based on these results, the ability of whole cells to generate a covalent, fluorescent alkyl-enzyme intermediate was investigated.
  • Figure 29 shows the results of an in vivo labeling experiment comparing each of the DhaA.E130 mutants with positive (DhaA.H272F mutant) and negative (DhaA-) controls.
  • the DhaA.H272F mutant was capable of generating a covalent alkyl-enzyme intermediate as evidenced by the single fluorescent band near the molecular weight predicted for the DhaA fusion ( Figure 29, lane 3).
  • no such product could be detected with either the wild-type or negative control cultures ( Figure 29, lanes 2 and 3) but very faint fluorescent bands migrating at the correct position were again detected with all three DhaA.E130 substituted mutants ( Figure 29, lanes 5-7).
  • DhaA catalytic acid residue DhaA.E130 plays an important structural role in the correct folding of the enzyme.
  • the DhaA protein was clearly sensitive to substitutions at this amino acid position as evidenced by the presence of largely insoluble protein complexes in the DhaA.E130Q, DhaA.E130L and DhaA.E130A crude lysates. Nevertheless, based on SDS-PAGE and immunoblot analyses, a significant quantity of soluble DhaA protein was detected in the cell-free lysates of all three DhaA.E 130 mutants.
  • CHO-Kl cells were plated in 24 well plates (Labsystems) at a density of
  • protease inhibitors Sigma #P8340
  • the cells were lysed by trituriation through a needle (IMl 23GTW).
  • cell lysatcs were incubated with MagnaBind Streptavidin coated beads (Pierce #21344) according to the manufacturer's protocol. Briefly, cell lysates were incubated with beads for 60 minutes at room temperature (RT) using a rotating disk.
  • N0 2 -Cl was efficiently hydrolyzed by DhaA.WT, and covalently bound to DhaA.H272F and DhaA.H272F fusion proteins in vitro and in vivo. Moreover, binding was observed both in E. coli and in mammalian cells. Control experiments indicated that about 80% of the DhaA.H272F-Flag protein expressed in CHO-Kl cells was labeled after a 60 minute treatment. CHO-Kl cells transiently expressing DhaA.H272F-Flag were treated with biotin-CioH 2 iN0 2 -Cl.
  • Biotin-CioH 2 iN0 2 -Cl treated cells were lysed and cell lysates were incubated with SA-coated beads. Binding of DhaA.H272F to beads was analyzed by Western blot using anti-Flag antibody. As shown in Figure 3OD, DhaA.H272F-Flag capturing was not detected in the absence of biotin-C ⁇ oH 2 iN ⁇ 2 -Cl treatment. At the same time, more than 50% of the
  • DhaA.H272F-Flag expressed in cells was captured on SA-coated beads if the cells were treated with biotin-C ⁇ oH2i NO 2 -Cl.
  • DhaA Mutants with Increased Rates of Covalent Bond Formation Replacement of the DhaA catalytic base His272 with a phenylalanine residue is compatible with the Asp nucleophile and resulted in a modified protein, designated DhaA.H272F, that accumulates substantial amounts of the covalent alkyl-enzyme intermediate (Figure 2C).
  • the absence of the water activating His272 residue allows trapping of the covalent ester intermediate ( Figure 2C).
  • a structural model of such a mutant before binding and after binding a substrate is shown in Figures 2E and 2F respectively.
  • a DhaA mutant containing a cysteine substitution for the nucleophile residue AsplO ⁇ was also capable of trapping covalent intermediates.
  • This mutant displaces the halide moiety through the action of a thiolate nucleophile.
  • the resulting thioether bond is stable to hydrolysis even in the presence of the water activating H272 residue ( Figure 2D).
  • the ability to generate a stable, covalent linkage between protein and haloalkane ligand provides for a universal reporter technology which can site- specifically label, localize, immobilize and/or fluorescently visualize proteins in mammalian cells (see Examples II-IX).
  • active-site mutants of dehalogenase (DhaA) tether fusion proteins with those mutants via a stable, covalent bond to synthetic haloalkane conjugated substrates are examples of active-site mutants of dehalogenase (DhaA) tether fusion proteins with those mutants via a stable, covalent bond to synthetic haloalkane conjugated substrates.
  • Ampicillin 100 ⁇ g/mL; Amp was added to the medium to select for recombinant plasmids.
  • the expression vector pCI-Neo (Promega Corporation, Madison, WI) was used to examine expression and labeling of DhaA mutants in mammalian cells.
  • Carboxytetramethylrhodamine-Cio ⁇ iNC ⁇ - Cl Carboxyfluorescein-C ⁇ oH2iN ⁇ 2 -Cl, diacetyl carboxyfluorescein-CioH2iN ⁇ 2- Cl, and biotin-containing chlorohaloalkane ligands (e.g., biotin-14-Cl, biotin-X- 14-Cl, and biotin-PEG4-14-Cl, see Figure 7) were synthesized by Promega Biosciences Inc. (San Luis Abispo, CA).
  • DNA analysis and protein modeling DNA analysis was performed using Vector NTI software package, version 8. Protein structures were obtained from the Protein Data Bank (PDB http://www.rcsb.org/pdb/). Structural analyses and modeling were performed with InsightII 2000.1 including modules Biopolymer, Discover, Homology, and Modeler (Accelrys http : //www . accelrys . com/) .
  • NNK 5' ATCGAGGGTGCGCTCCCGNNKTGCGTCGTCCGTCCGCTTACGG 3' (SEQ ID NO: 66)
  • V245T 5' GGGCACACCCGGCACCCTGATCCCCCCGG 3' (SEQ ID NO:83)
  • the underlined nucleotides indicate the position of the altered codons.
  • Site- directed mutagenesis was performed using the QuikChange Multi kit according to the manufacturer's instructions (Stratagene, La Jolla, CA). The mutagenesis reactions were introduced into competent E. coli and transformants were selected on LB agar plates containing Amp (100 ⁇ g/mL). Library quality was evaluated by DNA sequence analysis of 12-48 randomly selected clones from each library. Plasmids for sequence analysis were isolated from E. coli using Wizard SV Miniprep Kits (Promega Corp.). DNA sequence analysis was performed by Seq Wright DNA Technology Services (Houston, TX).
  • Sequencing primers for analyzing the 175, 176 and 175/176 libraries included: “175/176", 5'-GCCT ATCCCG ACGTGGGACG-3' (SEQ ID NO:71); “255R”, 5'-AGGTCTCGCGGCTTCGGCCGGGGG ⁇ ' (SEQ ID NO:72); “F70", 5'-AAAATCGGACAAACCAGACCTCG-S' (SEQ ID NO:73); “Fl 89", 5'- ATCGCG AGCCCTTCCTC A AGCCTG-3' (SEQ ID NO: 74); and "R 121", 5'- GTTCCGG ATTGCGCTTGGCCC AGT-3' (SEQ ID NO:75). Screening assay development.
  • E. coli colonies harboring DhaA.H272F or DhaA.DlO ⁇ C encoding plasmids were inoculated into 200 ⁇ L LB +100 ⁇ g/ml Amp and grown over night at 37°C in flat bottom 96 wells plates. Overnight cultures were diluted 1 :20 into 200 ⁇ L TB +100 ⁇ g/mL Amp + 0.1 mM IPTG and grown overnight at 30 0 C.
  • the volume of cells used for in vivo labeling was normalized to growth (OD f ,oo)- 50 to 100 ⁇ L of induced cells were transferred to a U-bottom 96 well plate, pelleted, re-suspended with 50 ⁇ l PBS + 15 ⁇ M carboxytetramethylrhodamine-CioH 2 iN0 2 -Cl and labeled at room temperature for 60 minutes on a rotating shaker. To remove the unbound ligand, cells were harvested at 2500 rpm for 5 minutes, supernatants were discarded and the cells were re-suspended with 100 ⁇ l of 10 mM Tris-HCl pH 7.5, 0.9% NaCl and
  • DhaA.H272F or DhaA.DlO ⁇ C mutant proteins (purified, 50 ng from E. coli lysates generated using FastBreakTM cell lysis reagent, Promega Corp.) was immobilized using 96-well microtiter plates (flat bottom; Nunc MaxiSorp) previously coated with anti-Flag M2 IgG (Sigma). Coating took place overnight at 4 0 C using 100 ⁇ L anti-Flag (5 ⁇ g/mL) in 0.1 M NaHCO 3 pH 9.6. The next day plates were emptied and blocked with 300 ⁇ L PBS containing 3% BSA for 1 hour at 25 0 C.
  • btrepravi ⁇ in 100 ⁇ L btrepravi ⁇ in (bAj-HKr ( l ::>,u ⁇ in PBS TB; Prozyme) was then added to the wells and incubated for 1 hour at 25 0 C.
  • the plates were emptied and washed 8x with PBST, and TMB was added in a volume of 100 ⁇ L. After 15 minutes, color development was stopped by the addition of an equal volume of 0.2 M H 2 SO 4 and signals were quantitated by measuring the absorbance at 450 nm.
  • a cocktail containing MagneGSTTM cell lysis reagent, MagneGSTTM PMPs and carboxytetramethylrhodamine-Ci 0 H 2 ⁇ NO 2 -Cl (15 ⁇ M) was pipetted into the 96 well plates containing the cell pellets. The plates were shaken at about 900 rpm for 10 minutes at room temperature. The particles were washed three times with PBST using a MagnaBot® 96 magnetic separation device. The wash solution was removed and MagneGST I M elution solution was added and the plates were allowed to shake at room temperature (about 900 rpm for 5 minutes). Supernatants were transferred to a new, flat bottom, transparent 96 well plate and the fluorescence intensity was measured using an excitation wavelength at 550 nm and an emission wavelength at 580 nm.
  • the DhaA mutant libraries were screened with the MagneGSTTM based assay on a custom Tecan Freedom robotic workstation.
  • the assay parameters were automated using the FACTS scheduling software and allowed the processing of multiple 96 well plates in parallel.
  • the cell pellets were stored in a refrigerated Storex incubator (4°C) until the plates were automatically retrieved for further processing.
  • Reagents were transferred to plates using a TeMo liquid handling system (Tecan US). The plates were shaken at about 900 rpm for 10 minutes on Tecan Te-ShakeTM at room temperature.
  • the particles were washed with PBST using a MagnaBot® 96 magnetic separation devices that were adapted to be used on a TeMo liquid dispensing system and compatible with the FACTS scheduling software. Fluorescence intensity measurements were performed using a Tecan Safire spectrofluorometer. Raw fluorescence intensity data were imported into an Excel spreadsheet for analysis. The screening data was examined for wells with higher intensity than the parental controls indicating the potential presence of improved DhaA clones.
  • pellets were resuspended with 2 mL lysis buffer (containing 1 mM DTT + 20 ⁇ L RQ DNase in the presence of IX protease inhibitor cocktail (Becton-Dickinson Biosciences) and incubated on a rotating shaker for 30 minutes.
  • lysis buffer containing 1 mM DTT + 20 ⁇ L RQ DNase in the presence of IX protease inhibitor cocktail (Becton-Dickinson Biosciences) and incubated on a rotating shaker for 30 minutes.
  • IX protease inhibitor cocktail Becton-Dickinson Biosciences
  • the particles were added directly to the lysate and the mixture was incubated for 30 minutes at room temperature on a rotating shaker to allow binding of the GST-DhaA fusion protein to the magnetic particles.
  • the GST-DhaA protein was eluted by incubation for 15 minute with elution buffer (100 mM glutathione, 50 mM Tris HCl, pH 8.1, 1 mM DTT and IX BD protease inhibition cocktail).
  • the eluted protein was dialyzed twice against storage buffer (50 mM Tris HCl, pH 7.5, 200 mM NaCl, 1 mM DTT, I mM EDTA, 20% glycerol).
  • GST-DhaA mutants (9 nM) were incubated with carboxytetramethylrhodamine- C 10 H 21 NO 2 -CI, carboxyfluorescein-Ci(jH 2 iNO 2 -Cl, or rhodamine green- C 1 0H 21 NO 2 -CI at various concentrations and temperatures in 50 mM Tris HCl (pH 7.5). Reactions were initiated by the addition of substrate, and for time course experiments 18 ⁇ L aliquots of the reactions were removed to tubes containing 6 ⁇ L SDS gel loading buffer, boiled for 5 minutes, and resolved on pre-poured, 4-20% gradient SDS-polyacrylamide gels in Tris-glycine (Invitrogen, Carlsbad, CA).
  • Fluorescence polarization was used to analyze the reaction kinetics of DhaA mutants. Measurements were taken on the Beacon 2000 (Invitrogen, Carlsbad, CA) or in a 96 well format using the Ultra plate reader (Tecan, Research Triangle Park, NC). Carboxytetramethylrhodamine-C]oH 2 iN ⁇ 2 -Cl or carboxyfluorescein- C 10 H 21 NO 2 -CI substrates (7.5-10 11M) were incubated with an excess of purified GST-DhaA proteins.
  • thermostability profiles of the DhaA mutants were determined by measuring the residual activity of the purified proteins following 15, 30 or 60 minute incubations at 4, 22, 30, 37, 42, 50 or 6O 0 C.
  • the FP assay was performed at room temperature (about 25°C).
  • 15 ⁇ M parental or 1.5-0.15 nM of 1 st generation clones were labeled with carboxytetramethylrhodamine-CioH 2 iN ⁇ 2 -Cl and 0.15 nM of 2 nd generation clones were labeled with carboxyfluorescein-Ci 0 H 2 ]NO 2 -Cl.
  • the labeling rate (slope of the linear range) was calculated for each condition. The rate observed following a 15 minute incubation at 4 0 C was arbitrarily assigned as 100% activity. The residual activity (%) was calculated for each condition. To determine stability, for each incubation time, the % of residual activity was plotted against the incubation temperatures. To calculate half-life, for each incubation temperature, the % of residual activity was plotted against the incubation time. The time where 50 % activity was lost was extrapolated from the graph.
  • the chloroalkylation reactions proceeded for 1 hour and were then added (in a volume of 100 ⁇ l) to washed plates containing immobilized DhaA. These incubations lasted for 1 to 2 hours at 25 0 C, and were stopped by emptying the plates and washing 4x with PBST.
  • TMB was added to the plates in a volume of 100 ⁇ L. Color was developed for 15 minutes and then stopped by the addition of an equal volume of 0.2 M H 2 SO 4 . Signals were quantitated by measuring absorbance at 450 run.
  • a secondary anti-rabbit IgG- HRP conjugate 100 ⁇ L of a 1 :5,000 dilution in PBSTB; 1 hour at 25 0 C was used to detect bound anti-carboxytetramethylrhodamine IgG. Plates were washed 8x with PBST, developed with TMB, and quantitated as above.
  • Biotinylated chloroalkane substrates biotin-14-Cl, biotin-X-14-Cl, and biotin-PEG4-14-Cl, were immobilized using streptavidin high binding capacity coated 96 well microtiter plates (flat bottom, Pierce). Using an excess of substrate (about 2 ⁇ mol), the plates could bind approximately 75 pmol of biotin per well.
  • PBSTB PBS + 0.05% Tween 20 + 0.5% BSA
  • Reactions between immobilized substrate and mutant DhaAs were performed using purified GST- DhaA-Flag fusions.
  • Various concentrations of protein 100 ⁇ L; diluted in PBSTB) were incubated with immobilized substrate for various times at 25 0 C, and the reactions were stopped by emptying the plates and wasning 4x witn PBST.
  • 100 ⁇ L anti-GST-HRP 100 ⁇ L was added to each well at a 1 : 10,000 dilution (in PBSTB) and the plates incubated for 1 hour at 25 0 C. Plates were emptied and washed 8x with PBST and then TMB was added in a volume of 100 ⁇ L. After 15 minutes, color development was stopped by the addition of an equal volume of 0.2 M H 2 SO 4 , and signals were quantitated by measuring the absorbance at 450 nm.
  • DhaA mutants Characterization of DhaA mutants in mammalian cells. Select sequence verified DhaA mutants were cloned into the mammalian expression vector pCI- neo as follows: The DhaA-FLAG portion of the mutant genes were removed from pGEX5X3 with Sail and Notl restriction endonucleases. Fragments were separated by electrophoresis in 1% agarose (IXTAE), excised and purified using QIAquick Gel Extraction Kit (QIAGEN). The pCI-neo vector backbone was also digested with Sail and Notl, separated and purified in the same manner. Ligations were performed using Promega's LigaFast System, at an approximate insert:vector ratio of 5: 1.
  • DNA was transformed into chemically competent JM 109 cells and plated onto LB agar plates containing Amp. Transformant colonies were picked into 96 well assay blocks (Fisher Scientific) containing 1 mL of LB + Amp and shaken overnight at 37°C. Cells were harvested and plasmids purified using the Wizard 96 plasmid purification kit (Promega Corp.). Plasmids were screened for the presence of the DhaA insert by a Sall-Notl restriction digest, and screened by electrophoresis in 1% agarose (IXTAE). Positive clones were verified by DNA sequence analysis.
  • Plasmid pHT2 was created to improve protein production in mammalian cells and to facilitate the generation of fusion proteins.
  • DhaA.H272F YL was amplified from pCIneo containing DhaA.H272F YL-FLAG with oligonucloetides 10055643 (5' CTA TAG GCT AGC CAG CTG GCG CGG ATA TCG CCA CCA TGG GAT CCG AAA TCG GTA CAG GCT TCC CCT TCG 3'; SEQ ID NO:84) and 10055644 (5' AGG GAA GCG GCC GCC TAC TTA ATT AAC TAT TAG CCG GCC AGC CCG GGG AGC CAG CGC GCG ATC TCA CTG C 3'; SEQ ID NO:85).
  • CHO-Kl cells ATCC-CCL61
  • HeLa cells ATCC-CCL2
  • FBS fetal bovine serum
  • penicillin 100 U/ml penicillin
  • streptomycin 100 mg/ml streptomycin
  • Mammalian cell transfection To study transient expression of different proteins, cells were plated in 24 well plates (Labsystems) or 8 well LT cover glass chamber slides (Nunc) at a density of 30,000 cells/cm 2 . At about 80-90% confluency, the cells were exposed to a mixture of lipofectamine/DNA/antibiotic free media according to the manufacturer's (Invitrogen) instructions. The following day, media was replaced with fresh media and cells were allowed to grow for various periods of time.
  • CHO-Kl cells were plated in 24 well plates (Labsystems) and transfected with a pCIneo-CMV.DhaA mutant-Flag vector. Twenty- four hours (in some experiments 12, 24 or 48 hours) later, media was replaced with fresh media containing 0.2, -25.0 ⁇ M carboxytetramethylrhodamine-CioH 2 iN0 2 -Cl or DiAc carboxyfluorescein- CioH 2 iN0 2 -Cl and the cells were placed into a CO 2 incubator for 1, 5, 15 or 60 minutes.
  • HeLa cells were plated in 8 well LT cover glass chamber slides (Nunc) and transfected with a pCIneo-CMV.DhaA mutant or ⁇ -arrestin2- connector-DhaA.Hl IYL vector. Twenty- four hours later, media was replaced with fresh media containing different concentrations (0.2-10.0 ⁇ M) of carboxytetramethylrhodamine-C ⁇ oH 2 iN ⁇ 2 -Cl or DiAc carboxyfluorescein- C 10 H 21 NO 2 -CI and the cells were placed into a CO 2 incubator for 15 minutes.
  • a ⁇ -arrestin2-connector-HT2 fusion cassette was constructed by subcloning ⁇ -arrestin2 (See Example VII) into Nhel/BamHI restriction sites of the pHT2 vector (Promega).
  • Two primers (5'- CTATAGGCTAGCCAGCTGGCGCGGATATCGCCACCATGGGGGAGAAA CCCGGGACCAGGG-B 1 ; SEQ ID NO:76, and 5'- GATTTCGGATCCCATTCTAGAGGGCCCGCGGTACCGCAAGCTTGATC CGGAGCAGAGTTGATCATCATAGTCGTCATCC-S'; SEQ ID NO: 77) were designed to add a sequence encoding a connector and a BamHI site to the 3' end of ⁇ -arrestin2 coding region, and to amplify the fragment from a ⁇ -arrestin2- connector-DhaA.H272F template.
  • the phRLuc-connector-HT2-Flag fusion cassette was constructed by replacing the DhaA.H272F coding region in the vector encoding phRLuc- connector-DhaA.H272F-Flag (See Example IX) with the HT2 coding region.
  • CHO-Kl cells were plated in 24 well plates (Labsystems) and transfected with a pCIneo.hRLuc-connector-HT2-Flag vector. Twenty-four hours later, media was replaced with fresh media containing 25 ⁇ M biotin-X-14- Cl and 0.1% DMSO, or 0.1 % DMSO alone, and the cells were placed in a CO 2 incubator for 60 minutes. At the end of the incubation, the media was removed, cells were quickly washed with PBS (pH 7.4; two consecutive washes; 1.0 ml/cm 2 ; 5 seconds each) and new media was added to the cells. In some experiments, the media was not changed. The cells were placed back in a CO 2 incubator.
  • the reference structure for model calculation was lBN ⁇ .pdb (Rhodococcus species DhaA). Five high-optimization models were calculated and one best model selected based on the overall lowest energy and lowest violations of structural parameters. The best model was then structurally aligned with the reference structure lBN ⁇ .pdb to obtain a measure of their overall and pair-wise differences, expressed as the Root Mean Square Deviation (in A) of aligned Ca atoms ( Figure 2A). Identification of substrate tunnel
  • DhaA-substrate model A structural model of DhaA.H272F with a covalently attached substrate was generated ("DhaA-substrate model").
  • carboxyfluorescein-CioFtiNCh- Cl was manually docked into the substrate tunnel of DhaA.H272F.
  • a covalent bond was created between one of the carboxyl oxygens of the nucleophilic aspartate of DhaA and the terminal carbon of the substrate that becomes available after removal of the chloride (Figure 2E).
  • the length of this covalent bond was restrained to about 3 A to approximate the transition state.
  • the covalently attached substrate was energy minimized separately and then together with DhaA.H272F residues in the vicinity of the substrate.
  • the Lys residue at position 175 is located on the surface of DhaA at the substrate tunnel entrance: removal of this large charged side chain might improve substrate entry into the tunnel ( Figure 2F).
  • the Cys residue at position 176 lines the substrate tunnel and its bulky side chain causes a constriction in the tunnel: removal of this side chain might open up the tunnel and improve substrate entry ( Figure 2F).
  • the VaI residue at position 245 lines the substrate tunnel and is in close proximity to two oxygens of the bound substrate: replacement of this residue with threonine may add hydrogen bonding opportunities that might improve substrate binding (Figure 2F).
  • Bosma et al. reported the isolation of a catalytically proficient mutant of DhaA with the amino acid substitution Tyr273Phe.
  • the starting material for all library and mutant constructions were pGEX5X3 based plasmids (Figure 3A) containing genes encoding DhaA.H272F and DhaA.D106C ( Figure 2B). These plasmids harbor genes that encode the parental DhaA mutants capable of forming stable covalent bonds with haloalkane ligands. Codons at positions 175, 176 and 273 in the DhaA.H272F and DhaA.D106C templates were randomized using a NNK site-saturation mutagenesis strategy. In addition to the single-site libraries at these positions, combination 175/176 NNK libraries were also constructed.
  • the second assay that was considered as a primary screen was an in vitro assay that effectively normalized for protein concentration by capturing saturating amounts of DhaA mutants on immobilized anti-FLAG antibody in a 96 well format.
  • Figure 3 IB shows the screening results obtained from one plate of the DhaA.H272F 175/176 combination library using the protein capture assay. Like the in vivo assay, this assay was also able to clearly identify potential improved DhaA mutants from a large background of parental activities.
  • FIG. 35B shows the mutated codons of the DhaA mutants identified in the DhaA.D106C libraries. Except for the single C176G mutation, most of the clones identified contained double 175/176 mutations. A total of 11 different amino acids were identified at the 175 position. In contrast, only three amino acids (GIy, Ala and GIn) were identified at position 176 with GIy appearing in almost % of the D 106C double mutants. Characterization of DhaA mutants
  • FIG. 36A shows that the DhaA.H272F based mutants A7 and Hl 1, as well as the DhaA.DlO ⁇ C based mutant D9, generate a considerably higher signal with carboxytetramethylrhodamine-CioH 2 iN0 2 -Cl than the respective parents.
  • second generation DhaA mutants In order to distinguish these recombined protein mutants from the mutants identified in round one of screening (first generation), they are referred to as "second generation" DhaA mutants.
  • second generation DhaA mutants To facilitate comparative kinetic studies several improved DhaA mutants were selected for purification using a Glutathione Sepharose 4B resin.
  • production of DhaA.H272F and DhaA.D106C based fusions in E. coli was robust, although single amino acid changes may have negative consequences on the production of DhaA (data not shown).
  • the overall yield of the DhaA mutants also varied considerably (1-15 mg/mL).
  • Preliminary kinetic labeling studies were performed using several DhaA.H272F derived mutants.
  • Figure 37A shows that many, if not all, of the mutants chosen for analysis had faster labeling kinetics than the H272F parent.
  • a more expanded time course analysis was performed on the DhaA.H272F A7 and the two second generation DhaA.H272F mutants A7YM and Hl IYL.
  • the labeling reactions of the two second generation clones are for the most part complete by the first time point (20 seconds).
  • the A7 mutant appears only to be reaching completion by the last time point (7 minutes).
  • the fluorescent bands on gel were quantitated and the relative rates of product formation are shown in Figure 37C.
  • the concentration of the Hl IYL was reduced from 50 ng to 10 ng and a more refined time-course was performed.
  • the results shown in Figure 38A demonstrate that under these labeling conditions a linear initial rate can be measured. Quantitation of the fluorimaged gel data allowed second order rate constants to be calculated (Figure 38B).
  • Fluorescence polarization is ideal for the study of small fluorescent ligands binding to proteins. It is unique among methods used to analyze molecular binding because it gives direct nearly instantaneous measure of a substrate bound/free ratio. Therefore, an FP assay was developed as an alternative approach to fluorimage gel analysis of the purified DhaA mutants.
  • Figure 39A shows the relative labeling rate of the H272F parent, compared to the A7 and Hl IYL mutants. Under the labeling conditions used in this experiment, the second generation mutant DhaA.H272F Hl IYL was significantly faster than its A7 and H272F counterparts.
  • FIG. 39B shows the FP results using carboxyfluorescein- C 10 H 21 NO 2 -CI. Under the labeling conditions used in this experiment, it is evident that the Hl IYL mutant was also considerably faster than A7 and parental, DhaA.H272F proteins with the fluorescein-based substrate.
  • Hl IYL had a calculated second order rate constant with carboxytetramelhylrhodamine- C10H 21 NO2-CI that was over four orders of magnitude higher than the DhaA.H272F parent.
  • the Hl IYL rate constant of 2.2 x 10 6 M “1 sec "1 was nearly identical to the rate constant calculated for a carboxytetramethylrhodamine- coupled biotin/streptavidin interaction (Figure 41). This value is consistent with an on-rate of 5 x 10 M "1 sec " determined for a biotin-streptavidin interaction using surface plasmon resonance analysis (Qureshi et al., 2001).
  • the substrate carboxytetramethylrhodamine-CiotLjiNCVCl was covalently attached to the best structural models of DhaA.H272F and DhaA.H272F Hl IYL.
  • the substrate was manually docked into the substrate tunnel, and then a covalent bond was created between one of the carboxyl oxygens of the nucleophilic aspartate of the protein and the terminal carbon of the substrate that becomes available after removal of the chloride.
  • Substrate conformations were adjusted to be as similar as possible for both models.
  • the initial models of DhaA.H272F and DhaA.H272F H 1 1 YL without and with covalently attached substrate were then prepared for energy minimization by adding hydrogens at pH 7.0 and assigning potentials using the CFF91 force field. Both models were energy minimized with Disco ver-3 using non-bond interactions with group-based or atom-based cutoffs, a distance- dependent dielectric of 1.0, and a final convergence of 0.01 for the last minimization step.
  • the following minimization cascade was used for models without substrate: a) minimize hydrogens of whole system and fix other atoms, b) minimize side chains of residues within about 8 A of substrate and fix other atoms, d) minimize residues within about 8 A of substrate with harmonic Ca restraint and fix other atoms.
  • This minimization cascade was used for models with substrate: a) minimize hydrogens of whole system and fix other atoms, b) minimize substrate and fix other atoms, c) minimize substrate plus side chains of residues within about 8 A of substrate and fix other atoms, d) minimize substrate plus residues within about 8 A of substrate with harmonic Ca restraint and fix other atoms.
  • the nucleoph ⁇ e Asp 106 moves slightly more into the tunnel upon binding of carboxytetramethylrhodamine-CioftiNCh- Cl in both mutants.
  • W107 located next to nucleophile and responsible for holding substrate bound to active site in proper orientation for nucleophilic attack, does not change its position significantly.
  • DhaA.H272F the F272 side chain is sticking into the runnel in the absence of substrate, and rotates out of the tunnel about 45° in the presence of substrate.
  • DhaA.H272F Hl IYL the F272 side chain does not stick into the tunnel and adjusts its position only slightly in the presence of substrate.
  • Glul30 shows a similar orientation in all structures except for DhaA.H272F with substrate, where the GIu 130 side chain is pushed away from the tunnel by the F272 side chain rotation necessary to accommodate the substrate.
  • Carboxytetramethylrhodamine-CioH 2 iN ⁇ 2 -Cl shows bumps to Lysl75 and Cysl76 in DhaA.H272F, but no bumps to any residues in DhaA.H272 Hl IYL. This suggests that the mutations introduced in DhaA.H272F Hl IYL have widened the runnel to some degree. Substrate tunnel shape and size. The substrate cavity was visualized as a
  • thermostability profiles of selected first and second generation DhaA.H272F mutants were determined by measuring the residual activity of the purified proteins following 60 minute incubations at various temperature.
  • Figure 43A shows the thermostability profiles of the first generation DhaA.H272F mutants and corresponding parent.
  • the most active first generation mutants (DhaA.H272F YL, DhaA.H272F YC and DhaA.H272F YM) were relatively unstable at temperatures above 30 0 C. This is in contrast to the DhaA.H272F parent and the DhaA.H272F A7 mutant protein that were stable up to temperatures of 4O 0 C.
  • DhaA.H272F Hl 1 retained significant labeling activity following incubation as high as 50 0 C (half-life of 58 minutes at 50 0 C).
  • DhaA.H272F Hl IYL retained the most activity following incubation at 42°C ( Figure 43B), however, certainly not to the degree of DhaA.H272F Hl 1 ( Figure 43 A). It is likely that the same mutations that confer thermostability on DhaA.H272F Hl 1 (i.e., K175M and C176G) also contribute to the stabilization of the DhaA.H272FYL mutant.
  • DhaA mutants In vivo and in vitro labeling of DhaA mutants.
  • the production of some DhaA mutant proteins in E. coli was compromised at 37°C, while other improved DhaA mutants retained considerable activity when grown and induced at elevated temperatures.
  • These clones may have a selective folding advantage at higher temperatures, and, as a result, may therefore be able to better tolerate mammalian cell culture conditions.
  • genes encoding the mutant proteins DhaA.H272F A7 and Hl 1 (along with the two parents DhaA.H272F and DhaA.D106C) were cloned into the mammalian expression vector pCI-neo and transfected into CHO cells.
  • Figures 46C-D show the labeling results comparing DhaA.H272F A7, DhaA.H272F Hl IYL and DhaA.DlO ⁇ C 30H4.
  • DhaA.H272F Hl IYL the second generation DhaA.H272F Hl IYL was labeled to completion in 15 minutes. This was half the time it required for complete labeling of DhaA.H272F A7.
  • DhaA.D106C 30H4 (the DhaA.H272F Hl 1 equivalent in the DhaA.DlO ⁇ C background) required over 2 hours to achieve the same degree of labeling.
  • Figures 46A-C demonstrate the superior labeling properties of DhaA.Hl IYL in mammalian cell lysates, particularly at low carboxytetramcthylrhodamine-CioH 2
  • Figure 48A shows the fluorescent signal obtained from the parental and two first generation mutants DhaA.H272F A7 and Dha ⁇ .H272F Hl 1, after labeling cells with carboxytetramethylrhodamine-CioH 2 iN ⁇ 2 -Cl 12, 24, and 48 hours post- transfection. Quantitation of the fluorimage gel shows that the production of active protein from all four clones tested peaks at 24 hours post-transfection and then declined to the levels observed at 48 hours ( Figure 48B).
  • CHO-Kl cells transfected with the construct encoding the DhaA.H272F Hl IYL mutant also retained a significant labeling potential at 48 hours. In fact, there was little to no detectable reduction in the signal produced by DhaA.H272F Hl IYL during the 24-48 hour period. Imaging of DhaA,H272F HI lYL in live and fixed mammalian cells.
  • DhaA.H272F Hl IYL expressed in mammalian cells could be efficiently labeled by carboxytetraniethylrhodamine-C ⁇ oH 2 iN ⁇ 2 -Cl or DiAc-carboxyfluorescein- C 10 H 21 NO 2 -CI. Images are bright and show excellent signal-to-noise ratio.
  • DhaA.H272F HI l YL HT2 ( Figure 49)and DhaA.H272F could be efficiently labeled with TAMRA-C,
  • Images of the cells expressing DhaA.Hl IYL HT2 and stained with 0.2, 1.0 or 5.0 ⁇ M TAMRA-C 1 ,H 2 , N, O 3 -Cl for 5 minutes are brighter than images of the cells expressing DhaA.H272F and stained with 5.0 ⁇ M carboxytetramethylrhodamine-Ciofti NO 2 -Cl for 30 minutes. This strongly indicates that in mammalian cells, carboxytetramethylrhodamme-Ci 0 H 2 i NO 2 -Cl labels DhaA.H272F Hl IYL HT2 with higher efficiency than DhaA.H272F. Imaging of 6 ⁇ rrestin2-connector-DhaA.H272F Hl I YL HT2 fusion protein expressed in living mammalian cells.
  • ⁇ -arrestin2-connector- DhaA.H272F Hl IYL HT2 expressing cells have a typical cytosolic localization for ⁇ -arrestin2 using either DiAc-carboxyfluorescein-CioH 2 i NO 2 -Cl or carboxytetramethylrhodamine-C 10H2 1 NO 2 -Cl to label the protein fusion.
  • DhaA Rhodococcus dehalogenase
  • the substrate cavity of the Rhodococcus dehalogenase (DhaA) protein is significantly larger, in both length and breath, than the substrate tunnel of the Xanthobacter DhIA protein (Newman et al., 1999).
  • DhaA mutants should be capable of accommodating a range of substrates containing different linker structures.
  • alternative substrates include the p-phenethyl and furanyl propyl derivatives, e.g., a compound such as those shown in Figure 56.
  • Figure 52A shows the binding rates of various carboxytetramethylrhodamine-based substrates determined using FP analysis.
  • the apparent binding rate constant determined for interaction of the carboxytetramethylrhodamine-p-phenethyl-Cl substrate to DhaA.H272F Hl IYL was only 3 -fold lower than the rate determined for carboxytetramethylrhodamine-CioH 2 iN ⁇ 2 -Cl.
  • no binding was detected for the carboxytetramethylrhodamine-furanyl propyl substrate under these reaction conditions.
  • the relative labeling rates of the carboxytetramethylrhodamine-based substrates was confirmed using fluorimage gel analysis. Under the reaction conditions used, all three carboxytetramethylrhodamine substrates were found to react with the protein
  • Figure 53 shows the relative binding rates of the various carboxyfluorescein-based substrates using FP analysis.
  • the apparent binding rate constant determined for the carboxyfluorescein-p-phenethyl-Cl substrate (5.6 x 10 M "1 sec "1 ) was approximately 5-fold lower than that for carboxyfluorescein- 14-Cl ( Figure 53A).
  • Figure 53A As previously observed with the carboxytetramethylrhodamine chloroalkane binding experiments, no binding was detected for the carboxyfiuorescein-furanyl substrate under these reaction conditions.
  • FIG. 53B shows the amount of fluorescent product fo ⁇ ned over the course of 20 minutes. Under the reaction conditions used all three carboxyfluorescein substrates were found to react with the protein ( Figure 53B). Quantitation of these product bands revealed that the DhaA.H272F Hl IYL labeled approximately 3-fold slower with the carboxyfluorescein-p-phenethyl-Cl substrate compared to the carboxyfluorescein-CiotbiNCh-Cl substrate ( Figure 53C).
  • the labeling rate with the carboxyfluorescein-furanyl-propyl-Cl substrate was over 100-fold slower than the carboxyfluorescein-CioH 2 i NO 2 -Cl substrate.
  • the in vivo labeling rates of the various carboxytetramethylrhodamine- based substrates was determined in mammalian cells. CHO-Kl cells transiently transfected with pHT2 vector (DhaA.H272F Hl IYL) were labeled with different concentrations of carboxytetramethylrhodamine-Cl-alkanes for over a time course of 60 minutes. Cells were collected at various times, lysed, and proteins were resolved on SDS-PAGE.
  • Figure 54A shows the accumulation of labeled product over time at various substrate concentrations of 1 , 5 and 20 ⁇ M. Quantitation of fluorescent product accumulation demonstrates that labeling of DhaA.H272F Hl IYL with carboxytetramethylrhodamine-p-phenethyl-Cl substrate was comparable to the carboxytetramethylrhodamine-CioH 2 iN ⁇ 2 -Cl substrate at all concentrations tested ( Figure 54B).
  • the labeling rate of the DhaA.H272F Hl IYL mutant with the carboxytetramethylrhodamine-furanyl-propyl-Cl substrate was noticeably slower at the 1 and 5 ⁇ M substrate concentrations.
  • the biotin-p-phenethyl-Cl substrate was tested in its ability to react with immobilized DhaA protein.
  • the general reaction scheme for the ELISA type assay performed is shown in Figure 55A.
  • Two pmol of DhaA.H272F Hl IYL was immobilized onto wells of a microtiter plate using anti-FLAG antibody.
  • the bound substrate was detected using a streptavidin-HRP conjugate.
  • the amount of color after development was an indication of the reactivity of each biotin haloalkane substrate.
  • Figure 55B shows that the biotin-p-phenethyl substrate reacted with the immobilized DhaA protein but to a lesser extent than either the biotin-14-Cl and biotin-PEG4-14-Cl substrates.
  • Example XT Exemplary DhaA Fusions for Cell Surface Display
  • Many membranous enzymes, receptors, differentiation antigens and other biologically active proteins are bound to fatty acids, isoprenoids, diacylglycerols, and glycosylphosphatidylinositols (GPI) through post-translational processing, and anchored to the membrane by these lipids.
  • GPI-linked proteins are expressed on a wide variety of cell types and have diverse functions ranging from control of cell adhesion (e.g., CD48, CD58, Thy-l/CD90) to protection against complement (CD55, CD59) and enzyme activity (alkaline phosphotase).
  • GPI anchors are covalently linked to carboxyl-terminal ends of proteins.
  • the core structure for GPI anchors in eukaryotes is composed of ethanolamine phosphate, trimannoside, glucosamine and inositol phospholipid in that order. All known GPI-anchored proteins are synthesized with a C-terminal cleavable peptide (reviewed in Stevens, 1995; Tiede et al., 1999; Sevelever et al., 2000).
  • the C-terminal peptide (a) is comprised of 15-30 amino acids that are generally hydrophobic, (b) contains no downstream cytosolic domain (Medof and Tykocinski, (1990), and (c) establishes a pattern defined by certain sets of amino acids around the "cleavage-attachment" site. This site, which is the amino aci ⁇ iert a ⁇ er removal or the C-terminal signal and the attachment of the GPI anchor, has been termed the ⁇ amino acid.
  • GPI is synthesized by sequential addition of sugars and ethanolamine phosphates to phosphatidylinositol in the endoplasmic reticulum (ER) (Udenfriend and Kodukula, 1995; Kinoshita and Inoue, 2000).
  • ER endoplasmic reticulum
  • Pre-formed GPI is attached to proteins in the ER.
  • Precursor proteins to be modified with GPI have two signals. One at the N-terminus is a signal required for translocation across the ER membrane. The other, at the C-terminus, is a GPI attachment signal.
  • the GPI attachment signal peptide is recognized by the GPI transamidase, which cleaves the signal peptide and replaces it with GPI.
  • PNKGSGTTSGTTRLLSGHTCFTLTGLLGTLVTMGLLT (SEQ ID NO: 18).
  • Hiscox et al. (2002) successfully expressed GFP on the surface of CHO cells.
  • the authors used three-stage PCR to ligate GFP downstream of the signal peptide of human CD59 (amino acids -25 to 1 , e.g., MGIQGGSVLFGLLLVLAVFCHSGHSL; SEQ ID NO:25) and upstream of amino acids 67-102 of human CD59, e.g.,
  • FEHCNFNDVTTRLRENELTYYCCKKDLCNFNEQLEN (SEQ ID NO:44), which contains the GPI attachment site at residue 77.
  • GFP and DhaA have a drastically different structure. Therefore, to generate GPI-anchored DhaA mutant fusions for mammalian cells, a signal sequence and GPI attachment sequence of different GPI-anchored proteins, e.g.
  • CD73 5'-nucleotidase (CD73), CAMPATH (CD52), the decay accelerating factor (DAF or DC55), the membrane inhibitor of reactive lysis (CD59), leucocyte function associated protein-3 (LFA-3 or CD90), placental alkaline phosphatase (PLAP), acetylcholinesterase (AchE), Thy-1 (CD90), Prion, and the like, may be employed.
  • a peptide connector may be introduced between DhaA and the GPI attachment sequence.
  • Integrins are the major receptors connecting cells to the surrounding extracellular matrix (Danen & Yamada, 2001 ; Hohesnester & Engel, 2002). They not only support cell attachment but also act in concert with receptors for soluble factors to regulate survival, differentiation, and proliferation. //; vitro, integrin ⁇ 5 ⁇ l -mediated cell adhesion to fibroncctin is particularly efficient in supporting mitogen-dependent proliferation of fibroblastic, epithelial, and endothelial cells. Integrins are hcterodimeric transmembrane receptors connected via scaffolding proteins to the cortical actin cytoskeleton.
  • the extracellular regions of the ⁇ and ⁇ subunits are non-covalently linked to fo ⁇ n a globular head domain that binds specific extracellular matrix (ECM) with specificity determined by the particular combination of ⁇ and ⁇ subunits.
  • ECM extracellular matrix
  • a fusion of DhaA mutant and an integrin e.g., an ⁇ or ⁇ integrin
  • an integrin e.g., an ⁇ or ⁇ integrin
  • Such a fusion protein includes a transmembrane domain, cytosolic domain, and/or an extracellular stalk domain of integrin, and a DhaA mutant.
  • the cytosolic domain of integrin may be a truncated domain, and an extracellular stalk domain of integrin may be replaced with an extracellular stalk domain of another protein (e.g., fractalkine), a portion of a stalk domain and/or a genetically engineered peptide, e.g., a synthetic peptide.
  • Fusions of integrins with other proteins of interest e.g., reporter proteins such as GFP, or enzymes such as luciferase, is also envisioned, e.g., for cell surface display of the protein of interest.
  • the cadherins comprise a family of calcium-dependent cell adhesion molecules that form and maintain adhesive contacts between cells of solid tissues (Takeichi et al., 1981 ; Hatta and Takeichi, 1986; Hatta et al., 1998).
  • Cadherins are single-pass transmembrane proteins characterized by the presence of distinctive cadherin repeat sequences in their extracellular segment (Patel et al., 2003). Each of these repeats, consisting of 1 10 amino acids, forms a beta- sandwich domain.
  • Cadherins typically have several of these "cadherin domains" tandemly repeated in their extracellular segments. The connections between these domains are rigidified by the specific binding of three Ca + ions between each successive domain pair.
  • Cadherins can be classified into several subfamilies (Nollet et al., 2000): type I (classical) and type II cadherins, which are ultimately linked to the actin cytoskeleton; the desmosomal cadherins
  • a fusion of Dha ⁇ mutant and a cadherin e.g., cadherin type I, cadherin type II, or atypical cadherin
  • a fusion protein includes a transmembrane domain, cytosolic domain, one or more extracellular cadherin domains, and a DhaA mutant.
  • the cytosolic domain of cadherin may be a truncated domain, and an extracellular cadherin domain(s) may be removed or replaced with an extracellular stalk domain of another protein or genetically engineered peptide.
  • Truncated cadherin is a type of cadherin and is unusual because it lacks a transmembrane segment and the conserved W2, but has a GPI anchor.
  • an N-terminal leader peptide for directing the nascent polypeptide through the phospholipid bilayer of membrane (e.g., ER membrane) is needed.
  • the N-terminal leader peptide may be a leader peptide of the fusion partner of a DhaA fusion polypeptide or a leader peptide of another polypeptide.
  • an additional peptide e.g., a connector
  • a connector may be inserted between DhaA and the N- terminal leader peptide, DhaA and the transmembrane domain of a fusion partner, and/or DhaA and an extracellular domain(s) of a fusion partner.
  • a fusion of a DhaA mutant and any membrane protein that has a defined N-te ⁇ ninal extracellular domain(s) e.g., ligand-gated ion channels such as n-methyl-D- aspartate (NMDA) receptors; 5-methyl-4-isoxazolopropionic acid (AMPA) receptors, glycine receptors, nicotinic acetylcholine receptors (nAChRs), P2X receptors, 5-hydroxytryptamine3 (5-HT3) receptors) (for review see Galligan, 2002), may be employed.
  • ligand-gated ion channels such as n-methyl-D- aspartate (NMDA) receptors; 5-methyl-4-isoxazolopropionic acid (AMPA) receptors, glycine receptors, nicotinic acetylcholine receptors (nAChRs), P2X receptors, 5-hydroxytryptamine3 (5-HT3) receptors
  • a fusion of a DhaA mutant and any membrane protein that has an extracellular C-terminal domain is employed.
  • the DhaA is attached to or inserted into C-terminal domain of the protein.
  • a peptide connector might be introduced between DhaA and the C-terminal domain of protein.
  • a mutant hydrolase on the cell surface when fused to a protein expressed on the cell surface, a mutant hydrolase on the cell surface, when combined with a ligand of the invention, e.g., one which contains a fluorophore, may be employed to monitor internalization of membrane protein.
  • a ligand of the invention e.g., one which contains a fluorophore
  • the system may be employed to monitor changes of environment surrounding membrane protein.
  • the ligand of the invention is one that has low or no permeability to the cell membrane.
  • labeling of DhaA expressed on cell surface with non-permeant ligand followed by treatment of the cells with cell permeant ligand can be used to monitor simultaneously relocation of surface and internal pool of membrane protein.
  • such a system can be used to monitor the effect of different agents, e.g., drugs, on different pools of membrane proteins.
  • a mutant hydrolase on the cell surface when fused to a protein expressed on the cell surface, a mutant hydrolase on the cell surface, when combined with a ligand of the invention, e.g., one which contains a detectable functional group, may be employed to monitor modification of the membrane proteins (e.g., proteolysis, glycosylation, etc.). Alternatively, such a system can be used to monitor the effect of different agents, e.g., drugs, on modification of the membrane proteins.
  • a mutant hydrolase on the cell surface when fused to an ion channel, a mutant hydrolase on the cell surface, when combined with a ligand of the invention, e.g., one which contains a microenvironmental sensitive functional group, may be employed to monitor functional activity of the channel.
  • such a system can be used to monitor the effect of different agents (and/or conditions), e.g., drugs (and/or a change of temperature, stretching of cell membrane, interaction of the cells with solid surfaces, other cells, proteins) on ion channel activity.
  • agents e.g., drugs (and/or a change of temperature, stretching of cell membrane, interaction of the cells with solid surfaces, other cells, proteins) on ion channel activity.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Composite Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

L'invention concerne une hydrolase mutante facultativement fusionnée à une protéine d'intérêt. Ladite hydrolase mutante est capable de former une liaison avec un substrat en vue de l'hydrolase non mutante correspondante (de type sauvage) plus stable que la liaison formée entre l'hydrolase de type sauvage et le substrat et présente au moins deux substitutions d'acides aminés par rapport à l'hydrolase de type sauvage. Cette invention a aussi pour objet des substrats destinés à des hydrolases comprenant au moins un groupe fonctionnel, des méthodes d'utilisation de l'hydrolase mutante et des substrats de ladite invention, ainsi qu'une protéine hybride capable de former une liaison stable avec un substrat et des cellules qui expriment la protéine hybride.
EP05857556.4A 2004-07-30 2005-07-29 Liaison covalente de groupes fonctionnels a des proteines et substrats associes Active EP1782071B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP17152698.1A EP3179252B1 (fr) 2004-07-30 2005-07-29 Fixation covalente de groupes fonctionnels à des protéines et substrats associés
EP11003761.1A EP2395078B1 (fr) 2004-07-30 2005-07-29 Fixation covalente de groupes fonctionnels à des protéines
EP11003760.3A EP2395358B1 (fr) 2004-07-30 2005-07-29 Fixation covalente de groupes fonctionnels à des protéines

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59249904P 2004-07-30 2004-07-30
US11/006,031 US7429472B2 (en) 2003-01-31 2004-12-06 Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
PCT/US2005/027307 WO2006093529A2 (fr) 2004-07-30 2005-07-29 Liaison covalente de groupes fonctionnels a des proteines et substrats associes

Related Child Applications (5)

Application Number Title Priority Date Filing Date
EP11003760.3A Division-Into EP2395358B1 (fr) 2004-07-30 2005-07-29 Fixation covalente de groupes fonctionnels à des protéines
EP11003760.3A Division EP2395358B1 (fr) 2004-07-30 2005-07-29 Fixation covalente de groupes fonctionnels à des protéines
EP17152698.1A Division EP3179252B1 (fr) 2004-07-30 2005-07-29 Fixation covalente de groupes fonctionnels à des protéines et substrats associés
EP11003761.1A Division EP2395078B1 (fr) 2004-07-30 2005-07-29 Fixation covalente de groupes fonctionnels à des protéines
EP11003761.1A Division-Into EP2395078B1 (fr) 2004-07-30 2005-07-29 Fixation covalente de groupes fonctionnels à des protéines

Publications (2)

Publication Number Publication Date
EP1782071A2 true EP1782071A2 (fr) 2007-05-09
EP1782071B1 EP1782071B1 (fr) 2014-10-08

Family

ID=36828617

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11003761.1A Active EP2395078B1 (fr) 2004-07-30 2005-07-29 Fixation covalente de groupes fonctionnels à des protéines
EP05857556.4A Active EP1782071B1 (fr) 2004-07-30 2005-07-29 Liaison covalente de groupes fonctionnels a des proteines et substrats associes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP11003761.1A Active EP2395078B1 (fr) 2004-07-30 2005-07-29 Fixation covalente de groupes fonctionnels à des protéines

Country Status (6)

Country Link
US (6) US7429472B2 (fr)
EP (2) EP2395078B1 (fr)
JP (2) JP5214244B2 (fr)
CN (1) CN101115995A (fr)
CA (1) CA2575611A1 (fr)
WO (1) WO2006093529A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9938564B2 (en) 2010-11-02 2018-04-10 Promega Corporation Substituted imidazo[1,2-a]pyrazines for use in bioluminogenic methods

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1301118B1 (fr) 2000-07-14 2006-09-06 Xillix Technologies Corp. Systeme video compact d'endoscopie en fluorescence
US20060241496A1 (en) 2002-01-15 2006-10-26 Xillix Technologies Corp. Filter for use with imaging endoscopes
US20060063178A1 (en) * 2002-06-27 2006-03-23 Trex Enterprises Corporation Optical sensor and methods for measuring molecular binding interactions
US7429472B2 (en) * 2003-01-31 2008-09-30 Promega Corporation Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
WO2004072232A2 (fr) 2003-01-31 2004-08-26 Promega Corporation Fixation covalente de groupes fonctionnels a des proteines
US9696298B2 (en) 2003-04-03 2017-07-04 Enzo Life Sciences, Inc. Multisignal reagents for labeling analytes
US20070087400A1 (en) * 2004-07-30 2007-04-19 Aldis Darzins Covalent tethering of functional groups to proteins and substrates therefor
EP2395358B1 (fr) * 2004-07-30 2017-03-29 Promega Corporation Fixation covalente de groupes fonctionnels à des protéines
US7425436B2 (en) 2004-07-30 2008-09-16 Promega Corporation Covalent tethering of functional groups to proteins and substrates therefor
WO2007067733A2 (fr) * 2005-12-09 2007-06-14 Massachusetts Institute Of Technology Compositions et procédés pour suivre l'absorption d'arn par des cellules
US20090303317A1 (en) 2006-02-07 2009-12-10 Novadaq Technologies Inc. Near infrared imaging
US20070224620A1 (en) * 2006-02-08 2007-09-27 Promega Corporation Compositions and methods for capturing and analyzing cross-linked biomolecules
ATE478559T1 (de) 2006-05-03 2010-09-15 Univ California Nachweis von protease und protease-aktivität mithilfe einer einzel-nanosteigerungs-sers-sonde
JP2010504759A (ja) 2006-09-29 2010-02-18 サノフィ パスツール バイオロジクス カンパニー ライノウイルスの新規中和性免疫原（ｎｉｍｉｖ）およびワクチン応用のためのその利用
WO2008054821A2 (fr) 2006-10-30 2008-05-08 Promega Corporation Protéines hydrolase mutantes à cinétique et expression fonctionnelle améliorées
ES2452318T3 (es) 2006-12-21 2014-03-31 F. Hoffmann-La Roche Ag Método para la detección de AMPc y GMPc
US7910087B2 (en) * 2007-03-02 2011-03-22 University Of Massachusetts Luciferins
US20080299592A1 (en) * 2007-03-02 2008-12-04 Miller Stephen C Red-Shifted Luciferase
JP2008222084A (ja) * 2007-03-14 2008-09-25 Yamaha Motor Electronics Co Ltd 電動ゴルフカーのブレーキ劣化検出方法及びこれを用いた電動ゴルフカー
EP1978093A1 (fr) * 2007-04-04 2008-10-08 Ecole Polytechnique Fédérale de Lausanne (EPFL) Procédé pour la réticulation de deux objets d'intérêt
US9395352B2 (en) 2007-04-06 2016-07-19 Arizona Board Of Regents On Behalf Of Arizona State University Devices and methods for target molecule characterization
CN101363849A (zh) * 2008-09-24 2009-02-11 深圳市菲鹏生物股份有限公司 间接标记纳米颗粒的抗体检测捕获法及其试剂盒
WO2010042514A1 (fr) 2008-10-06 2010-04-15 Arizona Board Of Regents Séquenceur d'adn basé sur des nanopores et des nanotubes de carbone et éléments de reconnaissance sériels
EP2367562B1 (fr) 2008-12-10 2019-11-20 University Of Georgia Research Foundation, Inc. Outils analytiques spécifiques des glycanes
JP2011026294A (ja) * 2009-06-26 2011-02-10 Canon Inc 化合物
JP5779837B2 (ja) * 2010-02-24 2015-09-16 株式会社Ihi 微生物検出方法
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
CN103180324A (zh) 2010-11-02 2013-06-26 普罗美加公司 腔肠素衍生物及其使用方法
EP2578695A1 (fr) 2011-10-05 2013-04-10 Albert-Ludwigs-Universität Freiburg Analyse de neurotoxine botulique de Clostridium
CA2863658C (fr) * 2012-02-03 2023-03-14 Emory University Compositions immunostimulatrices, particules et applications associees
JP6231503B2 (ja) 2012-03-09 2017-11-15 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ ｐＨセンサー
US10060910B2 (en) 2012-07-24 2018-08-28 Enzo Life Sciences, Inc. Multisignal reagents for labeling analytes
US9783841B2 (en) * 2012-10-04 2017-10-10 The Board Of Trustees Of The Leland Stanford Junior University Detection of target nucleic acids in a cellular sample
US9274430B2 (en) 2012-10-10 2016-03-01 Arizona Board Of Regents On Behalf Of Arizona State University Systems and devices for molecule sensing and method of manufacturing thereof
SG11201504520XA (en) * 2012-12-12 2015-07-30 Promega Corp Compositions and methods for capture of cellular targets of bioactive agents
EP2969435B1 (fr) 2013-03-15 2021-11-03 Promega Corporation Substrats pour la fixation covalente de protéines à des groupes fonctionnels ou des surfaces solides
US10168323B2 (en) 2013-03-15 2019-01-01 Promega Corporation Compositions and methods for capture of cellular targets of bioactive agents
WO2014145458A1 (fr) 2013-03-15 2014-09-18 Arizona Board Of Regents On Behalf Of Arizona State University Compositions à acides nucléiques marqués et méthodes de profilage d'interactions protéines-protéines multiplexes
US9504981B2 (en) * 2013-05-15 2016-11-29 True Health Diagnostics Llc Methods for purifying nucleic acids and devices thereof
US20160108002A1 (en) * 2013-05-30 2016-04-21 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Universal reader molecule for recognition tunneling
BR112015031114B1 (pt) * 2013-06-11 2020-10-13 University Of Houston aparelho e método para deposição de um revestimento
WO2015116867A1 (fr) 2014-01-29 2015-08-06 Promega Corporation Sondes masquées par quinone utilisées comme réactifs de marquage pour mesurer l'absorption cellulaire
WO2015116806A1 (fr) 2014-01-29 2015-08-06 Promega Corporation Pro-substrats pour applications se rapportant à des cellules vivantes
WO2015131073A1 (fr) 2014-02-27 2015-09-03 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Molécules de lecture à base de triazole et procédés pour leur synthèse et leur utilisation
CN103880938B (zh) * 2014-03-06 2015-10-14 福州大学 一种海洋源金属螯合肽的制备方法
WO2015175755A1 (fr) * 2014-05-15 2015-11-19 Arizona Board Of Regents On Behalf Of Arizona State University Ensembles de protéines ordonnées guidées par acides nucléiques et procédés correspondants
CN107076764A (zh) * 2014-11-20 2017-08-18 通用电气医疗集团英国有限公司 检测稳定在固体载体材料上的痴呆和阿尔茨海默病相关生物标记
US10717773B2 (en) 2015-05-19 2020-07-21 Regents Of The University Of Minnesota Polypeptide tagging fusions and methods
US9994638B2 (en) * 2015-05-20 2018-06-12 Immunwork Inc. Peptide core-based multi-arm linkers for treating infectious diseases
US10618907B2 (en) 2015-06-05 2020-04-14 Promega Corporation Cell-permeable, cell-compatible, and cleavable linkers for covalent tethering of functional elements
EP3424940A4 (fr) * 2016-03-01 2019-10-30 National University Corporation Chiba University Médicament radiomarqué
US10293122B2 (en) 2016-03-17 2019-05-21 Novadaq Technologies ULC Endoluminal introducer with contamination avoidance
CN109661407A (zh) 2016-06-06 2019-04-19 西北大学 融合蛋白构建体
US10648978B2 (en) 2017-02-09 2020-05-12 Mayo Foundation For Medical Education And Research Methods for detecting novel autoantibodies in Crohn's disease
WO2018200478A2 (fr) 2017-04-24 2018-11-01 University Of Georgia Research Foundation, Inc. Polypeptide de liaison à l'acide sialique
US11331019B2 (en) 2017-08-07 2022-05-17 The Research Foundation For The State University Of New York Nanoparticle sensor having a nanofibrous membrane scaffold
WO2019118314A2 (fr) * 2017-12-13 2019-06-20 Merck Sharp & Dohme Corp. Système de dosage de la scintillation par proximité comprenant une déshalogénase mutante
JP7432529B2 (ja) 2018-05-30 2024-02-16 プロメガ コーポレイション 広域スペクトルキナーゼ結合剤
CN108918495B (zh) * 2018-08-21 2020-10-09 辽宁大学 基于2-醛基罗丹明类衍生物的分光光度法定量检测氰根离子的方法
EP3891503A2 (fr) 2018-12-04 2021-10-13 Promega Corporation Agents de liaison aux rcpg à large spectre
EP3941195A4 (fr) 2019-03-20 2023-03-22 Promega Corporation Sondes de photoaffinité
US20220275350A1 (en) 2019-04-16 2022-09-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. Circularly permutated haloalkane transferase fusion molecules
EP3816180A1 (fr) 2019-10-31 2021-05-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Molécules de fusion d'haloalcane transférase permutées de façon circulaire
GB201913598D0 (en) * 2019-09-20 2019-11-06 Univ Birmingham Labelling of biomolecules
CN114981363A (zh) * 2019-11-20 2022-08-30 北卡罗莱纳州立大学 包含受体染料和供体发光体的聚合化合物
US12061202B2 (en) 2019-12-10 2024-08-13 Promega Corporation Compositions and methods for bioluminescent detection using multifunctional probes
US20230046728A1 (en) * 2019-12-11 2023-02-16 Fog Pharmaceuticals, Inc. Technologies useful for assessing permeability
CN111564187B (zh) * 2020-05-08 2023-03-14 东北师范大学 有机物与单线态氧反应速率常数的预测方法及系统
EP4153770A2 (fr) 2020-05-22 2023-03-29 Promega Corporation Amélioration de l'engagement de cibles kinases
CN112063608B (zh) * 2020-08-27 2022-06-17 浙江工业大学 一种脂肪酸光脱羧酶突变体及其在l-草铵膦合成中的应用
JP2023540934A (ja) 2020-08-28 2023-09-27 プロメガ コーポレイション Ｒａｓタンパク質のターゲットエンゲージメントアッセイ
CN112649605B (zh) * 2020-12-14 2022-11-01 哈尔滨理工大学 一种基于NaBiF4上转换纳米粒子的ECL生物传感器
KR20230147105A (ko) 2021-01-28 2023-10-20 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 리가제 융합 단백질 및 그 응용
EP4206674A1 (fr) 2021-12-28 2023-07-05 Encodia, Inc. Dosages de sérotypage et de profilage d'anticorps à haut débit
US20240174992A1 (en) 2022-05-04 2024-05-30 Promega Corporation Split modified dehalogenase variants
US20240132859A1 (en) 2022-05-04 2024-04-25 Promega Corporation Modified dehalogenase with extended surface loop regions
WO2023215514A2 (fr) 2022-05-04 2023-11-09 Promega Corporation Marquage photocatalytique déclenché par bioluminescence

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US603104A (en) 1898-04-26 Coin-controlled meter
DE1229532B (de) 1961-04-14 1966-12-01 Boehringer Sohn Ingelheim Verfahren zur Herstellung neuer Piperidinderivate
US3131122A (en) * 1961-04-14 1964-04-28 Boehringer Sohn Ingelheim Method of producing analgesia with n-substituted-4-phenyl-4-carbalkoxypiperidines
US4574079A (en) * 1983-05-27 1986-03-04 Gavras Haralambos P Radiolabeled angiotensin converting enzyme inhibitors for radiolabeling mammalian organ sites
US4612302A (en) 1983-11-14 1986-09-16 Brigham And Women's Hospital Clinical use of somatostatin analogues
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US4812409A (en) 1986-01-31 1989-03-14 Eastman Kodak Company Hydrolyzable fluorescent substrates and analytical determinations using same
US4853371A (en) 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
EP0258898B1 (fr) * 1986-09-04 1992-04-22 Idemitsu Kosan Company Limited Polymères liquides cristallins
US4810636A (en) 1986-12-09 1989-03-07 Miles Inc. Chromogenic acridinone enzyme substrates
CS259396B1 (en) 1987-05-06 1988-10-14 Jozef Luston 1,2,2,6,6-pentamethyl-4-(delta-bromalkoxy) piperidines and method of their preparation
SE8900130L (sv) * 1989-01-16 1990-07-17 Klaus Mosbach Konceptet att med hjaelp av molekylavtrycksmetoden framstaella konstgjorda antikroppar genom imprinting av t ex antigener samt att framstaella konstgjorda entzymer genom imprintning med transition state analoger
US5071469A (en) * 1989-04-21 1991-12-10 E. I. Du Pont De Nemours And Company Herbicidal benzylsulfonamides
US5498694A (en) * 1989-05-25 1996-03-12 La Jolla Cancer Research Foundation Peptides of the cytoplasmic domain of integrin
US5128247A (en) 1989-08-14 1992-07-07 Board Of Regents, The University Of Texas System Methods for isolation of nucleic acids from eukaryotic and prokaryotic sources
US5099020A (en) * 1989-11-27 1992-03-24 Abbott Laboratories Barbiturate assay compositions and methods
DK0564531T3 (da) * 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5576424A (en) * 1991-08-23 1996-11-19 Molecular Probes, Inc. Haloalkyl derivatives of reporter molecules used to analyze metabolic activity in cells
JP3183968B2 (ja) * 1992-10-20 2001-07-09 本田技研工業株式会社 車両用動力伝達装置
FR2700855B1 (fr) 1993-01-28 1995-03-03 Commissariat Energie Atomique Dosage immunométrique d'un antigène ou d'un haptène.
US5372944A (en) * 1993-10-14 1994-12-13 The Dow Chemical Company Method for conversion of halogenated hydrocarbons to halohydrins
US5523209A (en) * 1994-03-14 1996-06-04 The Scripps Research Institute Methods for identifying inhibitors of integrin activation
US5503977A (en) * 1994-04-22 1996-04-02 California Institute Of Technology Split ubiquitin protein sensor
JP3583489B2 (ja) 1994-12-22 2004-11-04 日清紡績株式会社 カルボジイミド誘導体
CH689633A5 (de) 1995-01-10 1999-07-30 Von Roll Umwelttechnik Ag Verfahren zur Kuehlung und Reinigung von Rauchgasen.
EP0856026A1 (fr) 1995-10-19 1998-08-05 Receptagen Corporation Polyethylene glycols de longueur discrete
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US5786428A (en) * 1996-03-27 1998-07-28 California Institute Of Technology Adsorbents for amino acid and peptide separation
US6255461B1 (en) * 1996-04-05 2001-07-03 Klaus Mosbach Artificial antibodies to corticosteroids prepared by molecular imprinting
US6162931A (en) 1996-04-12 2000-12-19 Molecular Probes, Inc. Fluorinated xanthene derivatives
US5945526A (en) 1996-05-03 1999-08-31 Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US6416733B1 (en) * 1996-10-07 2002-07-09 Bristol-Myers Squibb Pharma Company Radiopharmaceuticals for imaging infection and inflammation
US5932421A (en) * 1996-12-06 1999-08-03 The Scripps Research Institute Methods and cell lines for identification of regulators of integrin activation
IL131209A0 (en) 1997-02-13 2001-01-28 Dow Chemical Co Recombinant haloaliphatic dehalogenases
US6333154B1 (en) * 1997-12-04 2001-12-25 Institut Pasteur Bacterial multi-hybrid system and applications thereof
WO2001046476A1 (fr) * 1999-12-23 2001-06-28 Maxygen, Inc. Alteration de genes de l'hydrolase et recherche de la capacite a catalyser des reactions specifiques par criblage des bibliotheques resultantes
FR2804116B1 (fr) * 2000-01-20 2002-08-23 Centre Nat Rech Scient Composes organosilicies, leur procede de preparation et leurs utilisations
WO2001060415A1 (fr) 2000-02-18 2001-08-23 The Immune Response Corporation Methodes et compositions d'administration de genes
US20020045194A1 (en) * 2000-04-10 2002-04-18 Cravatt Benjamin F. Proteomic analysis
EP1322625A2 (fr) 2000-10-02 2003-07-02 Molecular Probes Inc. Reactifs pour le marquage de biomolecules a fractions aldehyde ou cetone
US7078504B2 (en) 2000-12-01 2006-07-18 Diversa Corporation Enzymes having dehalogenase activity and methods of use thereof
JP2005502310A (ja) 2000-12-01 2005-01-27 ディヴァーサ コーポレイション ハイドロラーゼ酵素および速度論的分割における用途
CA2434139C (fr) * 2001-01-23 2014-05-27 President And Fellows Of Harvard College Reseaux de proteines a acide nucleique programmable
DE60237792D1 (de) 2001-04-10 2010-11-04 Ecole Polytech Verfahren zur Verwendung von O6-Alkylguanin-DNS Alkyltransferasen
US7176242B2 (en) 2001-11-08 2007-02-13 Elan Pharmaceuticals, Inc. N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives
AU2003252111A1 (en) 2002-07-19 2004-02-09 Diversa Corporation Fluorescent proteins, nucleic acids encoding them and methods for making and using them
WO2004048530A2 (fr) 2002-11-22 2004-06-10 Carnegie Mellon University Compositions et procedes de capture reversible de biomolecules
US7429472B2 (en) 2003-01-31 2008-09-30 Promega Corporation Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
WO2004072232A2 (fr) 2003-01-31 2004-08-26 Promega Corporation Fixation covalente de groupes fonctionnels a des proteines
US20050095651A1 (en) 2003-08-12 2005-05-05 The Regents Of The University Of California Photoswitchable method for the ordered attachment of proteins to surfaces
US7425436B2 (en) * 2004-07-30 2008-09-16 Promega Corporation Covalent tethering of functional groups to proteins and substrates therefor
US20070087400A1 (en) * 2004-07-30 2007-04-19 Aldis Darzins Covalent tethering of functional groups to proteins and substrates therefor
EP2395358B1 (fr) * 2004-07-30 2017-03-29 Promega Corporation Fixation covalente de groupes fonctionnels à des protéines
US20070224620A1 (en) * 2006-02-08 2007-09-27 Promega Corporation Compositions and methods for capturing and analyzing cross-linked biomolecules
WO2008054821A2 (fr) 2006-10-30 2008-05-08 Promega Corporation Protéines hydrolase mutantes à cinétique et expression fonctionnelle améliorées

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006093529A2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9938564B2 (en) 2010-11-02 2018-04-10 Promega Corporation Substituted imidazo[1,2-a]pyrazines for use in bioluminogenic methods

Also Published As

Publication number Publication date
EP2395078B1 (fr) 2017-05-10
EP1782071B1 (fr) 2014-10-08
WO2006093529A3 (fr) 2007-03-22
JP2013208136A (ja) 2013-10-10
US20050272114A1 (en) 2005-12-08
US20190085305A1 (en) 2019-03-21
WO2006093529A2 (fr) 2006-09-08
US20110207195A1 (en) 2011-08-25
CA2575611A1 (fr) 2006-09-08
EP2395078A3 (fr) 2012-10-24
CN101115995A (zh) 2008-01-30
US7429472B2 (en) 2008-09-30
US7888086B2 (en) 2011-02-15
JP5214244B2 (ja) 2013-06-19
US8779221B2 (en) 2014-07-15
US8202700B2 (en) 2012-06-19
US20120330001A1 (en) 2012-12-27
US20090098627A1 (en) 2009-04-16
EP2395078A2 (fr) 2011-12-14
US10604745B2 (en) 2020-03-31
US20150140587A1 (en) 2015-05-21
JP2008507983A (ja) 2008-03-21

Similar Documents

Publication Publication Date Title
US10604745B2 (en) Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
US10101332B2 (en) Covalent tethering of functional groups to proteins and substrates therefor
US20070087400A1 (en) Covalent tethering of functional groups to proteins and substrates therefor
EP3179252B1 (fr) Fixation covalente de groupes fonctionnels à des protéines et substrats associés
EP2455457B1 (fr) Fixation covalente de groupes fonctionnels à des protéines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070226

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20090507

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WOOD, MONIKA G.

Inventor name: JOHNSON, TONNY

Inventor name: DARZINS, ALDIS

Inventor name: KLAUBERT, DIETER

Inventor name: ZIMPRICH, CHAD

Inventor name: WOOD, KEITH V.

Inventor name: LOS, GEORGYI V.

Inventor name: MCDOUGALL, MARK

Inventor name: ENCELL, LANCE P.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140130

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 690899

Country of ref document: AT

Kind code of ref document: T

Effective date: 20141015

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005044900

Country of ref document: DE

Effective date: 20141120

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20141008

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 690899

Country of ref document: AT

Kind code of ref document: T

Effective date: 20141008

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141008

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150209

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150208

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141008

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141008

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141008

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141008

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141008

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141008

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141008

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141008

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150109

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005044900

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141008

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141008

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141008

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141008

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141008

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141008

26N No opposition filed

Effective date: 20150709

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141008

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141008

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150729

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150731

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150731

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150729

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20050729

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141008

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141008

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141008

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240729

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240729

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240725

Year of fee payment: 20